A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Phase: PHASE3
Conditions: Spondyloarthritis
Sponsor: Eli Lilly and Company

Protocol I1F-MC-RHBW(d)
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study 
Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) 
in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
NCT02696798   
Approval Date: 02-Jun-2017

I1F-MC-RHBW(d) Clinical Protocol
Page 1
LY2439821
Protocol I1F-MC-RHBW(d)
A Multicenter, Randomized, Double-Blind, 
Placebo-Controlled 16-Week Study Followed by Long-Term 
Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) 
in TNFi-Experienced Patients with Radiographic Axial 
Spondyloarthritis
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
ixekizumab (LY2439821), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Ixekizumab (LY2439821)
Study I1F-MC-RHBW is a Phase 3, multicenter, randomized, double-blind, 
placebo-controlled, parallel-group, outpatient study examining the efficacy and safety of 
ixekizumab (LY2439821) compared to placebo over 16 weeks in tumor necrosis factor 
(TNF) inhibitor-experienced patients with radiographic axial spondyloarthritis (rad-axSpA).  
Patients will be randomized to subcutaneous (SC) placebo, or 1 of 2 treatment regimens of 
ixekizumab (80 mg every 2 weeks [Q2W] or every 4 weeks [Q4W]).  This study will also 
evaluate long-term efficacy and safety of ixekizumab during an Extended Treatment Period 
(36 weeks).  All patients entering into the Extended Treatment Period from the placebo 
treatment group will be re-randomized to ixekizumab 80 mg Q2W or Q4W.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly: 23 November 2015
Amendment (a) Electronically Signed and Approved by Lilly:  19 September 2016
Amendment (b) Electronically Signed and Approved by Lilly:  14 January 2017
Amendment (c) Electronically Signed and Approved by Lilly:  01 May 2017
Amendment (d) Electronically Signed and Approved by Lilly on approval date provided 
below.
Approval Date: 02-Jun-2017 GMT

I1F-MC-RHBW(d) Clinical Protocol
Page 2
LY2439821
Table of Contents
Section
Page
1.
Protocol Synopsis..............................................................................................................10
2.
Introduction ......................................................................................................................13
2.1.
Background..................................................................................................................13
2.2.
Study Rationale............................................................................................................14
3.
Objectives and Endpoints..................................................................................................15
4.
Study Design.....................................................................................................................18
4.1.
Overview of Study Design ...........................................................................................18
4.2.
End of Trial Definition.................................................................................................20
4.3.
Scientific Rationale for Study Design...........................................................................20
4.4.
Justification for Dose ...................................................................................................21
4.5.
Benefit/Risk Assessment..............................................................................................21
5.
Study Population...............................................................................................................22
5.1.
Inclusion Criteria..........................................................................................................22
5.2.
Exclusion Criteria ........................................................................................................24
5.3.
Screen Failures.............................................................................................................29
5.4.
Lifestyle and/or Dietary Requirements .........................................................................30
6.
Treatment..........................................................................................................................31
6.1.
Treatments Administered .............................................................................................31
6.1.1.
Administration of Investigational Product ............................................................34
6.2.
Method of Treatment Assignment ................................................................................34
6.2.1.
Selection and Timing of Doses.............................................................................35
6.3.
Blinding .......................................................................................................................35
6.4.
Packaging and Labelling ..............................................................................................36
6.5.
Preparation/Handling/Storage.......................................................................................36
6.6.
Dose Modification........................................................................................................36
6.6.1.
Special Treatment Considerations ........................................................................37
6.7.
Treatment Compliance .................................................................................................38
6.8.
Concomitant Therapy...................................................................................................38
6.9.
Treatment After Study Completion...............................................................................40
6.9.1.
Study Extensions..................................................................................................40
6.9.2.
Continued Access.................................................................................................41
7.
Discontinuation Criteria ....................................................................................................42
7.1.
Discontinuation from Study Treatment.........................................................................42
7.1.1.
Discontinuation from Study Treatment.................................................................42

I1F-MC-RHBW(d) Clinical Protocol
Page 3
LY2439821
7.1.1.1.
Discontinuation of Study Treatment Prior to Week 16....................................44
7.1.2.
Discontinuation of Inadvertently Enrolled Patients...............................................44
7.1.3.
Permanent Discontinuation from the Study ..........................................................44
7.1.4.
Patients Lost to Follow-Up...................................................................................44
8.
Study Assessments and Procedures ...................................................................................46
8.1.
Efficacy Assessments...................................................................................................46
8.1.1.
Primary Efficacy Assessments:  ASAS40.............................................................46
8.1.2.
Secondary Efficacy Assessments..........................................................................46
8.1.2.1.
ASAS20, ASAS Individual Components, ASAS Partial 
Remission, and ASAS 5/6...............................................................................46
8.1.2.1.1.
ASAS20 ...................................................................................................46
8.1.2.1.2.
ASAS Partial Remission ...........................................................................47
8.1.2.1.3.
ASAS 5/6 .................................................................................................47
8.1.2.2.
Patient Global (Assessment of Disease Activity) ............................................47
8.1.2.3.
Spinal Pain .....................................................................................................47
8.1.2.4.
Bath Ankylosing Spondylitis Disease Activity Index......................................47
8.1.2.5.
Bath Ankylosing Spondylitis Functional Index ...............................................47
8.1.2.6.
Bath Ankylosing Spondylitis Metrology Index—Spinal 
Mobility .........................................................................................................47
8.1.2.7.
Chest Expansion.............................................................................................48
8.1.2.8.
Occiput to Wall Distance................................................................................48
8.1.2.9.
Ankylosing Spondylitis Disease Activity Score ..............................................48
8.1.2.10.
Maastricht Ankylosing Spondylitis Enthesitis Score .......................................49
8.1.2.11.
Spondyloarthritis Research Consortium of Canada–
Enthesitis Score..............................................................................................49
8.1.2.12.
Peripheral Arthritis .........................................................................................49
8.1.2.12.1.
Tender Joint Count ...................................................................................49
8.1.2.12.2.
Swollen Joint Count..................................................................................50
8.1.2.13.
Nonsteroidal Anti-Inflammatory Drug Intake .................................................50
8.1.2.14.
Assessment of Spondyloarthritis International Society 
Health Index...................................................................................................50
8.1.2.15.
Medical Outcomes Study 36-Item Short-Form Health 
Survey............................................................................................................50
8.1.2.16.
Fatigue Severity Numeric Rating Scale...........................................................51
8.1.2.17.
Work Productivity and Activity Impairment 
Questionnaire–Spondyloarthritis.....................................................................51
8.1.2.18.
Jenkins Sleep Evaluation Questionnaire..........................................................51
8.1.2.19.
Laboratory Tests Used for Efficacy Measures and 
Disease Diagnosis...........................................................................................51

I1F-MC-RHBW(d) Clinical Protocol
Page 4
LY2439821
8.1.2.19.1.
High Sensitivity C-Reactive Protein..........................................................51
8.1.2.20.
Imaging Used for Efficacy Measures and Disease 
Diagnosis........................................................................................................51
8.1.2.20.1.
Imaging of Sacroiliac Joints and Spine......................................................51
8.1.3.
Other Assessments...............................................................................................52
8.1.3.1.
European Quality of Life–5 Dimensions–5 Level ...........................................52
8.1.3.2.
Healthcare Resource Utilization......................................................................52
8.2.
Adverse Events ............................................................................................................53
8.2.1.
Serious Adverse Events........................................................................................54
8.2.1.1.
Suspected Unexpected Serious Adverse Reactions..........................................54
8.2.2.
Adverse Events of Special Interest .......................................................................54
8.2.3.
Complaint Handling.............................................................................................55
8.3.
Treatment of Overdose.................................................................................................55
8.4.
Safety Assessments ......................................................................................................56
8.4.1.
Electrocardiograms ..............................................................................................56
8.4.2.
Vital Signs ...........................................................................................................56
8.4.3.
Laboratory Tests ..................................................................................................56
8.4.4.
Physical Examination...........................................................................................56
8.4.5.
Eye Symptom Assessment ...................................................................................56
8.4.6.
Chest X-Ray and Tuberculosis Testing.................................................................57
8.4.7.
Quick Inventory of Depressive Symptomatology–Self-
Report (16 Items) .................................................................................................58
8.4.8.
Columbia–Suicide Severity Rating Scale..............................................................58
8.4.9.
Immunogenicity...................................................................................................59
8.4.10.
Safety Monitoring ................................................................................................59
8.4.10.1.
Neutropenia....................................................................................................59
8.4.10.1.1.
During Treatment (Periods 2 and 3) ..........................................................59
8.4.10.1.2.
At Early Termination Visit........................................................................60
8.4.10.1.3.
Post-Treatment Follow-Up Period.............................................................61
8.4.10.2.
Hepatitis B Monitoring...................................................................................61
8.4.10.3.
Hypertension ..................................................................................................62
8.5.
Pharmacokinetics .........................................................................................................62
8.6.
Pharmacodynamics ......................................................................................................62
8.7.
Genetics .......................................................................................................................62
8.8.
Biomarkers...................................................................................................................63
8.8.1.
Samples for Immunogenicity Research.................................................................63
8.9.
Health Economics ........................................................................................................64
9.
Statistical Considerations and Data Analysis.....................................................................65

I1F-MC-RHBW(d) Clinical Protocol
Page 5
LY2439821
9.1.
Determination of Sample Size ......................................................................................65
9.2.
General Statistical Considerations ................................................................................65
9.2.1.
General Considerations for Analyses during the Blinded 
Treatment Dosing Period (Period 2).....................................................................65
9.2.2.
General Considerations for Analyses during the Extended 
Treatment Period (Period 3) .................................................................................67
9.2.3.
General Considerations for Analyses during the Post-
Treatment Follow-Up Period (Period 4) ...............................................................67
9.2.4.
Analysis Populations............................................................................................68
9.2.5.
Missing Data Imputation......................................................................................68
9.2.5.1.
Nonresponder Imputation ...............................................................................68
9.2.5.2.
Modified Baseline Observation Carried Forward ............................................69
9.2.5.3.
Last Observation Carried Forward..................................................................69
9.2.6.
Adjustment for Multiple Comparisons..................................................................69
9.3.
Treatment Group Comparability...................................................................................71
9.3.1.
Patient Disposition...............................................................................................71
9.3.2.
Patient Characteristics..........................................................................................72
9.3.3.
Concomitant Therapy...........................................................................................72
9.3.4.
Treatment Compliance .........................................................................................72
9.4.
Primary and Secondary Analyses .................................................................................72
9.4.1.
Primary Analyses.................................................................................................72
9.4.2.
Secondary Analyses .............................................................................................73
9.4.2.1.
Major Secondary Analyses .............................................................................73
9.4.2.2.
Other Secondary Efficacy Analyses................................................................74
9.4.2.2.1.
Period 2 (Blinded Treatment Dosing Period).............................................74
9.4.2.2.2.
Period 3 (Extended Treatment Period) ......................................................75
9.4.3.
Other Exploratory Analyses .................................................................................75
9.5.
Safety Analyses............................................................................................................75
9.5.1.
Adverse Events ....................................................................................................75
9.5.2.
Clinical Laboratory Tests .....................................................................................76
9.5.3.
Vital Signs, Physical Findings, and Other Safety Evaluations...............................76
9.6.
Pharmacokinetic/Pharmacodynamic/Immunogenicity Analyses ...................................77
9.7.
Other Analyses.............................................................................................................77
9.7.1.
Health Economics ................................................................................................77
9.7.2.
Subgroup Analyses ..............................................................................................78
9.7.3.
Immunogenicity...................................................................................................78
9.8.
Interim Analyses ..........................................................................................................79
10.
Study Governance Considerations.....................................................................................80

I1F-MC-RHBW(d) Clinical Protocol
Page 6
LY2439821
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ...........................................................................................................80
10.1.1.
Informed Consent.................................................................................................80
10.1.2.
Ethical Review.....................................................................................................80
10.1.3.
Regulatory Considerations ...................................................................................80
10.1.4.
Investigator Information.......................................................................................81
10.1.5.
Protocol Signatures ..............................................................................................81
10.1.6.
Final Report Signature .........................................................................................81
10.2. Data Quality Assurance................................................................................................81
10.2.1.
Data Capture System............................................................................................82
10.3. Study and Site Closure .................................................................................................82
10.3.1.
Discontinuation of Study Sites .............................................................................82
10.3.2.
Discontinuation of the Study................................................................................82
11.
References ........................................................................................................................83

I1F-MC-RHBW(d) Clinical Protocol
Page 7
LY2439821
List of Tables
Table
Page
Table RHBW.1. Objectives and Endpoints...............................................................................15
Table RHBW.2. Treatment Regimens from Weeks 0 to 14
Blinded Treatment Dosing Period (Period 2)..................................................32
Table RHBW.3. Treatment Regimens from Weeks 16 to 50
Extended Treatment Period (Period 3) ...........................................................33
Table RHBW.4. Imaging Requirements for Sacroiliac Joints and Spine...................................52
Table RHBW.5. Primary and Major Secondary Outcome Analyses..........................................74

I1F-MC-RHBW(d) Clinical Protocol
Page 8
LY2439821
List of Figures
Figure
Page
Figure RHBW.1. Illustration of study design for Clinical Protocol I1F-MC-RHBW..................19
Figure RHBW.2. Illustration of graphical multiple testing procedure. .......................................71

I1F-MC-RHBW(d) Clinical Protocol
Page 9
LY2439821
List of Appendices
Appendix
Page
Appendix 1.
Abbreviations and Definitions........................................................................90
Appendix 2.
Schedule of Activities....................................................................................94
Appendix 3.
Clinical Laboratory Tests.............................................................................104
Appendix 4.
Hepatic Monitoring Tests for Treatment-Emergent Abnormality..................106
Appendix 5.
Spondyloarthritis Features ...........................................................................107
Appendix 6.
Protocol Amendment I1F-MC-RHBW(d) Summary:  A Multicenter, 
Randomized, Double-Blind, Placebo-Controlled 16-Week Study 
Followed by Long-Term Evaluation of Efficacy and Safety of 
Ixekizumab (LY2439821) in TNFi-Experienced Patients with 
Radiographic Axial Spondyloarthritis ..........................................................108

I1F-MC-RHBW(d) Clinical Protocol
Page 10
LY2439821
1.
Protocol Synopsis
Title of Study:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation 
of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients with Radiographic Axial 
Spondyloarthritis
Rationale: 
Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (MAb) that 
neutralizes the cytokine interleukin-17A (IL-17A, also known as IL-17).  Strong scientific evidence exists indicating 
an important role of the IL23/IL-17 pathway in axial spondyloarthritis (axSpA) pathogenesis (Baeten et al. 2010, 
2014a; Maksymowych 2010; Barkaliakos et al. 2011; Reveille 2011; Yeremenko et al. 2014).  Pivotal studies of 
secukinumab (Cosentyx®), another IL-17A MAb, have recently demonstrated the efficacy of blocking IL-17A in 
the treatment of radiographic axial spondyloarthritis (rad-axSpA; ankylosing spondylitis [AS]) in biological disease-
modifying antirheumatic drug (bDMARD)-naive as well as in tumor necrosis factor (TNF) inhibitor-experienced 
patients (Sanford and McKeage 2015).
Objective(s)/Endpoints:
Objectives
Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg every 2 weeks [Q2W] or 80 mg every 
4 weeks [Q4W]) versus placebo in patients with active 
radiographic axial spondyloarthritis (rad-axSpA) at 
Week 16.

Proportion of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS40) response.
Secondary
The major secondary objective is:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo at Week 16

Proportion of patients achieving an ASAS20 
response 

Change from baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) 

Proportion of patients achieving Bath Ankylosing 
Spondylitis Disease Activity Index 50 (BASDAI50)
response

Change from baseline in Bath Ankylosing 
Spondylitis Functional Index (BASFI)

Proportion of patients achieving ASDAS inactive 
disease

Change from baseline in Short Form 36 (SF-36) 
physical component score (PCS)

Change from baseline in ASAS Health Index 
(ASAS HI) 

Change from baseline in magnetic resonance 
imaging (MRI) of the spine (Spondyloarthritis 
Research Consortium of Canada [SPARCC] score).  
(This endpoint applies to MRI addendum only.)

I1F-MC-RHBW(d) Clinical Protocol
Page 11
LY2439821
Summary of Study Design:  
Study I1F-MC-RHBW (RHBW) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-
group, outpatient study examining the efficacy and safety of 2 treatment regimens of ixekizumab, 80 mg Q2W and 
80 mg Q4W subcutaneous (SC), as compared to placebo SC in patients with rad-axSpA, during a 16-week Blinded 
Treatment Dosing Period.
Treatment Groups and Duration:  
Study RHBW has 3 treatment groups during the 16-week Blinded Treatment Dosing Period: ixekizumab 80 mg 
Q4W, ixekizumab 80 mg Q2W, and placebo at 1:1:1 ratio.  All patients randomized to an ixekizumab treatment 
group will receive a starting dose of ixekizumab 80 mg or 160 mg (1:1 ratio) at Week 0 followed by ixekizumab 
80 mg Q4W or Q2W thereafter. All administrations are SC.  Randomization will be stratified by country, baseline 
C-reactive protein (CRP) status (nonelevated or elevated, elevated defined as >5.00 mg/L), and number of prior TNF
inhibitors used (1 or 2).  At Week 16, placebo patients will be rerandomized at a 1:1 ratio to ixekizumab 80 mg 
Q2W or Q4W. All patients will be on an ixekizumab regimen for the Extended Treatment Period (Weeks 16 to 52).  
The study duration will be up to 1 year for ixekizumab administration, and up to 1 year and approximately 4 months 
for study participation over 4 periods ([1] Screening Period:  up to 42 days; [2] Blinded Treatment Dosing Period:  
16 weeks; [3] Extended Treatment Period:  36 weeks; [4] Post-Treatment Follow-Up Period:  at least 12 weeks after 
the date of the patient’s early termination visit [ETV] or last regularly scheduled visit).  Patients who complete 
Study RHBW may have the opportunity to continue into a long-term study instead of the Post-Treatment Follow-Up 
Period.
Study Population:
This study will include approximately 300 randomized patients. Patients are eligible to be included in the study if 
they have an established diagnosis of rad-axSpA with sacroiliitis defined radiographically according to the modified 
New York (mNY) criteria, based on central reading, associated with ≥1 spondyloarthritis (SpA) feature, and have 
active disease defined as BASDAI ≥4 and back pain ≥4 on a numeric rating scale (NRS).  Patients must have had an 
inadequate response, as determined by the investigator, to 2 or more nonsteroidal anti-inflammatory drugs 
(NSAIDs) at the therapeutic dose range (for a total duration of at least 4 weeks) and a history of prior rad-axSpA 
therapy for at least 3 months.  Patients must also have a history of prior TNF inhibitor therapy use for at least 3 
months or intolerance to TNF inhibitor.  Only TNF inhibitor-experienced patients can be enrolled.  Prior use of 
maximum 2 TNF inhibitors will be allowed.
Statistical Analysis:
Approximately 300 patients will be randomized at a 1:1:1 ratio in the Blinded Treatment Dosing Period to 
ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W, and placebo.  With 100 patients per treatment group, this study 
will have approximately 96% power to test the superiority of ixekizumab Q2W to placebo for the ASAS40 at 
Week 16.  The following assumptions were used for the power calculations for ASAS40 response rates at Week 16
regardless of ixekizumab starting dose:  27% for ixekizumab Q2W treatment group and 7% for placebo group.  A 
2- sided Fisher’s exact test at the 0.05 level is assumed.  The efficacy analyses for the Blinded Treatment Dosing 
Period will be conducted on the intent-to-treat (ITT) population, and safety analyses will be conducted on the safety 
population.  
Comparisons between each ixekizumab treatment group (80 mg Q2W or 80 mg Q4W) and placebo will be 
performed for all analyses in the Blinded Treatment Dosing Period.  Unless otherwise specified, ixekizumab 80 mg 
Q2W and Q4W groups will be analyzed without regard to starting dose.  The primary analysis method for treatment 
group comparisons of categorical efficacy and health outcomes variables will be a logistic regression analysis with 
treatment, geographic region, baseline CRP status (nonelevated or elevated), and prior number of TNF inhibitor
used (1 or 2) as factors, using the nonresponder imputation (NRI) method.  Under NRI, all nonresponders at Week 

I1F-MC-RHBW(d) Clinical Protocol
Page 12
LY2439821
16 (Visit 8), as well as all patients who discontinue study treatment at any time prior to Week 16 for any reason, will 
be defined as nonresponders for the NRI analysis at Week 16.  Randomized patients without any postbaseline 
observation will also be defined as nonresponders for the NRI analysis.  A graphical multiple testing strategy for the 
primary and major secondary objectives will be implemented to control the family-wise type I error rate at a 2-sided
α level of 0.05.  
The primary analyses for the continuous efficacy and health outcomes variables will be made using mixed-effects 
model of repeated measures (MMRM) analysis with treatment, geographic region, baseline CRP status, prior 
number of TNF inhibitor used, baseline value, visit, baseline value-by-visit, and treatment-by-visit as fixed factors.
A secondary analysis for continuous efficacy and health outcomes variables will be made using analysis of 
covariance (ANCOVA) with treatment, geographic region, baseline CRP status, baseline value, and number of prior 
TNF inhibitors in the model.
Fisher’s exact test will be used for all adverse events (AEs), baseline, discontinuation, and other categorical safety 
data.  Continuous vital sign and laboratory values will be analyzed by ANCOVA with treatment and baseline values
in the model.
Efficacy, health outcomes, and safety variables during the Extended Treatment Period will also be summarized.

I1F-MC-RHBW(d) Clinical Protocol
Page 13
LY2439821
2.
Introduction
2.1.
Background
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the 
axial skeleton (sacroiliac joints [SIJ] and spine) (Poddubnyy 2013).  AxSpA is now recognized 
as a single disease entity, with a subset defined by the presence of radiographically defined 
structural damage of the SIJ (rad-axSpA) and a subset without clear structural damage defined 
radiographically (nonrad-axSpA).  When comparing axSpA with rheumatoid arthritis (RA), it 
can be noted that while RA can be divided into erosive and nonerosive or seropositive and 
seronegative subsets, it is well accepted that it is still one disease.  AxSpA, in a similar fashion, 
also has subsets, and thus can be considered a single disease (Deodhar et al. 2014).
Radiographic axSpA (rad-axSpA), formerly called ankylosing spondylitis (AS), represents a 
disease in which there is evidence of disease features on radiographic imaging.  It is a chronic 
inflammatory disease characterized by chronic inflammation of the axial and SIJ and variable 
involvement of the peripheral joints (Braun and Sieper 2007).  As the disease progresses, it can 
lead to new bone formation in the form of syndesmophytes and joint ankylosis, primarily in the 
axial skeleton.  Patients with rad-axSpA may also have extra-articular manifestations of the 
disease such as enthesitis, anterior uveitis, psoriasis, and inflammatory bowel disease (IBD), as 
well as comorbidities of aortitis or cardiac conduction abnormalities.  Compared with the general 
population, patients with rad-axSpA have increased rates of work disability, unemployment, and 
mortality (Boonen and van der Linden 2006).
AxSpA affects up to 1.4% of the adult population worldwide (Braun and Sieper 2007; Reveille et 
al. 2012; Strand et al. 2013).  Although the exact etiology is unknown, it has been indicated that 
genetic factors and several loci are likely to be involved in susceptibility to the disease (Reveille 
2011).  There is a strong association with the major histocompatibility complex, human 
leukocyte antigen (HLA)-B27.  About 90% to 95% of patients with rad-axSpA are positive for 
HLA-B27, and the risk of this disease developing is as high as about 5% in HLA-B27-positive 
individuals and substantially higher in HLA-B27-positive relatives of patients (Braun and Sieper 
2007).  Most of the other known genetic susceptibility comes from genes involved in cytokine 
production, specifically including genes in the T helper (Th)17 pathway (Maksymowych 2010; 
Reveille 2011).
Current standard of care for rad-axSpA includes regular exercise, physical therapy, nonsteroidal 
anti-inflammatory drugs (NSAIDs), and tumor necrosis factor (TNF) alpha inhibitors (Braun et 
al. 2011; Ward et al. 2015).  Corticosteroid injections may also be of some benefit.  Though 
NSAIDs are the first line of drug treatment for axSpA, they are not effective or well tolerated in 
all patients (Braun and Sieper 2009).  In contrast to patients with RA, patients with axSpA do not 
respond well to conventional disease-modifying antirheumatic drugs (cDMARDs) including 
methotrexate (MTX) or systemic corticosteroids (Braun and Sieper 2009; Haibel and Specker 
2009).
Tumor necrosis factor inhibitors are effective and frequently prescribed when NSAID treatment 
has failed or cannot be tolerated (Zochling et al. 2006).  While TNF inhibitors have proven to be 

I1F-MC-RHBW(d) Clinical Protocol
Page 14
LY2439821
effective treatments for axSpA, an unmet need remains, as not all patients respond well to or 
tolerate TNF inhibitor treatments (van der Heijde et al. 2006; Heiberg et al. 2008; Inman et al. 
2008; Glintborg et al. 2010).  While TNF inhibitors have demonstrated significant impact on 
signs and symptoms, function, and quality of life, they have not been able to demonstrate 
significant effect on structural progression in prospective clinical studies. The use of these 
biologic therapies in various diseases also is associated with safety concerns, such as
opportunistic infections, demyelinating disorders, blood dyscrasias, reactivation of tuberculosis 
(TB), and exacerbation of congestive heart failure (Moreland 2005; Smith et al. 2009).  There 
remains, therefore, a significant unmet need for safer, more effective treatments for patients with 
axSpA (Dougados and Baeten 2011).  Ixekizumab may offer an alternative treatment approach to 
TNF inhibitor therapy in patients with axSpA.
Ixekizumab (LY2439821) is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal 
antibody (MAb) that neutralizes the cytokine interleukin-17A (IL-17A, also known as IL-17).  
Ixekizumab treatment is administered by subcutaneous (SC) injections.  Compelling scientific 
information exists to date suggesting an important role of the IL-23/IL-17 pathway in the 
pathogenesis of axSpA (Baeten et al. 2010, 2014a; Maksymowych 2010; Baraliakos et al. 2011; 
Reveille 2011; Yeremenko et al. 2014).  The demonstration of increased IL-17 producing Th17 
lymphocyte numbers and serum IL-17 levels in rad-axSpA is consistent with a direct role of 
Th17 lymphocytes in this disease (Wendling et al. 2007; Jandus et al. 2008; Mei et al. 2011).  
IL-17 secreting cells have also been detected in situ in the bone marrow of facet joints obtained 
from patients with rad-axSpA (Appel et al. 2008). 
Selectively targeting IL-17A with ixekizumab is hypothesized to provide therapeutic benefit 
without unduly impacting host defenses.  As such, ixekizumab may offer a therapeutic option for 
patients who are candidates for initial systemic treatment as well as those patients who have lost 
response, failed to respond, or are intolerant to currently marketed drugs, and may also offer a 
more favorable safety profile compared to currently marketed therapies.
2.2.
Study Rationale
Eli Lilly and Company (hereafter Lilly) is investigating ixekizumab as a treatment option for rad-
axSpA based on its mechanism of action (MoA), selectively blocking IL-17A (detailed in the 
Investigator’s Brochure [IB]).  The following 2 SC ixekizumab treatment regimens will be 
studied in this trial: 80 mg every 4 weeks (Q4W) or 80 mg every 2 weeks (Q2W).  Starting 
doses of 80 mg and 160 mg (at Week 0) will be evaluated for each ixekizumab regimen.  A wide 
range of dosing regimens were evaluated in Phase 2 psoriasis and RA studies and demonstrated 
efficacy.  The 80 mg Q2W and Q4W treatment regimens with a 160 mg starting dose were 
evaluated in pivotal Phase 3 studies in psoriasis and psoriatic arthritis (PsA) and demonstrated 
efficacy, with a favorable benefit/risk profile (Gottlieb et al. 2015; Griffiths et al. 2015; Mease et 
al. 2015). Recently disclosed data from Phase 3 studies with secukinumab (Cosentyx®), a drug 
with a similar MoA as ixekizumab, selectively inhibiting IL-17A, have demonstrated the 
effectiveness of inhibiting IL-17A in patients with rad-axSpA who were biological disease-
modifying antirheumatic drug (bDMARD)-naive or had previously received anti-TNF agents 
(Sanford and McKeage 2015).

I1F-MC-RHBW(d) Clinical Protocol
Page 15
LY2439821
3.
Objectives and Endpoints
Table RHBW.1 shows the objectives and endpoints of the study.
Table RHBW.1.
Objectives and Endpoints
Objectives
Endpoints
Primary
The primary objective is to compare both ixekizumab 
regimens (80 mg Q2W or 80 mg Q4W) versus placebo 
in patients with active rad-axSpA at Week 16.

Proportion of patients achieving an Assessment of 
Spondyloarthritis International Society 40 
(ASAS40) response 
Secondary
The major secondary objective is:
To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo at Week 16

Proportion of patients achieving an ASAS20 
response 

Change from baseline in Ankylosing Spondylitis 
Disease Activity Score (ASDAS) 

Proportion of patients achieving Bath Ankylosing 
Spondylitis Disease Activity Index 50 (BASDAI50) 
response

Change from baseline in Bath Ankylosing 
Spondylitis Functional Index (BASFI)

Proportion of patients achieving ASDAS inactive 
disease

Change from baseline in Short Form 36 (SF-36) 
physical component score (PCS)

Change from baseline in ASAS Health Index 
(ASAS HI)

Change from baseline in magnetic resonance 
imaging (MRI) of the spine (Spondyloarthritis 
Research Consortium of Canada [SPARCC] score).  
(This endpoint applies to MRI addendum only.)

I1F-MC-RHBW(d) Clinical Protocol
Page 16
LY2439821
Objectives
Endpoints
Other secondary objectives are:

To compare both ixekizumab regimens (80 mg 
Q2W or 80 mg Q4W) to placebo during the 16-
week placebo-controlled period (Period 2)

Proportion of patients who achieve ASAS20, 
ASAS40, ASAS 5/6, and partial remission by 
ASAS criteria

Change from baseline in the individual components 
of the ASAS criteria

Change from baseline in BASDAI

Proportion of patients reaching BASDAI50

Change from baseline in ASDAS

Proportion of patients who experience clinically-
important improvement (change of ASDAS from 
baseline ≥1.1), major improvement (change of 
ASDAS from baseline ≥2.0), or inactive disease 
(ASDAS score <1.3)

Change from baseline in the measure of high 
sensitivity C-reactive protein (CRP)

Change from baseline in BASFI

Change from baseline in mobility
o
Bath Ankylosing Spondylitis Metrology 
Index (BASMI) (linear) and individual 
components
o
Chest expansion
o
Change from baseline in occiput to wall 
distance

Change from baseline in Maastricht Ankylosing 
Spondylitis Enthesitis Score (MASES)

Change from baseline in SPARCC Enthesitis Score

Change from baseline in MRI of the spine 
(Ankylosing Spondylitis Spinal Magnetic 
Resonance Imaging activity–Berlin Score 
[ASSpiMRI-Berlin]; this endpoint applies to MRI 
addendum only)  

Incidence and severity of peripheral arthritis by 
tender (TJC) and swollen joint count (SJC) scores of 
46/44 joints

Incidence rate of anterior uveitis or uveitis flares

Change from baseline in the following health 
outcomes measures: Fatigue Numeric Rating Scale 
(NRS) score, ASAS HI score, Jenkins Sleep 
Evaluation Questionnaire (JSEQ), Work 
Productivity Activity Impairment–Spondyloarthritis 
(WPAI-SpA) scores, SF-36 (both PCS and mental 
component scores [MCS]), and Quick Inventory of 
Depressive Symptomatology–Self-Report (16 
Items) (QIDS-SR16) score

I1F-MC-RHBW(d) Clinical Protocol
Page 17
LY2439821
Objectives
Endpoints
To determine if the effectof either ixekizumab 
regimen is maintained through Week 52
All endpoints assessed at Week 16 (above) and during 
the 16-week placebo-controlled period (above) will 
continue to be assessed through Week 52 (with the 
exception of MRI-related endpoints).
In addition,the following endpoint is added:
NSAID intake (ASAS-NSAID scoreand % of 
patients taking NSAIDs)
To explore effect of starting dose (160 mg 
comparedto 80 mg)
Onset of action and treatment response (ASAS, 
ASDAS, CRP, BASFI) during the placebo-
controlled period
To evaluate the incidence of anti-ixekizumab 
antibodies and theirrelationship to the efficacy of 
ixekizumab 
Efficacy response rates listedbelow at Weeks 16 
and 52 by treatment-emergent anti-drug antibody 
(TE-ADA) status and by neutralizing anti-drug 
antibody (NAb) status:
o Proportion of patients achieving ASAS40
o Proportion of patientsachieving ASAS20
o Proportion of patients achieving ASDAS 
inactive disease
To measure ixekizumab exposure and assess the 
relationship between exposure and efficacy, and 
exposure and immunogenicity
Serum trough concentrations of ixekizumab
Model parameters for the exposure-response 
relationship between ixekizumab serum trough 
concentrations and efficacy endpoints (for example, 
ASAS20, ASAS40) at Weeks16 and/or 52
Ixekizumabserum trough concentrations associated 
with ADA titer sub groups
CCI

I1F-MC-RHBW(d) Clinical Protocol
Page 18
LY2439821
4.
Study Design
4.1.
Overview of Study Design
Study I1F-MC-RHBW (RHBW) is a Phase 3, multicenter, randomized, double-blind, placebo-
controlled, parallel-group, outpatient study examining the efficacy and safety of 2 ixekizumab 
treatment regimens (80 mg Q2W and 80 mg Q4W SC), as compared to placebo SC in patients 
with active rad-axSpA who are TNF inhibitor-experienced, during a double-blind, 16-week 
treatment period (Period 2). Starting doses of 80 mg and 160 mg (at Week 0) will be evaluated 
for each ixekizumab regimen. 
Study RHBW will also evaluate long-term efficacy and safety of ixekizumab during the 
Extended Treatment Period (Period 3) for a total treatment duration of 1 year (52 weeks).  
Patients that complete Study RHBW may be eligible to enroll into a long-term study (Study I1F-
MC-RHBY [RHBY]) for up to 2 additional years.  Patients that do not enroll into Study RHBY 
will complete the Post-Treatment Follow-Up Period (Period 4) in Study RHBW.
Figure RHBW.1 illustrates the study design; all treatment groups and administration of the 
investigational product are described in Section 6.1; and the Study Drug Administration Log is 
described in Section 6.2.1.
All procedures to be conducted during the study, including timing of all procedures, are indicated 
in the Schedule of Activities (Appendix 2).  Selected study procedures are to be performed prior 
to administration of the investigational product, as applicable.  
For each patient, x-rays will be collected according to Section 8.1.2.20.1 and the Schedule of 
Activities (Appendix 2).  Appendix 3 lists the specific laboratory tests that will be performed for 
this study. 
Patients discontinuing from study treatment who have received at least 1 dose of investigational 
product will continue to the early termination visit (ETV) prior to proceeding to the Post-
Treatment Follow-Up Period.  For the management of patient safety, all patients are to be 
monitored through the Post-Treatment Follow-Up Period at least as frequently as indicated in the 
Schedule of Activities (Appendix 2).
In addition to procedures specified in the protocol, a subset of patients (approximately 150) will 
participate in an MRI addendum. (Sites will be selected by the sponsor, and all patients at those 
sites will be required to participate in the addendum, as long as they satisfy MRI inclusion 
criteria.)
Excluded and concomitant medications are detailed in Section 6.8.
Pharmacokinetic (PK) sampling is detailed in Section 8.5.
Section 9.8 outlines the information regarding the interim analyses including the primary 
database lock at Week 16.

I1F-MC-RHBW(d) Clinical Protocol
Page 19
LY2439821
Abbreviations:  LV = last visit; LY = ixekizumab; n = number of patients; Q2W = every 2 weeks; Q4W = every 4 weeks; SC = subcutaneous; V = study visit; W 
= study week.
a
All patients will receive 2 injections at baseline, as detailed in Section 6.1.  Patients randomized to an ixekizumab regimen will be randomized to a 160 mg 
starting dose or 80 mg starting dose at a 1:1 ratio (within each ixekizumab regimen).
b
All patients will receive 2 injections at Week 16, as detailed in Section 6.1.  Patients randomized to placebo at Week 0 will begin ixekizumab 80 mg Q4W or 
ixekizumab 80 mg Q2W at Week 16 with a 160 mg starting dose (Section 6.1).
c
Patients who discontinue from study treatment for any reason and who have received at least 1 dose of investigational product will continue to the early 
termination visit (ETV) before entering the Post-Treatment Follow-Up Period.  V801 and V802 are required for all patients; V803 may be needed depending 
on neutrophil counts (Section 8.4.10.1).
Figure RHBW.1.
Illustration of study design for Clinical Protocol I1F-MC-RHBW.

I1F-MC-RHBW(d) Clinical Protocol
Page 20
LY2439821
4.2.
End of Trial Definition
End of trial is the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities (Appendix 2) for the last patient in the trial.
4.3.
Scientific Rationale for Study Design
Two treatment regimens of ixekizumab 80 mg (Q2W and Q4W) will be studied as detailed in 
Section 6.1, and the effect of an 80 mg and a 160 mg starting dose will be evaluated for 
treatment outcomes.  Dose justification is outlined in Section 4.4.  The study blind is maintained 
as described in Section 6.3.
The placebo-controlled Blinded Treatment Dosing Period (Period 2) is designed to minimize bias 
in the evaluation of ixekizumab in patients with rad-axSpA for both efficacy and safety.  All 
patients may still receive treatment in the form of the allowed concomitant medications as 
described in the study inclusion and exclusion criteria (Sections 5.1 and 5.2) and concomitant 
therapy (Section 6.8).  Patients can be discontinued from study treatment at any time by 
investigator or patient decision if they are considered to be receiving insufficient benefit from 
study treatment (Section 7.1.1).
As of Week 16 (after completion of Period 2), investigators are allowed to adjust some 
concomitant medications, if needed, as specified in Section 6.8, across all treatment groups.
Patients originally assigned to placebo during Period 2 will be rerandomized at a 1:1 ratio to 
ixekizumab 80 mg Q2W or Q4W with a 160 mg starting dose at Week 16.  
Ixekizumab 80 mg Q2W and 80 mg Q4W treatment regimens are continued beyond Week 16 to 
further assess safety and efficacy during the Extended Treatment Period (Period 3).
The effectiveness of ixekizumab in treating rad-axSpA will be assessed primarily by the 
ASAS40 response rate at Week 16.  ASAS20 response will also be assessed at Week 16.  These 
measures and the Week 16 endpoint are in alignment with efficacy endpoints for currently 
approved rad-axSpA therapies and with regulatory guidance (EMA 2009).  Steady state exposure 
of ixekizumab is expected to be reached by Week 16.  Based on previous studies with 
ixekizumab in patients with psoriasis, RA, and PsA, it is anticipated that maximum or near 
maximum clinical effect in rad-axSpA will be achieved within this timeframe for both 
ixekizumab treatment regimens.  
Baseline CRP has been reported as a predictor of response in patients with rad-axSpA treated 
with TNF inhibitors (Inman et al. 2008; de Vries et al. 2009; Sieper et al. 2011; Vastesaeger et al. 
2011); hence, by including it as a stratification factor, it ensures balance in baseline CRP levels,
resulting in greater comparability across treatment groups at baseline.  Similarly, the number of 
prior TNF inhibitors used has been reported to potentially impact response rates of subsequently 
used biologics (Lie et al. 2011; Glintborg et al. 2013); therefore, patients will also be stratified 
based on the number of prior TNF inhibitors used (1 or 2).
The Extended Treatment Period (Period 3) will permit collection of data for the assessments of 
maintenance of efficacy and long-term safety with ixekizumab.

I1F-MC-RHBW(d) Clinical Protocol
Page 21
LY2439821
The Post-Treatment Follow-Up Period (Period 4) isimportantfor safety and efficacy monitoring 
following administration of the last study treatment.
4.4. Justificationfor Dose
Lilly considers it appropriate to evaluate 2 treatmentregimens in Study RHBWto enable 
appropriate evaluation of the relative benefit/risk associated with continuous ixekizumabtherapy
in axSpA. 
As referred to above, the current internal (ixekizumab) and external (TNFinhibitorsand 
secukinumab) scientific data in this area support the rationale for studying ixekizumab in patients 
with rad-axSpA with the proposed treatmentregimens.
4.5. Benefit/Risk Assessment
CCI
More information about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably anticipated adverse events (AEs) of ixekizumab are to be found in the IB. 

I1F-MC-RHBW(d) Clinical Protocol
Page 22
LY2439821
5.
Study Population
The study population will include patients with active rad-axSpA (with sacroiliitis defined 
radiographically according to the modified New York [mNY] criteria, based on central reading, 
associated with at least 1 SpA feature [Appendix 5]), who have given written informed consent.
Study investigator(s) will review patient history and screening test results from Visit 1 (all 
criteria) and Visit 2 as per the Schedule of Activities (Appendix 2) to determine if the patient 
meets all inclusion and none of the exclusion criteria to qualify for participation in the study.  All
screening activities must be completed and reviewed before the patient is randomized.  Patients 
may be rescreened in the circumstances described in Section 5.3.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.
In this protocol section, the following definitions apply:

Screening is defined as Visit 1, up to 42 days prior to baseline randomization.

Baseline randomization visit is defined as Visit 2 (Week 0).
5.1.
Inclusion Criteria
Patients are eligible to be included in the study only if they meet all of the following criteria at 
screening or as specified:
Type of Patient and Disease Characteristics
[1]
Have an established diagnosis of rad-axSpA with sacroiliitis defined 
radiographically according to the mNY criteria (van der Linden et al. 1984) 
based on central reading: sacroiliitis grade ≥2 bilaterally or grades 3 to 4 
unilaterally.
AND
At least 1 SpA feature, according to ASAS criteria (Rudwaleit et al. 2009; 
Sieper et al. 2009), listed in Appendix 5.
[2]
Patients have a history of back pain ≥3 months with age at onset <45 years.
[3]
Have active rad-axSpA defined as BASDAI ≥4 and total back pain ≥4 (Sieper 
et al. 2009, Box 25 Spinal Pain) on an NRS at screening and baseline.
[4]
Have had prior treatment with at least 1 and not more than 2 TNF 
inhibitors. The patient must have discontinued at least 1 TNF inhibitor due to 
either intolerance or an inadequate response (defined as:  In the opinion of the 
investigator, the patient had an inadequate response to at least 12 weeks of 
treatment with a TNF inhibitor at an adequate dose).
Note: The following washout periods prior to baseline randomization must be 
followed:  etanercept ≥28 days; infliximab, adalimumab, or certolizumab 
pegol ≥60 days; golimumab ≥90 days.

I1F-MC-RHBW(d) Clinical Protocol
Page 23
LY2439821
[5]
Must have had an inadequate response, as determined by the investigator, to 2 
or more NSAIDs at the therapeutic dose range for a total duration of at least 
4 weeks OR have a history of intolerance to NSAIDs.  
[6]
Patients must have a history of prior therapy for axSpA of at least 12 weeks 
prior to screening.  Examples of prior therapy may include but are not limited 
to physical therapy, NSAID, and TNF inhibitor treatment.
[7]
If taking NSAIDs or cyclooxygenase-2 (COX-2) inhibitors, the dose must be 
stable for at least 2 weeks prior to baseline randomization.
Patient Characteristics
[8]
Are ambulatory male or female patients ≥18 years of age at time of screening.
[9]
Must agree to use a reliable method of birth control:

If a male patient, patient agrees to use a reliable method of birth control 
during the study and for at least 12 weeks following the last dose of 
investigational product, whichever is longer.  Methods of birth control 
include, but are not limited to, condoms with spermicide and male 
sterilization.
OR

If a female patient is a woman of childbearing potential who tests negative 
for pregnancy and agrees to use a reliable method of birth control or 
remain abstinent during the study and for at least 12 weeks following the 
last dose of investigational product, whichever is longer.  Methods of 
contraception include, but are not limited to:  oral contraceptives, 
contraceptive patch, injectable or implantable contraceptives, intrauterine 
device, vaginal ring, diaphragm with contraceptive gel, or condom with 
contraceptive foam.
OR

If a female patient is a woman of nonchildbearing potential, she is not 
required to use any method of birth control. Nonchildbearing potential is 
defined as:  
Women who have had surgical sterilization (hysterectomy or 
bilateral oophorectomy or tubal ligation)  
-
or -
Women who are ≥60 years of age  
-
or -
Women ≥40 and <60 years of age who have had a cessation of 
menses for ≥12 months and a follicle stimulating hormone (FSH) 
test confirming nonchildbearing potential (≥40 mIU/mL or 
≥40 IU/L).

I1F-MC-RHBW(d) Clinical Protocol
Page 24
LY2439821
Informed Consent
[10] Have given written informed consent approved by Lilly, or its designee, and 
the Investigational Review Board (IRB)/Ethical Review Board (ERB)
governing the site.
5.2.
Exclusion Criteria
Patients will be excluded from study enrollment if they meet any of the following criteria at
screening or as specified:
Medical Conditions
[11] Have total ankylosis of the spine, as assessed locally, based on lateral 
radiographs of the cervical and lumbar spine.
[12] Have a history of other systemic inflammatory diseases (such as but not 
limited to lupus, vasculitis, or RA) or other chronic pain conditions (such as 
but not limited to fibromyalgia) that might confound the evaluations of benefit 
from ixekizumab therapy.  
Note:  Patients with psoriasis that have never received and do not require 
systemic treatment for psoriasis, such as, but not limited to, oral agents or 
biologic therapies, can be included provided these patients fulfill the entry 
criteria.
[13] Have active Crohn’s disease (CD) or active ulcerative colitis (UC).  
Note:  Patients may be enrolled if they have had a history of IBD, including 
CD and UC, but have had no exacerbation for ≥6 months prior to baseline 
randomization and, if currently on treatment, must be on stable treatment for 
≥6 months prior to baseline randomization.
[14] Have evidence of active anterior uveitis (an acute episode) within the last 4
weeks prior to baseline randomization.
Note:  These patients may be rescreened only one time ≥4 weeks after 
resolution of acute symptoms.
[15] Have current or a history of lymphoproliferative disease, or signs or 
symptoms of lymphoproliferative disease, within 5 years prior to baseline 
randomization; or have active or history of malignant disease within 5 years 
prior to baseline randomization. 
[16] Have a history of fluid overload, myocardial infarction (MI), uncompensated 
heart failure, or evidence of new-onset ischemic heart disease, or in the 
opinion of the investigator, other serious cardiac disease, within 12 weeks 
prior to baseline randomization.  

I1F-MC-RHBW(d) Clinical Protocol
Page 25
LY2439821
[17] Presence of significant uncontrolled cerebrocardiovascular events (for 
example, unstable angina, unstable arterial hypertension, moderate-to-severe 
heart failure [New York Heart Association class III/IV], or cerebrovascular 
accident) at screening that, in the opinion of the investigator, pose an 
unacceptable risk to the patient if participating in the study or of interfering 
with the interpretation of data. 
[18] Presence of any comorbid respiratory, hepatic, renal, gastrointestinal, 
endocrine, hematologic disorders, at screening that, in the opinion of the 
investigator, pose an unacceptable risk to the patient if participating in the 
study or of interfering with the interpretation of data.
[19] Presence of any neurologic or neuropsychiatric disorders at screening that, in 
the opinion of the investigator, poses an unacceptable risk to the patient if 
participating in the study or of interfering with the interpretation of data.
[20] Presence of significant uncontrolled neuropsychiatric disorder; have recent 
history (within 30 days prior to screening visit [Visit 1] and any time between 
screening visit [Visit 1] and baseline randomization [Visit 2]) of a suicide 
attempt; or have a score of 3 on Item 12 (Thoughts of Death or Suicide) of the 
Quick Inventory of Depressive Symptomatology–Self-Report (16 Items) 
(QIDS-SR16) at screening or baseline randomization; or are clinically judged 
by the investigator to be at risk for suicide. 
[21] Exclusion criterion [21] has been deleted.
[22] Patients who have:

in the past 12 weeks prior to baseline randomization:
o
had a serious infection (for example, pneumonia, cellulitis), 
o
have been hospitalized for an infection,
o
or have received intravenous (IV) antibiotics for an infection, 

or in the past 24 weeks prior to baseline randomization had a serious bone 
or joint infection

or have ever had, 
o
an infection of an artificial joint, 
o
an infection that occurs with increased incidence in an 
immunocompromised host (including, but not limited to, 
Pneumocystis jirovecii pneumonia, symptomatic histoplasmosis, or 
coccidioidomycosis)
[23] Have a known immunodeficiency or are immunocompromised to an extent 
such that participation in the study would pose an unacceptable risk to the 
patient.

I1F-MC-RHBW(d) Clinical Protocol
Page 26
LY2439821
[24] Have or had a herpes zoster or any other clinically apparent varicella-zoster 
virus infection within 12 weeks of baseline randomization.
[25] Have any other active or recent infection within 4 weeks of baseline 
randomization that, in the opinion of the investigator, would pose an 
unacceptable risk to the patient if participating in the study.
Note:  These patients may be rescreened one time ≥4 weeks after resolution of 
symptoms.
[26] Have a known allergy or hypersensitivity to any biologic therapy that would 
pose an unacceptable risk to the patient if participating in this study.  
[27] Have had surgical treatment of a joint that is to be assessed in the study within 
8 weeks prior to baseline randomization or will require surgical treatment of a 
joint that is to be assessed in the study during the first 16 weeks of the trial.  
[28] Have had any major surgery within 8 weeks prior to baseline randomization or 
will require major surgery during the study that, in the opinion of the 
investigator and in consultation with Lilly or its designee, would pose an
unacceptable risk to the patient.
Prior/Concurrent Therapy or Clinical Trial Experience
[29] Have received cDMARDs and/or other therapies such as, but not limited to:  
gold salts, cyclosporine, azathioprine, dapsone, 6-mercaptopurine, 
mycophenolate mofetil, or any other immunosuppressive agents within
4 weeks prior to baseline randomization.
Exception: MTX (oral or parenteral up to 25 mg/week), sulfasalazine (up to 
3 g/day), or hydroxychloroquine (up to 400 mg/day) may be allowed IF at 
stable dose for at least 4 weeks prior to baseline randomization
AND
if used, must not be in any combination with other cDMARDs.
Note: If MTX is used, local standard of care is to be followed for concomitant 
administration of folic or folinic acid with MTX.
[30] Use of oral corticosteroids >10 mg/day prednisone or its equivalent.
Note: If patients are taking prednisone or its equivalent and the dose is 
≤10 mg/day, the dose must be stable for at least 4 weeks prior to baseline 
randomization.
[31] Have received any prior, or are currently receiving, treatment with biologic or 
other immunomodulatory agents, including investigational therapies (such as 
but not limited to Janus kinase (JAK) inhibitors, IL-1, IL-6, IL-23, IL-17
[including ixekizumab], IL-17R, T cell, or B cell targeted therapies).
Note:  Previous TNF inhibitor therapy is permitted.

I1F-MC-RHBW(d) Clinical Protocol
Page 27
LY2439821
[32] Are currently enrolled in, have participated, or discontinued from a clinical
trial involving an investigational product or nonapproved use of a drug or
device within the last 30 days prior to screening or a period of at least 5 half-
lives of the last administration of the drug, whichever is longer.
Note:  Investigational products that are biologic or other immunomodulatory 
agents are not permitted, regardless of washout period (described in criterion
above).
[33] Are currently enrolled in any other clinical trial involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this study.
[34] Are currently receiving or have received treatment with denosumab within 
6 months prior to baseline randomization.
[35] Have received any parenteral glucocorticoid administered by intra-articular, 
intramuscular, or IV injection within 6 weeks prior to baseline randomization, 
or for whom a parenteral injection of glucocorticosteroids is anticipated 
during the Blinded Treatment Dosing Period (Period 2) of the study.  
[36] Use of any opiate analgesic at average daily doses >30 mg/day of morphine or 
its equivalent, or use of variable doses of any opiate analgesic within 6 weeks 
prior to baseline randomization.
[37] Had a live vaccination within 12 weeks prior to baseline randomization, or 
intend to have a live vaccination during the course of the study or within 
12 weeks of completing treatment in this study, or have participated in a 
vaccine clinical study within 12 weeks prior to baseline randomization.  
Investigators are to review the vaccination status of their patients and follow 
the local guidelines for adult vaccination with nonlive vaccines intended to 
prevent infectious disease prior to therapy.  
Note:  Killed/inactive or subunit vaccines are expected to be safe; however, 
their efficacy with concomitant ixekizumab treatment is unknown.
[38] Had a vaccination with Bacillus Calmette-Guérin (BCG) within 12 months 
prior to baseline randomization, or intend to have this vaccination with BCG 
during the course of the study or within 12 months of completing treatment in 
this study.
Diagnostics Assessments
[39] Have a body temperature ≥38°C (100.5°F) at baseline randomization.  
Note: These patients may be rescreened one time ≥4 weeks after documented 
resolution of elevated temperature.
[40] Have evidence or suspicion of active or latent TB (refer to Section 5.3 for 
rescreening and Section 8.4.6 for details on determining full TB exclusion 
criterion).

I1F-MC-RHBW(d) Clinical Protocol
Page 28
LY2439821
[41] Are positive for human immunodeficiency virus serology (HIV); that is, 
positive for human immunodeficiency virus antibody (HIVAb).  
[42] Have evidence of or test positive for hepatitis B virus (HBV) by testing 
positive for: 1) HBV surface antigen (HBsAg+), OR 2) anti-hepatitis B core 
antibody positive (HBcAb+) and are HBV DNA positive.
Note:  Patients who are HBcAb+ and HBV DNA negative may be enrolled in 
the study.  Patients who meet these criteria at screening will be identified by 
the central laboratory and monitored during the study as detailed in 
Section 8.4.10.2.
[43] Have evidence of or test positive for hepatitis C virus (HCV).  A positive test 
for HCV is defined as:  1) positive for hepatitis C antibody (anti–HCV Ab) 
and 2) positive via a confirmatory test for HCV (for example, 
HCV-polymerase chain reaction).
[44] Have electrocardiogram (ECG) abnormalities that are considered clinically 
significant and would pose an unacceptable risk to the patient if participating 
in the study.  
Laboratory tests may not be repeated unless there is a technical error or clinical reason to 
believe a result may need to be retested within the screening period. Laboratory tests can be 
repeated a maximum of 1 time, and results must be received and reviewed prior to 
randomization. For eligibility, the most recent lab panel must not meet any of the following 
criteria:
[45] At screening, have a neutrophil count <1500 cells/μL (<1.50x103/µL or 
<1.50 GI/L).  
[46] At screening, have a lymphocyte count <800 cells/μL (<0.80x103/µL or 
<0.80 GI/L).  
[47] At screening, have a platelet count <100,000 cells/μL (<100x103/µL or 
<100 GI/L).  
[48] At screening, have aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) >2.5 times the upper limit of normal (>2.5xULN).
[49] At screening, have a total white blood cell (WBC) count <3000 cells/μL 
(<3.00x103/µL or <3.00 GI/L).  
[50] At screening, have hemoglobin <8.5 g/dL (85.0 g/L) for male patients and 
<8.0 g/dL (80 g/L) for female patients.  
[51] Have other clinical laboratory test results at screening that are outside the 
normal reference range for the population and are considered clinically 
significant, per investigator assessment. 

I1F-MC-RHBW(d) Clinical Protocol
Page 29
LY2439821
Other Exclusions
[52] Have donated blood >450 mL within the last 4 weeks prior to screening, or 
intend to donate blood during the course of the study.
Note: Patients who have donated blood may be rescreened one time ≥4 weeks
have passed since initial screening.
[53] Are women who are lactating or breastfeeding.
[54] Are investigator site personnel directly affiliated with this study and/or their 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally adopted.
[55] Are Lilly employees or its designee or are employees of third-party 
organizations involved in the study.
[56] Are unwilling or unable to comply with the use of a data collection device to 
directly record data from the patient.
[57] Have any other condition that precludes the patient from following and 
completing the protocol, in the opinion of the investigator.
[58] This criterion is applicable only to patients enrolled in the MRI subgroup and 
was assigned in a Protocol Addendum.
[59] Do not meet the enrollment requirements for the open cohort once the other 
cohorts have closed (Section 6.2).
5.3.
Screen Failures
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened in the following circumstances: Patients who test positive for latent TB at screening 
may be rescreened following appropriate treatment as described in Section 8.4.6; patients who do 
not qualify at screening under Exclusion Criteria [14], [25], [39], or [52] may be rescreened one 
time, ≥4 weeks after documented resolution of symptoms or from time of blood donation.
Patients who do not qualify at screening for the elevated CRP cohort and therefore do not qualify 
for the study under Exclusion Criterion [59] may be rescreened once at least 4 weeks after the 
initial screening.  If the CRP is elevated (>5.00 mg/L) during rescreening, patients may be 
enrolled via the elevated CRP cohort, provided all other entry criteria are met.
If a patient is unable to complete all screening procedures within the screening period, the patient 
may be rescreened after consultation with Lilly medical.
When rescreening is performed, the individual must sign a new informed consent form (ICF) and 
will be assigned a new identification number.  To ensure all eligibility criteria are met, all 
screening procedures must be repeated unless previously conducted within timeframes specified 
in the Schedule of Activities (Appendix 2).

I1F-MC-RHBW(d) Clinical Protocol
Page 30
LY2439821
5.4.
Lifestyle and/or Dietary Requirements
Not applicable.

I1F-MC-RHBW(d) Clinical Protocol
Page 31
LY2439821
6.
Treatment
6.1.
Treatments Administered
The Blinded Treatment Dosing Period (Period 2) involves a comparison of 2 treatment regimens
of ixekizumab, 80 mg Q2W and 80 mg Q4W, to placebo.  Each ixekizumab treatment regimen 
will include patients receiving an 80 mg or a 160 mg starting dose; patients will be randomized 
to a starting dose at a 1:1 ratio.  All doses are administered via SC injection. Table RHBW.2
shows the treatment regimens. 
At baseline (Week 0), all patients will receive 2 injections, and will be randomized to a treatment 
regimen.  Patients assigned to an ixekizumab treatment regimen with a 160 mg ixekizumab
starting dose will receive 160 mg of ixekizumab as 2 SC injections.  Patients assigned to an 
ixekizumab treatment regimen with an 80 mg starting dose will receive 80 mg of ixekizumab as 
1 SC injection, and 1 SC injection of placebo.  Patients assigned to the placebo treatment group 
will receive 2 SC injections of placebo.  During the remainder of the Blinded Treatment Dosing 
Period (Period 2; Week 0 to Week 16), all patients will receive 1 injection every 2 weeks.  
Details are provided in Table RHBW.2.
During the Extended Treatment Period (Period 3; Week 16 to Week 52), patients originally 
assigned to either ixekizumab treatment regimen will remain on the same treatment regimen 
through Period 3.  At Week 16, patients originally assigned to placebo will be rerandomized at a 
1:1 ratio to ixekizumab 80 mg Q2W or Q4W with a 160 mg starting dose (as two 80 mg SC 
injections).  To maintain the blind, all patients, regardless of treatment group, will receive 2 SC 
injections at Week 16.  Treatment groups in this period are described in Table RHBW.3.  
To maintain blinding throughout the study, each patient will receive at least 1 SC injection Q2W 
regardless of his/her assigned treatment regimen (that is, placebo will be administered every 
other week as necessary for the Q4W treatment group).
The investigator or his/her designee is responsible for the following:

explaining the correct use of the investigational product to the patient/patient caregiver

verifying that instructions are followed properly

maintaining accurate records of investigational product dispensing, collection, and 
administration

returning all unused medication to Lilly or its designee at the end of the study.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be assessed.
Further instructions and special considerations for the administration of the investigational 
product are provided in Sections 6.1.1, 6.2.1, and 6.6.1.

I1F-MC-RHBW(d) Clinical Protocol
Page 32
LY2439821
Table RHBW.2.
Treatment Regimens from Weeks 0 to 14
Blinded Treatment Dosing Period (Period 2)
Initial Regimen
Dose
Week 0 (Day 1)
Dose
Week 2 to Week 14 
(Remainder of Period 2)
Total injections per patient
2 injections
1 injection Q2W
ixekizumab 
80 mg Q2W with 
160 mg starting dose
Treatment dose
2 ixekizumab 80 mg injections
1 ixekizumab 80 mg Q2W
(Beginning at Week 2, Q2W)
Injections to maintain blinding
None
ixekizumab 
80 mg Q2W with 
80 mg starting dose
Treatment dose
1 ixekizumab 80 mg injection
None
Injections to maintain blinding
1 placebo for ixekizumab injection
ixekizumab 
80 mg Q4W with 
160 mg starting dose
Treatment dose
2 ixekizumab 80 mg injections
1 ixekizumab 80 mg Q4W injection
(Beginning at Week 4, Q4W)
Injections to maintain blinding
None
ixekizumab
80 mg Q4W with 
80 mg starting dose
Treatment dose
1 ixekizumab 80 mg injection
1 placebo for ixekizumab injection 
(Beginning at Week 2, Q4W)
Injections to maintain blinding
1 placebo for ixekizumab injection
placebo
Injections to maintain blinding
2 placebo for ixekizumab injections
1 placebo for ixekizumab injection Q2W
(Beginning at Week 2, Q2W)
Abbreviations:  Q2W = every 2 weeks; Q4W = every 4 weeks.
Note: Shaded cells represent ixekizumab regimens with a starting dose (ixekizumab 160 mg).

I1F-MC-RHBW(d) Clinical Protocol
Page 33
LY2439821
Table RHBW.3.
Treatment Regimens from Weeks 16 to 50
Extended Treatment Period (Period 3)
Initial Regimen
Dose
Week 16a
Dose
Week 18 to Week 50
(Remainder of Period 3)
Total injections per patients
2 injections
1 injection Q2W
ixekizumab 
80 mg Q2W
Treatment dose
1 ixekizumab 80 mg injection
1 ixekizumab 80 mg injection Q2W
(Beginning at Week 18, Q2W)
Injections to maintain blinding
1 placebo for ixekizumab injection
None
ixekizumab 
80 mg Q4W
Treatment dose
1 ixekizumab 80 mg injection
1 ixekizumab 80 mg injection Q4W
(Beginning at Week 20, Q4W)
Injections to maintain blinding
1 placebo for ixekizumab injection
1 placebo for ixekizumab injection Q4W
(Beginning at Week 18, Q4W)
placebo
Treatment dose
2 ixekizumab 80 mg injections 
(starting dose)
ixekizumab 80 mg Q2W beginning at Week 18 
or
ixekizumab 80 mg Q4W beginning at Week 20
Injections to maintain blinding
None
None (ixekizumab 80 mg Q2W regimen)
or
1 placebo for ixekizumab injection Q4W beginning at 
Week 18 (ixekizumab 80 mg Q4W regimen)
placebo 
rerandomization
rerandomized to ixekizumab 80 mg Q2W 
or
ixekizumab 80 mg Q4W
Abbreviations:  Q2W = every 2 weeks; Q4W = every 4 weeks.
a
Patients on placebo will receive a starting dose of 160 mg ixekizumab (2 ixekizumab 80 mg injections) at Week 16.  All other patients will receive placebo 
injections as needed to maintain blinding.  

I1F-MC-RHBW(d) Clinical Protocol
Page 34
LY2439821
6.1.1. Administration of Investigational Product
Injections will be administered subcutaneously by the patient or caregiver after training by the 
clinical staff.
Training:  At Week 0 (baseline, Visit 2), each patient is scheduled to receive 2 injections of 
blinded investigational product.  For training purposes, the proper procedures for administration 
of the initial injection will be performed by clinical staff, and the second injection of 
investigational product at that visit will be administered by the patient or caregiver under the 
supervision of clinical staff.  If additional training is necessary, an injection may be administered 
by the patient or caregiver under the supervision of clinical staff at Week 2 (Visit 4).  
Administration:  If the patient is unable to perform the injection, a caregiver, who will also be 
trained under supervision of site staff, may administer the investigational product.  All 
subsequent injections of investigational product will be administered, unsupervised, by the 
patient or caregiver.  It is recommended that these injections be administered away from the 
investigational site, except for Weeks 0 and 16 when the injections have to be done at the site for 
post-dose monitoring.  If the patient or caregiver is not able to administer the second injection of 
the starting dose, or any dose throughout the study, study site staff may administer that injection.
Refer to the appropriate Manual Syringe Directions for Use provided by the sponsor for the
investigational product.  Note that injections are not to be given in the same arm from which 
patient blood samples, including PK/PD samples, are being drawn at relevant visits.
Study Drug Administration Logs will be dispensed to each patient as needed for recording 
pertinent data about each injection; details of the use of these logs are provided in Section 6.2.1.
Possible injection sites are identified in the syringe Directions for Use.  The injection site is to be 
rotated to another area for subsequent doses.
Observation:  Patients are to remain under observation for at least 1 hour after dosing at Week 0 
(Visit 2) and Week 16 (Visit 8) to monitor for safety, since some patients will be receiving 
ixekizumab for the first time at these visits.  Therefore, at Week 16 (Visit 8), injections of the 
investigational product will be administered by the patient or caregiver at the clinical site to 
allow for observation for any AEs and collection of post-injection blood pressure (BP) and pulse 
measurements approximately 1 hour after administration of the investigational product 
(Section 8.4.2 and Appendix 2).
6.2.
Method of Treatment Assignment
Patients who meet all criteria for enrollment will be randomized to double-blind treatment at 
Week 0 (Visit 2).  Assignment to treatment groups will be determined by a computer-generated 
random sequence using an interactive web-response system (IWRS).  The IWRS will be used to 
assign double-blind investigational product to each patient.  Site personnel will confirm that they 
have located the correct assigned investigational product package by entering a confirmation 
number found on the package into the IWRS.
To achieve between-group comparability, the randomization will be stratified by country and 

I1F-MC-RHBW(d) Clinical Protocol
Page 35
LY2439821
baseline CRP (nonelevated or elevated) and number of prior TNF inhibitors used (1 or 2).  The 
study will enroll approximately 60% of patients with elevated baseline CRP (>5.00 mg/L) and 
approximately 40% of patients with nonelevated baseline CRP (≤5.00 mg/L), and approximately 
60% of patients with 1 prior TNF inhibitor and approximately 40% of patients with 2 prior TNF
inhibitors.
Once a specific cohort is fully enrolled, the sponsor may stop further enrollment of patients 
fitting the criteria of that cohort.  Once the nonelevated CRP cohort is fully enrolled, patients 
with nonelevated CRP may be rescreened once at least 4 weeks after the initial screening.  If the 
CRP is elevated (>5.00 mg/L) during rescreening, patients may be enrolled via the elevated CRP 
cohort, provided all other entry criteria are met.
6.2.1. Selection and Timing of Doses
Investigational product is to be administered at approximately the same time each day, as much
as possible.  If an injection is missed, the missed dose should be administered as soon as possible.  
Injection(s) for missed dose(s) should not be given within 5 days of the next scheduled dose; 
injections should be ≥5 days apart.  Dates of subsequent study visits are not to be modified 
according to this delay.
A paper Study Drug Administration Log will be completed by randomized patients for each 
injection throughout study participation.  The data from the Study Drug Administration Log must 
be transcribed into the electronic case report form (eCRF) by site personnel.  
Patients will be instructed to contact their study site in the event of an injection problem.  In 
addition, site personnel review all Study Drug Administration Logs at each visit to identify any 
product complaints, and they will complete a Product Complaint Form for each operation failure 
reported on a Study Drug Administration Log (see Section 8.2.3 for additional instructions 
regarding complaint handling).
6.3.
Blinding
This is a double-blind study.  
Initial randomization (study treatment administered between Weeks 0 and 16) will remain 
blinded to study site personnel and patients until the final clinical trial database lock has 
occurred. The study treatment in the Extended Treatment Period (Period 3) will remain blinded 
to study site personnel and patients until final clinical trial database lock or patients entering 
Study RHBY, whichever comes first. 
Initial randomization will remain blinded to the sponsor until the clinical trial database through 
Week 16 has been locked.  Subsequent randomization at Week 16 for placebo patients (to 
ixekizumab 80 mg Q2W or Q4W) may be blinded to sponsor until the clinical trial database 
through Week 52 has locked.
Emergency unblinding for AEs may be performed through the IWRS, which may supplement or 
take the place of emergency codes generated by a computer drug-labeling system.  This option 

I1F-MC-RHBW(d) Clinical Protocol
Page 36
LY2439821
may be used ONLY if the patient’s well-being requires knowledge of the patient’s treatment 
assignment.  All actions resulting in an unblinding event are recorded and reported by the IWRS.
If an investigator, site personnel performing assessments, or patient is unblinded, the patient is to
be discontinued from the study treatment.  In cases where there are ethical reasons to have the 
patient remain on study treatment, the investigator must obtain specific approval from a Lilly 
clinical research physician or Lilly clinical research scientist for the patient to continue on study 
treatment.
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warranted.  Patient safety must always be the first 
consideration in making such a determination.  If the investigator decides that unblinding is 
warranted, the investigator is to make every effort to contact the Lilly clinical research 
physician/clinical research scientist prior to unblinding a patient’s treatment assignment.  If a 
patient’s treatment assignment is unblinded, the Lilly clinical research physician/clinical research 
scientist must be notified immediately.
6.4.
Packaging and Labelling
The investigational products will be supplied by the sponsor or its designee in accordance with 
current Good Manufacturing Practices (cGMP).  
Clinical trial materials will be labeled according to the country’s regulatory requirements.  All 
investigational products will be stored, inventoried, reconciled, and destroyed according to 
applicable regulations. 
Ixekizumab and placebo to match will be supplied as injectable solutions in 1-mL, single-dose, 
prefilled, disposable manual syringes with study-specific labels.  Each syringe of ixekizumab is 
designed to deliver ixekizumab 80 mg.  The syringes (and contents) containing either 
ixekizumab or placebo will be visibly indistinguishable from each other.  Syringes will be 
supplied in cartons, with the appropriate quantity of syringes specific to the planned dispensing 
schedule of the investigational product.
6.5.
Preparation/Handling/Storage
Investigational products will be supplied by Lilly or its representative, in accordance with 
cGMP, and will be supplied with lot numbers, expiry dates, and certificates of analysis, as 
applicable.
The investigational product is to be stored at 2°C to 8°C (36°F to 46°F) in its original carton to 
protect from light.  Investigational product must not be frozen.  Sites will be required to monitor 
temperature of the on-site storage conditions of the investigational product.  
6.6.
Dose Modification
No investigational product dose modifications are permitted (refer to Section 8.4.10.1.1 for 
instances where drug may be withheld). 

I1F-MC-RHBW(d) Clinical Protocol
Page 37
LY2439821
6.6.1.Special Treatment Considerations
Patients will be screened for eligibility in the study as described in Sections 5.1 and 5.2 and will 
be informed of the study-specific restrictions and requirements of the study.  Patients who are not 
willing to comply with the study restrictions and requirements of the study will not be eligible 
for enrollment.
All biological agents carry the risk of systemic allergic/hypersensitivity reactions.  Clinical 
manifestations of these reactions may include, but are not limited to:

skin rash

pruritus (itching)

urticaria (hives)

angioedema (for example, swelling of the lips and/or tongue)

anaphylactic reaction.
Sometimes these reactions can be life threatening.  Proteins may also cause redness, itching, 
swelling, or pain locally at the injection site; therefore, all patients should be closely monitored 
for signs or symptoms that could result from such reactions, educated on the signs or symptoms 
of these types of reactions, and instructed to contact the study site immediately if any of these
symptoms are experienced following an injection.  If a patient experiences an acute 
allergic/hypersensitivity reaction after an injection of investigational product, he or she is to be 
managed appropriately and given instruction to receive relevant supportive care.  Additionally, 
for an event judged by the investigator to be a potential systemic allergic/hypersensitivity 
reaction, a blood sample is to be drawn to test for anti-drug antibodies (ADA) and PK as soon as 
possible (see Section 8.4.9).  
For patients who experience a potential allergic/hypersensitivity reaction, consideration for any 
premedication for future injections will be agreed upon between the investigator and sponsor.  
Examples of potential allergic/hypersensitivity reactions that might merit premedication include 
mild-to-moderate skin rashes, mild-to-moderate generalized pruritus and/or urticaria, and 
mild-to-moderate injection site reactions (for example, injection site erythema, injection site 
pruritus, and so on).  Patients who develop clinically significant systemic allergic/
hypersensitivity reactions following administration of investigational product that do not respond 
to symptomatic medication or result in clinical sequelae (for example, hospitalization) are to be 
discontinued from study treatment and not receive further doses of investigational product, with 
or without premedication (see Section 7.1.1).  Medications considered appropriate for 
premedication include, but are not restricted to, acetaminophen/paracetamol up to 1000 mg and 
antihistamines (for example, oral diphenhydramine 50 mg) given after all efficacy assessments 
have been completed for a given visit, and 30 to 60 minutes prior to investigational product SC 
injections for visits where injections are administered at the clinic.  For all other injections, 
patients may self-premedicate at home prior to administration of investigational product, as 
directed by the investigator.  All such premedications will be recorded as concomitant 
medications.  Corticosteroids are not permitted as agents for premedication.

I1F-MC-RHBW(d) Clinical Protocol
Page 38
LY2439821
6.7.
Treatment Compliance
Patient compliance with study medication will be assessed at each visit.  Compliance will be 
assessed by review of the Study Drug Administration Log, return of empty or unused 
investigational product packaging, and/or direct questioning.  Deviation(s) from the prescribed 
dosage regimen are to be recorded in the eCRF.
Compliance is defined in Section 9.3.4.
6.8.
Concomitant Therapy
All concomitant medication taken during the study must be recorded in the eCRF.  Patients will 
maintain their usual medication regimen throughout the study unless specifically excluded in the 
protocol.  Patients taking permitted medications are to be on stable doses at the baseline visit 
(Week 0; Visit 2) through Week 16 as specified in the inclusion/exclusion criteria (Sections 5.1
and 5.2).  Up to Week 16, patients should not start new medications or make any changes to 
concomitant medications unless changes need to be made for an AE or for safety reasons.  
Beyond Week 16, some flexibility is allowed in concomitant medication as outlined below.
Vaccines:
Live vaccines are not allowed during any of the study periods.  Use of nonlive seasonal 
vaccinations and/or emergency vaccination (such as rabies or tetanus vaccinations) is allowed.
NSAIDs and Analgesics: 
Blinded Treatment Dosing Period (Period 2):
NSAIDs, including COX-2 inhibitors will be allowed up to the maximum recommended doses 
for pain.  Patients must be on a stable dose of NSAIDs/COX-2 inhibitors for at least 2 weeks 
prior to baseline randomization. Introduction of a new NSAID or dose adjustment to an existing 
NSAID is not permitted, unless required for safety reasons.
Short-acting analgesics with no anti-inflammatory action (such as paracetamol) are permitted 
and may be administered ad hoc as needed, and are to be withheld within the 24-hour period 
prior to any assessment.  Aspirin (dose not exceeding 350 mg/day) may be taken to manage 
cardiovascular risk.
Opiate analgesic use is allowed but not to exceed >30 mg/day of morphine or its equivalent.  
Patients are to be on stable dose during Period 2. Introduction of a new opiate analgesic or dose 
adjustment to an existing opiate analgesic is not permitted, unless required for safety reasons.
Extended Treatment and Post-Treatment Follow-Up Periods (Periods 3 and 4): 
After completion of the Week 16 assessments, alterations of NSAIDs, including COX-2 
inhibitors (dose change, introduction, or withdrawal) are allowed.  Doses are recommended to be 
stable in the 2 weeks prior to an arthritis assessment.
Short-acting analgesics with no anti-inflammatory action (such as paracetamol) are permitted 
and may be administered ad hoc as needed but are to be withheld within the 24-hour period prior 

I1F-MC-RHBW(d) Clinical Protocol
Page 39
LY2439821
to any assessment.  Aspirin (dose not exceeding 350 mg/day) may be taken to manage 
cardiovascular risk.
Use of variable doses of opiate analgesics is allowed, but not to exceed an average daily dose of 
30 mg morphine or its equivalent.
Conventional DMARDs: 
Blinded Treatment Dosing Period (Period 2):
Discontinuation of excluded oral or injectable cDMARDs before study enrollment must occur at 
least 4 weeks prior to baseline.  Methotrexate (oral or parenteral up to 25 mg/week), 
sulfasalazine (up to 3 g/day), or hydroxychloroquine (up to 400 mg/day) may be allowed IF at 
stable dose for at least 4 weeks prior to baseline randomization.
During Period 2, alteration of cDMARD dose or route, and/or introduction of a new cDMARD,
are not permitted, unless required for safety reasons.  Conventional DMARDs can only be used 
as single agents and not in combination with other cDMARDs.  If, at any time, the investigator 
believes that side effects or laboratory abnormalities may be attributable to the cDMARD, the 
cDMARD dose is to be lowered or the medication stopped. 
Extended Treatment and Post-Treatment Follow-Up Periods (Periods 3 and 4): 
During Periods 3 and 4, adjustment of allowed cDMARDs (for example, dose change, 
introduction, withdrawal of cDMARDs, or replacement of a current cDMARD with the 
introduction of a new cDMARD) is allowed after all assessments at Week 16 are completed.  
Not more than 1 adjustment of cDMARDs at 1 time within 12 weeks is recommended.  
Conventional DMARDs can only be used as single agents and not in combination with other 
cDMARDs.  Any changes must be recorded in the eCRF.
For all study periods, the maximum allowed doses are 25 mg/week MTX, 400 mg/day 
hydroxychloroquine, and 3 g/day sulfasalazine.  Local standards of care are to be followed for 
concomitant administration of folic or folinic acid if MTX is taken, and for administration of 
other cDMARDs. 
Corticosteroids:
Blinded Treatment Dosing Period (Period 2):
Oral corticosteroids: If on oral corticosteroids, the dose must not exceed 10 mg/day of 
prednisone or its equivalent and must be stable for at least 4 weeks prior to baseline 
randomization.  During Period 2, treatment alterations in oral corticosteroid dose are strongly 
discouraged.
Parenteral corticosteroids (IV, intramuscular, intra-articular): Treatment with any parenteral 
corticosteroids is not permitted within 6 weeks prior to baseline or during Period 2. 
Inhaled and topical steroids: Regular use of inhaled or topical steroids will be permitted during 
any study period.

I1F-MC-RHBW(d) Clinical Protocol
Page 40
LY2439821
Extended Treatment and Post-Treatment Follow-Up Periods (Periods 3 and 4): 
Oral corticosteroids: As of Week 16, adjustments of oral corticosteroids are allowed; however,
the maximum dose is not to exceed 10 mg/day of prednisone or its equivalent at any time during 
these periods. 
Parenteral corticosteroids (IV, intramuscular, intra-articular): As of Week 16, intra-articular 
injection of corticosteroid may be allowed, as needed.  The joint injected must be designated 
along with the medication in the eCRF and must be recorded as unevaluable on the TJC/SJC 
assessment.
Inhaled and topical steroids: Regular use of inhaled or topical steroids will be permitted during 
any study period.
Other Concomitant Medications (Periods 2, 3, and 4):
Patients requiring surgery at any time during the study are to interrupt administration of the 
investigational product beginning 8 weeks prior to the surgery, or as early as possible within 
8 weeks of surgery, and resume administration of the investigational product only after complete 
wound healing.
Additional drugs are to be avoided during the study unless required to treat an AE or for the 
treatment of an ongoing medical problem.  If the need for concomitant medication arises, the 
investigator is to base decisions on the patient and on clinical factors.  Any additional 
medication, whether prescription or over-the-counter, used at baseline (Week 0, Visit 2) and/or 
during the course of the study, must be documented with the start and stop dates in the eCRF.
Additional systemic drugs are to be avoided during the study, unless required to treat an AE.  
Other medications may be allowed, if approved by the sponsor or its designee.
Only for patients who discontinued study treatment and have entered the Post-Treatment Follow-
Up Period, axSpA therapy with another agent previously excluded during the treatment period of 
the study may be allowed, as determined appropriate by the investigator and approved by Lilly 
medical.  
Any changes in medications not addressed above are to be discussed with the investigator.  
Patients must be instructed to consult the investigator or other appropriate study personnel at the 
site before taking any new medications or supplements.
6.9.
Treatment After Study Completion
6.9.1. Study Extensions
Patients who complete this study through Visit 15 (Week 52) may be eligible to participate in a 
long-term study (RHBY) offering up to an additional 2 years of treatment, if enrollment criteria 
for Study RHBY are met.  For patients who have completed Study RHBW through Week 52 and 
meet exclusion criteria at Week 44 and Week 52, patients will complete the Post-Treatment 
Follow-Up Period (Period 4) in Study RHBW.

I1F-MC-RHBW(d) Clinical Protocol
Page 41
LY2439821
6.9.2. Continued Access
Investigational product will not be made available to patients after conclusion of this study.  
However, patients who complete Study RHBW and continue in the long-term study (RHBY) will 
have access to investigational product for up to an additional 2 years.

I1F-MC-RHBW(d) Clinical Protocol
Page 42
LY2439821
7.
Discontinuation Criteria
The reason for and date of discontinuation from study treatment (investigational product) and 
reason for and date of discontinuation from study participation will be collected for all 
randomized patients. 
For any patient permanently discontinuing from study treatment, the investigational product will 
be withheld, and the patient will complete the ETV and the Post-Treatment Follow-Up Period 
(Period 4), as shown in the Schedule of Activities (Appendix 2).  For patients discontinuing prior 
to Week 16, the patient will complete additional assessments as described in Section 7.1.1.1 and 
shown in the Schedule of Activities (Appendix 2).
7.1.
Discontinuation from Study Treatment
7.1.1. Discontinuation from Study Treatment
The following criteria must be followed for discontinuation from study treatment.  Patients will 
enter into the Post-Treatment Follow-Up Period (Period 4) if they discontinue from study 
treatment.
[1]
Discontinuation of the investigational product for abnormal liver tests should 
be considered by the investigator when a patient meets one of the following 
conditions, after consultation with the Lilly designated medical monitor:

ALT or AST >8xULN

ALT or AST >5xULN for more than 2 weeks

ALT or AST >3xULN and total bilirubin level >2xULN or prothrombin 
time >1.5xULN

ALT or AST >3xULN with the appearance of fatigue, nausea, vomiting, 
right upper-quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)

alkaline phosphatase >2.5xULN and total bilirubin >2xULN

alkaline phosphatase >2.5xULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
[2]
Other laboratory tests (Note:  Laboratory test(s) that may result in 
discontinuation based on a single result may be repeated only once if there is a 
technical error or clinical reason to believe a result may need to be retested.  
Laboratory tests can only be repeated after consultation with Lilly medical.  
Investigational product should not be administered in these cases until retest 
result is available.):

Neutrophil (segmented) counts (see safety monitoring for neutropenia in 
Section 8.4.10.1):

I1F-MC-RHBW(d) Clinical Protocol
Page 43
LY2439821
o
<500 cells/L (<0.50x103/µL or <0.50 GI/L)
o
≥500 and <1000 cells/L (≥0.50x103/µL and <1.00x103/µL or ≥0.50 
GI/L and <1.00 GI/L) (based on 2 test results; the second test 
performed within 1 week from knowledge of the initial result)  
o
≥1000 and <1500 cells/L (≥1.00x103/µL and <1.50x103/µL or ≥1.00 
GI/L and <1.50 GI/L) (based on 3 test results as specified in 
Section 8.4.10.1)
- AND - a concurrent infection

Total WBC count <2000 cells/L (<2.00x103/µL or <2.00 GI/L)

Lymphocyte count <500 cells/μL (<0.50x103/µL or <0.50 GI/L)

Platelet count <50,000 cells/μL (<50x103/µL or <50 GI/L) 
[3]
The patient experiences a severe AE, an SAE, or a clinically significant 
change in a laboratory value that, in the opinion of the investigator, merits the 
discontinuation of the investigational product and appropriate measures being 
taken.  In this case, Lilly or its designee is to be notified immediately.  Refer 
to Section 8.2.
[4]
Clinically significant systemic hypersensitivity reaction following SC 
administration of investigational product that does not respond to 
symptomatic medication or results in clinical sequelae.  
[5]
The patient becomes pregnant.  
[6]
The patient develops a malignancy. 
Note:  Patients may be allowed to continue if they develop no more than 
2 nonmelanoma skin cancers during the study.
[7]
Enrollment in any other clinical trial involving an investigational product or 
enrollment in any other type of medical research judged not to be 
scientifically or medically compatible with this study.
[8]
The patient, at any time during the study, scores a 3 for Item 12 (Thoughts of 
Death or Suicide) on the QIDS-SR16
-OR-
develops active suicidal ideation with some intent to act with or without a 
specific plan (yes to question 4 or 5 on the “Suicidal Ideation” portion of the 
Columbia–Suicide Severity Rating Scale [C-SSRS])
-OR-
develops suicide-related behaviors as recorded on the C-SSRS.  

I1F-MC-RHBW(d) Clinical Protocol
Page 44
LY2439821
It is recommended that the subject be assessed by a psychiatrist or 
appropriately trained professional to assist in deciding whether the subject is 
to be discontinued from the study.  
[9]
The investigator or attending physician decides that the patient is to be 
withdrawn from study treatment.
[10] The patient requests to be withdrawn from study treatment.
[11] Lilly or its designee stops the patient’s participation in the study or Lilly stops 
the study for medical, safety, regulatory, or other reasons consistent with 
applicable laws, regulations, and good clinical practice (GCP). 
[12] The patient becomes HBV DNA positive, at which time the patient is to be 
referred to a specialist physician. Discussion of the timing of discontinuation 
from the study and from study treatment is provided in Section 8.4.10.2.
7.1.1.1.
Discontinuation of Study Treatment Prior to Week 16
Patients who discontinue prior to Week 16 will complete the ETV and the Post-Treatment 
Follow-Up Period (Period 4).  In addition, patients will complete several additional assessments, 
as detailed in the Schedule of Activities (Appendix 2).
7.1.2. Discontinuation of Inadvertently Enrolled Patients
The criteria for enrollment must be followed explicitly. If the sponsor or investigator identifies a 
patient who did not meet enrollment criteria and was inadvertently enrolled, a discussion must 
occur between the sponsor clinical research physician/clinical research scientist and the 
investigator to determine if the patient may continue in the study.  If both agree, it is medically 
appropriate to continue, the investigator must obtain documented approval from the sponsor 
clinical research physician/clinical research scientist to allow the inadvertently enrolled patient to 
continue in the study with or without treatment with investigational product.
7.1.3. Permanent Discontinuation from the Study
Some possible reasons that may lead to permanent discontinuation include:

Enrollment in any other clinical trial involving an investigational product or enrollment in 
any other type of medical research judged not to be scientifically or medically compatible 
with this study

Participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and GCP

Patient decision:  The patient requests to be withdrawn from the study.
Patients who discontinue the study early will have end-of-study procedures performed as shown 
in the Schedule of Activities (Appendix 2).
7.1.4. Patients Lost to Follow-Up
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make 

I1F-MC-RHBW(d) Clinical Protocol
Page 45
LY2439821
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site.

I1F-MC-RHBW(d) Clinical Protocol
Page 46
LY2439821
8.
Study Assessments and Procedures
Appendix 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for timing).
Appendix 3 lists the laboratory tests that will be performed for this study.
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards.
8.1.
Efficacy Assessments
Below are brief descriptions of key aspects of the scales used in the study.  Complete 
assessments are included in site training materials.
The following ASAS domains are used to determine ASAS20, ASAS40, ASAS partial 
remission, and ASAS 5/6 (Sieper et al. 2009, ASAS Handbook): 
1) Patient Global (Section 8.1.2.2)
2) Spinal Pain (Section 8.1.2.3)
3) Function (Section 8.1.2.5) 
4) Inflammation (mean of BASDAI questions 5 and 6) (Section 8.1.2.4)
5) CRP (Section 8.1.2.19.1) and 
6) Spinal mobility (lateral spinal flexion) (Section 8.1.2.6).
8.1.1. Primary Efficacy Assessments:  ASAS40
The ASAS40 (Anderson et al. 2001; Brandt et al. 2004; Sieper et al. 2009) is derived from 
patient-reported assessments.  An ASAS40 response is defined as a ≥40% improvement and an 
absolute improvement from baseline of ≥2 units (range 0 to 10) in ≥3 of 4 domains (Patient 
Global, Spinal Pain, Function, and Inflammation) without any worsening in the remaining 
domain.
8.1.2. Secondary Efficacy Assessments 
8.1.2.1.
ASAS20, ASAS Individual Components, ASAS Partial Remission, and 
ASAS 5/6 
The ASAS20, ASAS individual components, ASAS partial remission, and ASAS 5/6 responses 
(Davis et al. 2003; Sieper et al. 2009) are secondary efficacy assessments that are calculated as 
improvements in respective response rates in multiple disease domains.
Complete definitions of each assessment are provided below.  
8.1.2.1.1. ASAS20
The ASAS20 is derived from patient-reported assessments.  An ASAS20 response is defined as a 
≥20% improvement and an absolute improvement from baseline of ≥1 units (range 0 to 10) in 

I1F-MC-RHBW(d) Clinical Protocol
Page 47
LY2439821
≥3 of 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), and no worsening of 
≥20% and ≥1 unit (range 0 to 10) in the remaining domain.
8.1.2.1.2. ASAS Partial Remission
The ASAS partial remission is derived from patient-reported assessments.  An ASAS partial 
remission response is defined as a value not above 2 units (range 0 to 10, NRS) in each of the 
following 4 domains: Patient Global, Spinal Pain, Function, and Inflammation. 
8.1.2.1.3. ASAS 5/6
The ASAS 5/6 includes assessment of all 6 individual ASAS domains listed in Section 8.1 and 
represents improvement of ≥20% in at least 5 domains.
8.1.2.2.
Patient Global (Assessment of Disease Activity)
From the ASAS Handbook (Sieper et al. 2009), the patient is asked to respond to the following 
question:  “How active was your spondylitis on average during the last week?”  The answer is 
recorded on an NRS and is rated between “0” (not active) and “10” (very active).
8.1.2.3.
Spinal Pain
From the ASAS Handbook (Sieper et al. 2009), the patient is asked to respond to the following 
2 questions (on average during the last week):
1. “How much pain of your spine due to ankylosing spondylitis do you have?”
2. “How much pain of your spine due to ankylosing spondylitis do you have at night?”
The answers are recorded on an NRS and are each rated between “0” (no pain) and “10” (most 
severe pain).  The first question is used to derive responses (that is, ASAS40, ASAS20, and so 
on).
8.1.2.4.
Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI is a patient-reported assessment consisting of 6 questions that relate to 5 major
symptoms relevant to rad-axSpA (Garrett et al. 1994; Sieper et al. 2009):  1) Fatigue, 2) Spinal 
pain, 3) Peripheral arthritis, 4) Enthesitis, 5) Intensity, and 6) Duration of morning stiffness.  
Patients need to score each item with a score from 0 to 10 (NRS).
BASDAI50 represents an improvement of ≥50% of the BASDAI score from baseline.
8.1.2.5.
Bath Ankylosing Spondylitis Functional Index
The BASFI is a patient-reported assessment that establishes a patient’s functional baseline and 
subsequent response to treatment (Calin et al. 1995).  To complete the BASFI, a patient is asked 
to rate the difficulty associated with 10 individual basic functional activities.  Patients respond to 
each question using an NRS scale (range 0 to 10) with a higher score indicating worse function.
The patient’s final BASFI score is the mean of the 10 item scores completed on an NRS. 
8.1.2.6.
Bath Ankylosing Spondylitis Metrology Index—Spinal Mobility 
The BASMI is a combined index comprising the following 5 clinical measurements of spinal 
mobility in patients with rad-axSpA (Jenkinson et al. 1994):

I1F-MC-RHBW(d) Clinical Protocol
Page 48
LY2439821

Lateral spinal flexion

Tragus-to-wall distance

Lumbar flexion (modified Schrober)

Maximal intermalleolar distance

Cervical rotation.
The BASMI includes these 5 measurements that are each scaled to a score of 0 to 10 depending 
on the result of the assessment (BASMI linear function).  The average score of the 5 assessments 
gives the BASMI linear result (van der Heijde et al. 2008; Sieper et al. 2009). 
The BASMI must be assessed by a rheumatologist or health care provider who meets the 
qualifications for study assessment.
8.1.2.7.
Chest Expansion 
While patients have their hands resting on or behind the head, the assessor will measure the 
chest’s encircled length by centimeter at the fourth intercostal level anteriorly.  The difference 
between maximal inspiration and expiration in centimeters will be recorded.  Two tries will be 
recorded.  The better measurement (larger difference) of 2 tries (in centimeters) will be used for 
analyses.
The measurement of chest expansion must be assessed by a rheumatologist or health care 
provider who meets the qualifications for study assessment.
8.1.2.8.
Occiput to Wall Distance 
The patient is to make a maximum effort to touch the head against the wall when standing with 
heels and back against the wall (occiput).  Then the distance from occiput to wall is measured.  
Two tries will be recorded.  The better (smaller) measurement of 2 tries (in centimeters) will be 
used for analyses.
The measurement of occiput to wall distance must be assessed by a rheumatologist or health care 
provider who meets the qualifications for study assessment.
8.1.2.9.
Ankylosing Spondylitis Disease Activity Score
The ASDAS is a composite index to assess disease activity in AS (Machado et al. 2011a, 2011b; 
Zochling 2011).  The parameters used for the ASDAS (with CRP as acute phase reactant) are the 
following:
1) Total back pain (BASDAI question 2)
2) Patient global (Section 8.1.2.2)
3) Peripheral pain/swelling (BASDAI question 3)
4) Duration of morning stiffness (BASDAI question 6)
5) CRP in mg/L.
The ASDAScrp is calculated with the following equation:  0.121 × total back pain + 0.110 × 
patient global + 0.073 × peripheral pain/swelling + 0.058 × duration of morning stiffness + 0.579 
× Ln(CRP+1) (Machado et al. 2015).  (Note:  CRP is in mg/liter, the range of other variables is 
from 0 to 10; Ln represents the natural logarithm.)

I1F-MC-RHBW(d) Clinical Protocol
Page 49
LY2439821
Four disease activity states have been defined by ASAS consensus (Machado et al. 2011c):

ASDAS <1.3 defines inactive disease

1.3 ≤ ASDAS <2.1 defines moderate disease activity

2.1≤ ASDAS ≤3.5 defines high disease activity

ASDAS > 3.5 defines very high disease activity. 
Clinically important improvement is defined as change ≥1.1 units, and major improvement is 
defined as change ≥2.0 units (Machado et al. 2011b).
8.1.2.10. Maastricht Ankylosing Spondylitis Enthesitis Score
The MASES is an index used to measure the severity of enthesitis (Heuft-Dorenbosch et al. 
2003).  The MASES assesses 13 sites for enthesitis using a score of “0” for no activity or “1” for 
activity.  Sites assessed include costochondral 1 (right/left), costochondral 7 (right/left), spinal 
iliaca anterior superior (right/left), crista iliaca (right/left), spina iliaca posterior (right/left), 
processus spinosus L5, and Achilles tendon proximal insertion (right/left).  The MASES is the 
sum of all site scores (range 0 to 13); higher scores indicate more severe enthesitis.
The MASES must be assessed by a rheumatologist or health care provider who meets the 
qualifications for study assessments.
8.1.2.11. Spondyloarthritis Research Consortium of Canada–Enthesitis Score
The SPARCC enthesitis is an index used to measure the severity of enthesitis (Maksymowych et 
al. 2009).  The SPARCC assesses 16 sites for enthesitis using a score of “0” for no activity or 
“1” for activity.  Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle 
(L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), 
Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into 
inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R),
and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores 
(range 0 to 16). Higher scores indicate more severe enthesitis.
The SPARCC must be assessed by a rheumatologist or health care provider who meets the 
qualifications for study assessments.
8.1.2.12. Peripheral Arthritis
8.1.2.12.1.Tender Joint Count
The number of tender and painful joints will be determined by examination of 46 joints (23 joints 
on each side of the patient’s body).  The 46 joints to be assessed and classified as tender or not 
tender are detailed in site training materials.  Any joints that require intra-articular injections 
during the study (according to Section 6.8) are to be excluded from evaluation from the time of 
the injection to the conclusion of the study.
Joint assessments must be assessed by a rheumatologist or health care provider who meets the
qualifications for study assessments.  To minimize interobserver variation, particularly during 
the Blinded Treatment Dosing Period (Period 2), it is recommended that the same assessor 
performs the TJC for a given patient.  Missing, replaced, ankylosed, or arthrodesed joints will be 

I1F-MC-RHBW(d) Clinical Protocol
Page 50
LY2439821
identified by the investigator at the screening visit (Visit 1) and will be excluded from evaluation 
during the study.  
The TJC data will be collected electronically.
8.1.2.12.2.Swollen Joint Count
The number of swollen joints will be determined by examination of 44 joints (22 joints on each 
side of the patient’s body).  The 44 joints to be assessed and classified as swollen or not swollen 
are detailed in site training materials.  Any joints that require intra-articular injections during the 
study (according to Section 6.8) are to be excluded from evaluation from the time of the injection 
to the conclusion of the study.
Joint assessments must be assessed by a rheumatologist or health care provider who meets the 
qualifications for study assessments.  To minimize interobserver variation, particularly during 
the Blinded Treatment Dosing Period (Period 2), it is recommended that the same assessor 
performs the SJC for a given patient.  Missing, replaced, ankylosed, or arthrodesed joints will be 
identified by the investigator at the screening visit (Visit 1) and will be excluded from evaluation 
during the study.
The SJC data will be collected electronically.
8.1.2.13. Nonsteroidal Anti-Inflammatory Drug Intake 
Information regarding NSAID intake will be collected in the eCRF; the ASAS-NSAID score will 
be calculated at baseline and through Week 52 (Dougados et al. 2011).
8.1.2.14. Assessment of Spondyloarthritis International Society Health Index
The ASAS HI is a disease-specific health-index instrument designed to assess the impact of 
interventions for SpA, including axSpA.  This broader concept of health is included in the 
International Classification of Functioning, Disability, and Health, which has been published by 
the World Health Organization (WHO).  The ASAS has applied this classification as a basis to 
define a core set of items relevant for patients with rad-axSpA.  The 17-item instrument has 
scores ranging from 0 (good health) to 17 (poor health) (Kiltz et al. 2013).  Each item consists of 
one question that the patient needs to respond to with either “I agree” (score of 1) or “I do not 
agree” (score of 0). A score of “1” is given where the item is affirmed, indicating adverse health.  
All item scores are summed to give a total score or index.
8.1.2.15. Medical Outcomes Study 36-Item Short-Form Health Survey 
The SF-36 is a 36-item patient-administered measure designed to be a short, multipurpose 
assessment of health in the areas of physical functioning, role – physical, role – emotional, 
bodily pain, vitality, social functioning, mental health, and general health.  The 2 overarching 
domains of mental well-being and physical well-being are captured by the mental component 
summary (MCS) and physical component summary (PCS) scores.  The summary scores range 
from 0 to 100; higher scores indicate better levels of function and/or better health.  Items are 
answered on Likert scales of varying lengths.  The SF-36 version 2 (acute version) will be used, 
which utilizes a 1-week recall period (Ware 2000).

I1F-MC-RHBW(d) Clinical Protocol
Page 51
LY2439821
8.1.2.16. Fatigue Severity Numeric Rating Scale
The Fatigue Severity NRS is a patient-administered, single-item, 11-point horizontal scale 
anchored at 0 and 10, with 0 representing “no fatigue” and 10 representing “as bad as you can 
imagine” (Naegeli et al. 2013).  Patients rate their fatigue (feeling tired or worn out) by circling 
the one number that describes their worst level of fatigue during the previous 24 hours.  
8.1.2.17. Work Productivity and Activity Impairment Questionnaire–
Spondyloarthritis
The WPAI-SpA consists of 6 questions to determine employment status, hours missed from 
work because of SpA, hours missed from work for other reasons, hours actually worked, the 
degree to which SpA affected work productivity while at work, and the degree to which SpA
affected activities outside of work.  The WPAI-SpA has been validated in the rad-axSpA patient 
population (Reilly et al. 2010).  Four scores are derived:  percentage of absenteeism, percentage 
of presenteeism (reduced productivity while at work), an overall work impairment score that 
combines absenteeism and presenteeism, and percentage of impairment in activities performed 
outside of work.  Greater scores indicate greater impairment (Reilly Associates [WWW]).
8.1.2.18. Jenkins Sleep Evaluation Questionnaire
The JSEQ is a 4-item scale designed to estimate sleep problems in clinical research.  The JSEQ 
assesses the frequency of sleep disturbance in 4 categories:  1) trouble falling asleep, 2) waking 
up several times during the night, 3) having trouble staying asleep (including waking up far too 
early), and 4) waking up after the usual amount of sleep feeling tired and worn out.  Patients 
report the number of days they experience each of these problems in the past month on a 6-point 
Likert scale ranging from 0 = “no days” to 5 = “22-30 days.”  The total JSEQ score ranges from 
0 to 20, with higher scores indicating greater sleep disturbance (Deodhar et al. 2010).
8.1.2.19. Laboratory Tests Used for Efficacy Measures and Disease Diagnosis
8.1.2.19.1.High Sensitivity C-Reactive Protein
High sensitivity CRP will be the measure of acute phase reactant.  It will be measured with a 
high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on disease 
activity.  The results will not be shared with the investigative sites after baseline randomization
to maintain the study blind.
8.1.2.20. Imaging Used for Efficacy Measures and Disease Diagnosis
8.1.2.20.1.Imaging of Sacroiliac Joints and Spine
For each patient, x-ray images will be collected according to the Schedule of Activities 
(Appendix 2) and Table RHBW.4, and will follow the study-specific recommendations included 
in site training materials for this study.  The SIJ x-ray will be used to confirm patients have 
radiographic sacroiliitis as defined by the mNY criteria.  The screening x-ray of the spine will 
also serve as baseline for later evaluation of change from baseline in structural progression in the 
long-term study (RHBY).  
The site will read the screening x-ray of the spine (cervical+lumbar) for presence or absence of 
total ankylosis to determine study eligibility.  The site will then send the x-ray to the central 

I1F-MC-RHBW(d) Clinical Protocol
Page 52
LY2439821
reader to be maintained as a baseline for later structure assessments. All other images (x-ray of 
the SIJ) are centrally read for eligibility and/or for assessment of treatment effect.
Table RHBW.4.
Imaging Requirements for Sacroiliac Joints and Spine
Time Pointa
Type of Imageb
Purpose
Reading
Requirements
Screening
X-ray of the SIJ
Eligibility to determine 
rad-axSpA (per mNY 
criteria)
Centrally readc
Send to central reader; 
results must be received 
from central reader prior to 
baseline randomization
Screening
X-ray of the spine 
(cervical and 
lumbar)
Eligibility to determine 
total ankylosis
Locally read (by 
investigator)d
Send to central reader 
(as baseline for later 
structure assessments)
Abbreviations:  mNY = modified New York; rad-axSpA = radiographic axial spondyloarthritis; SIJ = sacroiliac
joints.
a
Screening procedures must be conducted within timeframes specified in the Schedule of Activities (Appendix 2).
b
Imaging to be reviewed and approved for quality; imaging that does not pass the quality assessment must be 
repeated prior to baseline randomization.
c
Patient cannot be randomized until centrally read results are received by site.
d
Patient can be enrolled by investigator for this inclusion/exclusion criterion of ankylosis.
8.1.3. Other Assessments
8.1.3.1.
European Quality of Life–5 Dimensions–5 Level
The European Quality of Life–5 Dimensions–5 Level (EQ-5D-5L) is a standardized measure of 
health status used to provide a simple, generic measure of health for clinical and economic 
appraisal.  The EQ-5D-5L consists of 2 components:  a descriptive system of the respondent’s 
health and a rating of his/her current health state using a 0- to 100-mm visual analog scale 
(VAS).  The descriptive system comprises the following 5 dimensions:  mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression.  Each dimension has 5 levels:  no problems, 
slight problems, moderate problems, severe problems, and extreme problems.  The respondent is 
asked to indicate his/her health state by ticking (or placing a cross) in the box associated with the 
most appropriate statement in each of the 5 dimensions.  It should be noted that the numerals 1 to 
5 have no arithmetic properties and are not to be used as ordinal scores.  The VAS records the 
respondent’s self-rated health on a vertical VAS in which the endpoints are labeled “best 
imaginable health state” and “worst imaginable health state.”  This information can be used as a 
quantitative measure of health outcomes.  The EQ-5D-5L health states, defined by the EQ-5D-
5L descriptive system, may be converted into a single summary index by applying a formula that 
essentially attaches values (also called weights) to each of the levels in each dimension (EuroQol 
Group 2011).
8.1.3.2.
Healthcare Resource Utilization
Healthcare resource utilization data regarding the number of visits to medical care providers, 
such as general practitioners, specialists, physical, or occupational therapists, and other 
nonphysical care providers for services outside of the clinical trial; emergency room admissions; 
hospital admissions; and concomitant medications will be recorded by the investigator in the 
study’s CRF.  These data will be collected to support economic evaluations of treatment.

I1F-MC-RHBW(d) Clinical Protocol
Page 53
LY2439821
8.2.
Adverse Events
An AE is defined as:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
Investigators are responsible for monitoring the safety of patients who have entered this study 
and for alerting Lilly or its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefit to the patient.
The investigator is responsible for the appropriate medical care of patients during the study.
Investigators must document their review of each laboratory safety report.
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the investigational 
product or the study, or that caused the patient to discontinue the investigational product before 
completing the study.  The patient is to be followed until the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency of follow-up 
evaluations of the AE is left to the discretion of the investigator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study site personnel will record via CRF the occurrence and nature of 
each patient’s preexisting conditions, including clinically significant signs and symptoms of the 
disease under treatment in the study.  In addition, site personnel will record via CRF any change 
in the condition(s) and any new conditions as AEs. Investigators must record their assessment of 
the potential relatedness of each AE to protocol procedure, investigational product, via CRF.
The investigator decides whether he or she interprets each AE as reasonably possibly related to 
the study product, study procedure, disease under study, or other concomitant medications, or 
pathologies. To assess the relationship of the AEs, the following is defined:
Reasonably Possibly Related: Reasonable possibility that there is a cause and effect 
relationship between the study product and/or study procedure and the AE.
The investigator answers yes/no when making this assessment.
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the study.
If a patient’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via electronic data entry, clarifying if possible, the 
circumstances leading to any dosage modifications, or discontinuations of treatment. 

I1F-MC-RHBW(d) Clinical Protocol
Page 54
LY2439821
Accurate start and stop dates (and times, where required) are to be reported via electronic data 
entry for all AEs.  Only AEs that are ongoing at the last study visit and/or communication are to 
be documented as “ongoing”.
8.2.1. Serious Adverse Events
An SAE is any AE from this study that results in one of the following outcomes:

death

initial or prolonged inpatient hospitalization

a life-threatening experience (that is, immediate risk of dying)

persistent or significant disability/incapacity

congenital anomaly/birth defect

important medical events that may not be immediately life-threatening or result in death 
or hospitalization but may jeopardize the patient or may require intervention to prevent 
one of the other outcomes listed in the definition above.
If an SAE occurs after signing the ICF, but prior to receiving investigational product, it needs to 
be reported ONLY if it is considered reasonably possibly related to study procedure.
Study site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator 
awareness of the event via a sponsor-approved method.  If alerts are issued via telephone, they 
are to be immediately followed with official notification on study-specific SAE forms.  This 24-
hour notification requirement refers to the initial SAE information and all follow-up SAE 
information.
Pregnancy (during maternal or paternal exposure to investigational product) does not meet the 
definition of an AE.  However, to fulfill regulatory requirements any pregnancy (during maternal 
or paternal exposure to investigational product) must be reported following the SAE process and 
data are to be collected on the outcome for both mother and fetus.
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study (the patient summary CRF has been completed).  
However, if the investigator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study, and he/she considers the event reasonably possibly related to the 
study treatment or study participation, the investigator must promptly notify Lilly.
8.2.1.1.
Suspected Unexpected Serious Adverse Reactions
Lilly has procedures that will be followed for the recording and expedited reporting of suspected 
unexpected serious adverse reactions (SUSARs) that are consistent with global regulations and 
the associated detailed guidances.
8.2.2. Adverse Events of Special Interest
The following adverse events of special interest (AESIs) will be used to determine the safety and 
tolerability of ixekizumab over the range of doses selected for this clinical study.
The AESIs for ixekizumab are:

I1F-MC-RHBW(d) Clinical Protocol
Page 55
LY2439821

cytopenias (leukopenia, neutropenia, and thrombocytopenia)

clinically significant hepatic events and/or significant elevations in liver function test 
changes/enzyme elevations (ALT, AST, bilirubin, and alkaline phosphatase)

infections

injection site reactions

allergic reactions/hypersensitivities

cerebrocardiovascular events 

malignancies

IBD

depression.
Sites will provide details on some of these AEs as instructed on the CRF.  Investigators will also 
educate patients and/or caregivers about the symptoms of allergic/hypersensitivity reactions and 
will provide instructions on dealing with these reactions (see also Section 6.6.1).  A blood 
sample is to be collected as soon as possible for any patient who experiences an AE of a potential 
systemic allergic/hypersensitivity reaction during the study as judged by the investigator.
Data on preferred terms associated with cerebrocardiovascular events (defined as death, cardiac 
ischemic events including MI and hospitalization for unstable angina, hospitalization for heart 
failure, serious arrhythmia, resuscitated sudden death, cardiogenic shock, coronary 
revascularization procedure, stroke/transient ischemic attack, peripheral revascularization 
procedure, and peripheral arterial event and hospitalization for hypertension) will be collected, 
and these events and any deaths will be adjudicated by an external Clinical Events Committee 
(CEC) made up of a chairman, 2 cardiologists, and a neurologist.  
Data on suspected IBD, as identified by events possibly indicative of ulcerative colitis and 
Crohn’s disease, will be collected and the events will be adjudicated by an external CEC with 
expertise in IBD.  
The role of external CECs is to adjudicate defined clinical events in a blinded, consistent, and 
unbiased manner throughout the course of a study. The purpose of the CEC for adjudication of 
cerebrocardiovascular events and the CEC for adjudication of suspected IBD events is to ensure 
that all reported events are evaluated uniformly by a single group.
8.2.3. Complaint Handling
Lilly collects product complaints on investigational products and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product improvements.
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be assessed.
8.3.
Treatment of Overdose
Refer to the IB.

I1F-MC-RHBW(d) Clinical Protocol
Page 56
LY2439821
8.4.
Safety Assessments
8.4.1. Electrocardiograms
For each patient, 12-lead ECGs must be collected locally at screening (Appendix 2).  Patients are 
to be resting for 5 minutes prior to the ECG.  It is recommended that patients be in a supine 
position.  
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient receives the first dose of the investigational treatment are to be reported to Lilly or its 
designee as AEs via CRF.  Any clinically significant ECG findings prior to receiving drug are to
be reported as a preexisting condition.
8.4.2. Vital Signs
For each patient, vital sign measurements are to be conducted according to the Schedule of 
Activities (Appendix 2).  Vital signs include BP and pulse.  Patients are to be resting for a 
minimum of 5 minutes prior to vital sign collection. 
Any clinically significant findings from vital sign measurements that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment are to be reported to Lilly or 
its designee as AEs via CRF.
8.4.3. Laboratory Tests
For each patient, laboratory tests (detailed in Appendix 3) will be sent to a central laboratory for 
processing and must be conducted according to the Schedule of Activities (Appendix 2).  Please 
reference the central laboratory manual for specific instructions.
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of investigational product are to be reported to Lilly or its 
designee as AEs via CRF.
8.4.4. Physical Examination
For each patient, a complete physical examination must be conducted according to the Schedule 
of Activities (Appendix 2).  
Any clinically significant findings from a complete physical examination that result in a 
diagnosis and that occur after the patient receives the first dose of study treatment are to be 
reported to Lilly or its designee as AEs via CRF.
8.4.5. Eye Symptom Assessment
At each study visit, study health care providers will evaluate the patient for any symptoms of 
anterior uveitis as specified in the Schedule of Activities (Appendix 2).  If the patient has no 
prior ophthalmologist-diagnosed anterior uveitis and develops eye pain or discomfort, eye 
redness, blurring of vision, or any other symptoms suggestive of anterior uveitis, the patient must 
be evaluated by an ophthalmologist.  If a patient has prior history of ophthalmologist-diagnosed 

I1F-MC-RHBW(d) Clinical Protocol
Page 57
LY2439821
anterior uveitis, then she/he must be evaluated by a physician for recurrence of anterior uveitis 
(whenever possible, diagnosis is to be confirmed by an ophthalmologist).
8.4.6. Chest X-Ray and Tuberculosis Testing
For each patient, a posterior anterior chest x-ray and TB testing must be conducted according to 
the Schedule of Activities (Appendix 2).  
The posterior anterior chest x-ray or results will be reviewed by the investigator or designee prior 
to baseline randomization to exclude patients with active TB infection.
Any clinically significant findings from a posterior anterior chest x-ray or TB testing that result 
in a new diagnosis and that occur after the patient receives the first dose of study treatment are to 
be reported to Lilly or its designee as AEs via CRF.
Patients with no TB test (purified protein derivative [PPD] and/or Interferon-Gamma 
Release Assay) results on file:  These patients will be tested at screening as indicated on the 
Schedule of Activities (Appendix 2) for evidence of active or latent TB indicated by a positive 
PPD skin test response, defined as ≥5 mm diameter of induration, between approximately 2 and 
3 days after test application, regardless of BCG vaccination history.  In countries where the 
Interferon-Gamma Release Assay (QuantiFERON®-TB Gold test, or T-SPOT®) is available 
and, in the judgment of the investigator, preferred as an alternative to the PPD skin test for the 
evaluation of TB infection, it may be used instead of the PPD test (positive tests excluded).  The 
QuantiFERON®-TB Gold test may be read locally or centrally, while the T-SPOT® must be 
read locally.  If the QuantiFERON®-TB Gold test is indeterminate, or the T-SPOT® is invalid or 
borderline, one retest is allowed.  If the retest for the QuantiFERON®-TB Gold test is 
indeterminate, or the retest for the T-SPOT® is invalid or borderline, then the patient is excluded 
from enrolling in the study.
However, patients with a PPD skin test ≥5 mm induration or a positive QuantiFERON®-TB 
Gold or positive T-SPOT® test at screening, but no other evidence of active TB, may be 
rescreened one time and may be enrolled without repeating a PPD or QuantiFERON®-TB Gold 
test or T-SPOT® (TB test) if the following conditions are met:

after receiving at least 4 weeks of appropriate latent TB infection (LTBI) therapy.

with no evidence of hepatotoxicity (ALT/AST must remain ≤2xULN) upon retesting of 
serum ALT/AST prior to randomization.  Such patients must complete appropriate LTBI 
therapy during the course of the study in order to remain eligible.

meet all other inclusion/exclusion criteria for participation.
If rescreening occurs within 6 months of the initial screening posterior anterior chest x-ray, there 
is no necessity for repeat of the chest x-ray for considering enrollment. 
Patients with negative TB test results on file:  Patients with documentation of a negative test 
result within 3 months prior to baseline (Week 0, Visit 2) do not need a TB screen at Visit 1.  
Documentation of a PPD test result must include a record of the size of the induration response
documenting no induration or induration measuring <5 mm in diameter. A PPD test recorded as 

I1F-MC-RHBW(d) Clinical Protocol
Page 58
LY2439821
negative without documenting the size of induration will result in a required test at screening to 
determine patient eligibility.
Patients with positive TB test results on file:  Patients with prior history of a positive TB test 
are not to have a TB test at Visit 1.  Documentation of this history and of at least 4 weeks of 
appropriate LTBI prior to baseline (Week 0, Visit 2) is required for study eligibility.  Patients 
who have a documented history of completing an appropriate TB treatment regimen with no 
history of re-exposure to TB since their treatment was completed, and no evidence of active TB,
are eligible to participate in the study.  Patients who have had household contact with a person 
with active TB are excluded, unless appropriate and documented prophylaxis for TB was 
completed.
8.4.7. Quick Inventory of Depressive Symptomatology–Self-Report 
(16 Items)
For each patient, a QIDS-SR16 assessment will be collected according to the Schedule of 
Activities (Appendix 2).
Any clinically significant findings from the QIDS-SR16 assessment that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment are to be reported to Lilly or 
its designee as AEs via CRF.
The QIDS-SR16 is a self-administered, 16-item instrument intended to assess the existence and 
severity of symptoms of depression as listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (APA 1994).  A patient is 
asked to consider each statement as it relates to the way they have felt for the past 7 days.  There 
is a 4-point scale for each item ranging from 0 to 3.  The 16 items corresponding to 9 depression 
domains are summed to give a single score ranging from 0 to 27, with higher scores denoting 
greater symptom severity.  The domains assessed by the instrument are (1) sad mood, 
(2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, 
(7) sleep disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in 
appetite/weight, and (9) psychomotor agitation/retardation.  Additional information and the 
QIDS-SR16 questions may be found at the University of Pittsburgh IDS/QIDS internet page 
(http://www.ids-qids.org/).
8.4.8. Columbia–Suicide Severity Rating Scale
The C-SSRS (Posner et al. 2007; Columbia University Medical Center [WWW]) is a scale that 
captures the occurrence, severity, and frequency of suicide-related ideations and behaviors 
during the assessment period.  The C-SSRS must be administered by appropriately trained site 
personnel.  The tool was developed by the National Institute of Mental Health (NIMH) 
Treatment of Adolescent Suicide Attempters (TASA) trial group for the purpose of being a 
counterpart to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) 
categorization of suicidal events.  Patients will be assessed according to the Schedule of 
Activities (Appendix 2).

I1F-MC-RHBW(d) Clinical Protocol
Page 59
LY2439821
The Self-Harm Supplement Form is a one-question form that is completed, at any visit, including 
baseline visits, that asks for the number of suicidal or nonsuicidal self-injurious behaviors the 
patient has experienced since the last assessment. For each unique event identified, a 
questionnaire (Self-Harm Follow-up Form) which collects supplemental information on the self-
injurious behavior is to be completed. This information is then documented in the eCRF. 
8.4.9. Immunogenicity
For each patient, an immunogenicity sample will be collected according to the Schedule of 
Activities (Appendix 2).  
Additionally, a blood sample is to be collected, as soon as possible, for any patient who 
experiences a potential systemic allergic/hypersensitivity reaction during the study as judged by
the investigator.  These samples will be tested for immunogenicity and PK, while other 
laboratory tests may be performed as needed to elucidate the cause of the allergic/
hypersensitivity reaction.
8.4.10. Safety Monitoring 
Lilly will periodically review evolving aggregate safety data within the study by appropriate 
methods.
If a study patient experiences elevated ALT ≥3xULN, alkaline phosphatase ≥2xULN, or elevated 
total bilirubin ≥2xULN, clinical and laboratory monitoring is to be initiated by the investigator.  
Details for hepatic monitoring depend upon the severity and persistence of observed laboratory 
test abnormalities.  For other AESIs or abnormal lab results, please refer to the appropriate 
protocol section that addresses these topics.  To ensure patient safety and comply with regulatory 
guidance, the investigator is to consult with the Lilly clinical research physician/clinical research 
scientist regarding collection of specific recommended clinical information and follow-up 
laboratory tests (see Appendix 4).
8.4.10.1. Neutropenia
8.4.10.1.1.During Treatment (Periods 2 and 3)
During treatment with investigational product, patients with neutrophil counts <1500 cells/L 
(<1.50x103/µL or <1.50 GI/L) are to be managed for neutropenia as follows:

<500 cells/L (<0.50x103/µL or <0.50 GI/L), see Discontinuation Criteria (Section 7.1)

≥500 cells/L and <1000 cells/L (≥0.50x103/µL and <1.00x103/µL or ≥0.50 GI/L and 
<1.00 GI/L), see Discontinuation Criteria (Section 7.1)

≥1000 cells/L and <1500 cells/L (≥1.00x103/µL and <1.50x103/µL or ≥1.00 GI/L and 
<1.50 GI/L), and the patient has a concurrent infection that requires systemic anti-
infective therapy (for example, antibiotic, antifungal agent, antiviral agent):  
o
The dose of investigational product is to be withheld, the patient is to receive 
appropriate medical care, and a repeat test for neutrophil count is to be performed 
within 4 weeks from knowledge of the initial report.  If the repeat neutrophil 
count has returned to ≥1500 cells/L (≥1.50x103/µL or ≥1.50x103/µL) and the 

I1F-MC-RHBW(d) Clinical Protocol
Page 60
LY2439821
infection has resolved or is resolving, the patient may resume dosing of 
investigational product and evaluation at scheduled visits.  If the neutrophil count 
remains ≥1000 cells/L and <1500 cells/L (≥1.00x103/µL and <1.50x103/µL or 
≥1.00 GI/L and <1.50 GI/L), investigational product is to continue to be withheld 
and a repeat neutrophil count is to again be performed within another 4 weeks.  If, 
after 2 repeat tests, the neutrophil count still remains ≥1000 cells/L and 
<1500 cells/L (≥1.00x103/µL and <1.50x103/µL or ≥1.00 GI/L and <1.50 GI/L), 
and:

the infection has not fully resolved, the patient will be discontinued from 
the study treatment.

the infection has resolved, the patient may resume dosing and evaluation 
at scheduled visits.  However, if resumption of dosing is not deemed 
appropriate by the investigator, the patient will be discontinued from the 
study treatment.

≥1000 cells/L and <1500 cells/L (≥1.00x103/µL and <1.50x103/µL or ≥1.00 GI/L and 
<1.50 GI/L), and the patient has no concurrent infection that requires systemic anti-
infective therapy (for example, antibiotic, antifungal agent, antiviral agent):  
o
Dosing may continue, and a repeat neutrophil count is to be performed 4 to 
8 weeks from knowledge of the initial report.  Testing may be at a regularly 
scheduled visit or at an unscheduled visit, as necessary.
Repeat testing is to be performed at 4- to 8-week intervals until the neutrophil 
count has returned to ≥1500 cells/L (≥1.50x103/µL or ≥1.50 GI/L).  If the 
patient has 3 or more postbaseline neutrophil counts of ≥1000 cells/L 
(≥1.00x103/µL or ≥1.00 GI/L) and <1500 cells/L (<1.50x103/µL or 
<1.50 GI/L), no value of <1000 cells/L (<1.00 x103/µL or <1.00 GI/L), and no 
postbaseline infection requiring systemic anti-infective therapy, the patient may 
continue or resume further evaluation at scheduled visits, as deemed appropriate 
by the investigator.
If a patient without initial concurrent infection develops an infection that requires systemic anti-
infective therapy, then the patient is to be managed as indicated above for patients with 
concurrent infection.  
8.4.10.1.2.At Early Termination Visit
For patients not enrolling in Study RHBY:  If, at the last scheduled study visit, the patient’s 
neutrophil count is <1500 cells/L (<1.50x103/µL or <1.50 GI/L) and less than the patient’s 
baseline neutrophil count, the following measures are to be taken:

Patients with Concurrent Infection:  If there is a concurrent infection that requires 
systemic anti-infective therapy, the patient is to receive appropriate medical care and a 
repeat test for neutrophil count is to be performed at least Q4W (or sooner as 
appropriate) until resolution of infection.  Upon resolution of infection, the neutrophil 
count is to be monitored using the required study visits in Post-Treatment Follow-Up 
Period (Period 4):  Visit 801 (4 weeks post-resolution of infection), Visit 802 (8 weeks 

I1F-MC-RHBW(d) Clinical Protocol
Page 61
LY2439821
after Visit 801 unless otherwise specified), and Visit 803 (if necessary; 12 weeks after 
Visit 802); additional visits may be required depending on the degree of neutropenia.  
For patients with a neutrophil count below the abovementioned threshold at Week 52 
who have already enrolled in Study RHBY, requirements for repeat test for neutrophil 
count will be specified in the Study RHBY protocol.

Patients without Concurrent Infection:  If there is no concurrent infection that requires 
systemic anti-infective therapy, the neutrophil count is to be monitored using the 
required study visits in the Post-Treatment Follow-Up Period (Period 4): Visit 801 
(4 weeks post-ETV or last regularly scheduled visit), Visit 802, and Visit 803 (if 
necessary); additional visits may be required depending on the degree of neutropenia.
8.4.10.1.3.Post-Treatment Follow-Up Period
For patients not enrolling in Study RHBY, at Visit 801 and subsequent visits, the following 
monitoring applies:

As long as a patient’s neutrophil count is <1000 cells/L (<1.00x103/µL or <1.00 GI/L)
at any follow-up visit, the patient is to return for visits at least Q4W (may require 
unscheduled visits).  

As long as a patient’s neutrophil count is ≥1000 cells/L and <1500 cells/L 
(≥1.00x103/µL and <1.50x103/µL or ≥1.00 GI/L and <1.50 GI/L) at any follow-up visit, 
the patient is to return for additional visit(s) at least every 4 to 8 weeks (may require 
unscheduled visits).  

If, at Visit 802 or Visit 803, the patient’s neutrophil count is ≥1500 cells/L 
(≥1.50x103/L or ≥1.50 GI/L) or greater than or equal to the patient’s baseline neutrophil 
count (whichever is lower), the patient’s participation in the study will be considered 
complete unless the investigator deems additional follow-up may be necessary.  
If, at Visit 803, the patient’s neutrophil count remains <1500 cells/L (<1.50x103/µL or 
<1.50 GI/L) and less than the patient’s baseline neutrophil count, or if the investigator deems 
additional follow-up may be necessary, the investigator, in consultation with Lilly, or qualified 
designee, will determine the appropriate management of the patient and the appropriate timing of 
additional contact(s) or visit(s).
8.4.10.2. Hepatitis B Monitoring
Patients that are HBcAb+ at screening, regardless of other hepatitis B testing results, will have a 
serum HBV DNA specimen obtained to be analyzed by the central laboratory.  Such patients that 
are determined to be HBV DNA negative (undetectable) may be enrolled into the study with 
required HBV DNA monitoring every 3 to 4 months during treatment and 12 weeks after the last 
dose of ixekizumab.  Patients that are found to be HBV DNA positive (detectable) at screening 
will be excluded from the trial.  
If the result of any subsequent HBV DNA testing is positive, the patient is to be discontinued 
from the study treatment, is to continue safety follow up, and is to receive appropriate follow-up 
medical care, including consideration for antiviral therapy. A specialist physician in the care of 
patients with hepatitis (for example, infectious disease or hepatologist subspecialists) is to be 

I1F-MC-RHBW(d) Clinical Protocol
Page 62
LY2439821
consulted and potentially start antiviral therapy prior to discontinuation of any 
immunosuppressant or immunomodulatory therapy (including investigational drug). Timing of 
discontinuation from the study and of any immunosuppressant/immunomodulatory therapy 
(including investigational product) needs to be based on the recommendations of the consulting 
specialist physician in conjunction with the investigator and medical guidelines/standard of care.
8.4.10.3. Hypertension
Patients who experience changes in BP (systolic BP at ≥160 mm Hg plus ≥20 mm Hg increase 
from baseline [Week 0, Visit 2]; and/or diastolic BP at ≥100 mm Hg plus ≥10 mm Hg increase 
from baseline) on 2 consecutive visits are to receive intervention for the management of 
hypertension.  Intervention could include the maximal intervention of withholding the dose of 
investigational product and/or the introduction of anti-hypertensive agent(s) as medically 
appropriate. 
8.5.
Pharmacokinetics
At the visits and times specified in the Schedule of Activities (Appendix 2), blood samples of 
approximately 4 mL each will be collected to determine the serum concentrations of ixekizumab.  
These blood samples for PK analysis are matched to the timing of samples for the assessment of 
immunogenicity.  It is expected that these PK samples will allow sufficient description of 
ixekizumab PK profiles at steady state throughout the study.  Instructions for the collection and 
handling of blood samples will be provided by the sponsor.  The actual date and time (24-hour 
clock time) of each sampling will be recorded.
Samples collected for PK analysis will be tested at a laboratory approved by Lilly or its designee.  
Concentrations of immunoreactive ixekizumab in human serum will be determined by a 
validated method.
Bioanalytical samples collected to measure investigational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study.
8.6.
Pharmacodynamics
Refer to Section 9.6.
8.7.
Genetics
A blood sample will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities (Appendix 2) where local regulations and ERBs allow. These samples are not being 
collected to create a biobank for conducting unspecified disease or population genetic research 
either now or in the future. Samples may be used to investigate variable response to ixekizumab 
and to investigate genetic variants thought to play a role in axSpA and/or associated 
autoimmune/inflammatory conditions. Assessment of variable response may include evaluation 
of AEs or differences in efficacy. These studies may include but are not limited to axSpA and/or 
associated autoimmune/inflammatory conditions to evaluate their association with observed 
response to ixekizumab.

I1F-MC-RHBW(d) Clinical Protocol
Page 63
LY2439821
All pharmacogenetic samples will be coded with the patient number. These samples and any 
data generated can be linked back to the patient only by the investigator site personnel. Samples 
will be destroyed according to a process consistent with local regulations.
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or 
for a shorter period if local regulations and/or ERBs impose shorter time limits, at a facility 
selected by the sponsor. This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in drug development or when the drug is commercially available.
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, candidate gene studies, and epigenetic 
analyses. Regardless of technology utilized, genotyping data generated will be used only for the 
specific research scope described here.
8.8.
Biomarkers
Urine, serum, plasma, RNA, and whole blood for epigenetics samples will be collected for non-
genetic biomarker research at the times specified in the Schedule of Activities (Appendix 2) 
where local regulations and ERBs allow.  Samples will be used for research on the drug target, 
disease process, pathways associated with axSpA and/or associated autoimmune/inflammatory
conditions, MoA of ixekizumab, and/or research method, or in validating diagnostic tools or 
assay(s) related to axSpA and/or associated autoimmune/inflammatory conditions.
All biomarker samples will be coded with the patient number. These samples and any data 
generated can be linked back to the patient only by the investigator site personnel. Samples will 
be destroyed according to a process consistent with local regulations.
Samples will be retained for a maximum 15 years after the last patient visit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by 
the sponsor. This retention period enables use of new technologies, response to regulatory 
questions, and investigation of variable response that may not be observed until later in drug 
development or when the drug is commercially available.
8.8.1. Samples for Immunogenicity Research
Blood samples for immunogenicity testing will be collected to determine antibody production 
against the investigational product(s) as specified in the Schedule of Activities
(Appendix 2). Immunogenicity will be assessed using a validated assay designed to detect ADA
in the presence of the investigational product(s).  Antibodies may be further characterized and/or 
evaluated for their ability to neutralize the activity of the investigational product(s). 
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or 
for a shorter period if regulations and ERBs impose shorter time limits, at a facility selected by 
the sponsor.  The duration allows the sponsor to respond to future regulatory requests related to 
the ixekizumab.

I1F-MC-RHBW(d) Clinical Protocol
Page 64
LY2439821
8.9.
Health Economics
Refer to Section 8.1.2.

I1F-MC-RHBW(d) Clinical Protocol
Page 65
LY2439821
9. Statistical Considerations and Data Analysis
9.1. Determination of Sample Size
Approximately 300 patients will be randomized at a 1:1:1ratio in the Blinded Treatment Dosing
Period (Period 2) to ixekizumab80mg Q2W, ixekizumab80 mg Q4W,and placebo.  With 
100patients per treatment group, 
 
 
assumptions are 
based on the review of historical clinical studies in rad-axSpA(etanercept, adalimumab, 
infliximab, certolizumab,and golimumab [Daviset al. 2003; van der Heijde et al. 2005,2006; 
Inman et al. 2008, Landewéet al. 2014]) and recent secukinumab data in patients who are TNF
inhibitorexperienced (Baeten et al.2014b;Sieper et al.2014).  
9.2. General Statistical Considerations
Statistical analysis of this study will be the responsibility of Lilly.
Continuous data will be summarized in terms of the mean, standard deviation, minimum, 
maximum, median, and number of observations.  Categorical data will be summarized as 
frequency counts and percentages.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the justification formaking the change, will be described 
in the clinical study report(CSR).  Additional exploratory analyses of the data will be conducted 
asdeemed appropriate.  
Complete details of the planned analyses will be documented in the SAP.
9.2.1. General Considerationsfor Analyses during the Blinded 
Treatment DosingPeriod(Period 2)
CCI
Comparisons between each ixekizumabregimen (80 mg Q2W or 80 mg Q4W) and placebowill 
be performed for all analyses in Period 2.  
Period 2 starts at the first injection of study treatmentat Week 0 (Visit 2) and ends prior to the 
first injection of study treatment at Week 16 (Visit 8) or the ETV (between Weeks0 and 16).
Baseline will be defined as the last available value before the first injection for efficacy, health 
outcomes,and safety analyses.  In most cases, this will be the measure recorded at Week 0 
(Visit2).  For efficacy measures, if the patient does not take any injection, the last available 
value on or prior to randomization date will be used.  Change from baseline will be calculated as 
the visit value of interest minus the baseline value. For safety analyses using a baseline period, 
the baseline period is defined as the time from Visit 1 to the date/time of the first injection.

I1F-MC-RHBW(d) Clinical Protocol
Page 66
LY2439821
The randomization to treatment groups is stratified by country, baseline CRP status (nonelevated
or elevated), and number of prior TNF inhibitors used (1 or 2) as described in Section 6.2. The 
countries will be categorized into geographic regions for analysis.  Geographic regions will be 
defined in the SAP upon country finalization. Unless otherwise specified, the statistical analysis 
models will adjust for geographic region, baseline CRP status, and number of prior TNF
inhibitors used.  
Unless otherwise specified, treatment groups of ixekizumab 80 mg Q2W and Q4W will be 
analyzed without regard to starting dose.
The primary analysis method for treatment comparisons of categorical efficacy and health 
outcomes variables at specific time points will be made using a logistic regression analysis with 
treatment, geographic region, baseline CRP status, and number of prior TNF inhibitors used in 
the model.  The odds ratio and 95% confidence intervals (CIs) will be reported; treatment 
difference and 95% CIs will also be reported.  Secondary analysis will be conducted using a 
Fisher’s exact test.
As a secondary analysis for the primary and major secondary categorical efficacy measures, a 
categorical mixed-effects model of repeated measures (categorical MMRM) estimating the 
percentage of patients achieving response across postbaseline visits may be used.  The model 
will include treatment, geographic region, baseline CRP status, number of prior TNF inhibitors
used, visit, and treatment-by-visit as fixed factors, as well as the continuous, fixed covariate of 
baseline value and baseline value-by-visit interaction (when appropriate).  The binomial 
distribution and the logit link will be used.  An unstructured covariance matrix will be used to 
model the within-patient variance-covariance errors.  The Kenward-Roger approximation will be 
used to estimate the denominator degrees of freedom.  The Newton-Raphson with ridging 
optimization technique will be used to aid with convergence.  The probability of response, the 
corresponding 2-sided 95% CI, and the p-value for treatment comparisons at Week 16 (Visit 8) 
and all other postbaseline visits will be reported.  
If the unstructured covariance matrix results in a lack of convergence, the heterogeneous 
Toeplitz covariance structure, followed by the heterogeneous autoregressive covariance 
structure, followed by the compound symmetry, will be used.  This order is specified according 
to a decreasing number of covariance parameters in the structure.  The sandwich estimator 
(Diggle et al. 1994) for the covariance estimation will be used by specifying the EMPIRICAL 
option in SAS PROC MIXED.  When sandwich estimation is used, the Kenward-Roger 
approximation for denominator degrees of freedom cannot be used.  Instead, the DDFM= 
BETWITHIN option will be used to estimate denominator degrees of freedom.
The primary analyses for continuous efficacy and health outcomes variables will be made using 
MMRM.  A secondary analysis for continuous efficacy and health outcomes variables will be 
made using analysis of covariance (ANCOVA).
When the MMRM is used, the model will include treatment, geographic region, baseline CRP 
status, number of prior TNF inhibitors used, baseline value, baseline value-by-visit, visit, and 
treatment-by-visit interaction as fixed factors.  The covariance structure to model the 

I1F-MC-RHBW(d) Clinical Protocol
Page 67
LY2439821
within-patient errors will be unstructured.  If the unstructured covariance matrix results in a lack 
of convergence, the similar approach specified above for categorical MMRM will be used.  The 
Kenward-Roger method will be used to estimate the denominator degrees of freedom.  Type III 
tests for the least-squares (LS) means will be used for the statistical comparison; the 95% CI will 
also be reported.  Treatment group comparisons with placebo at Week 16 (Visit 8) and all other 
visits will be tested.
When the ANCOVA is used, the model will include treatment, geographic region, baseline CRP 
status, number of prior TNF inhibitors used, and baseline value.  Type III sums of squares for the 
LS means will be used for the statistical comparison; the 95% CI will also be reported.
The impact of ixekizumab starting dose of 160 mg versus 80 mg on time-to-onset (focus on 
Week 4) and treatment response during the Period 2 (focus on Week 16) will be summarized and 
evaluated; details will be specified in the SAP.
For variables that are not collected at each postbaseline visit, data may exist at visits where the 
variable was not scheduled to be collected, due to early discontinuation visits.  In these 
situations, data from the early discontinuation visit that do not correspond to the planned 
collection schedule will be excluded from the MMRM and categorical MMRM analyses.  
However, the data will still be used in other analyses, including shift analyses, change from 
baseline to last observation carried forward (LOCF) or modified baseline observation carried 
forward (mBOCF) endpoint analyses and other categorical analyses.
Fisher’s exact test will be used for all AE, baseline, discontinuation, and other categorical safety 
data.  Continuous vital sign and laboratory values will be analyzed by an ANCOVA with 
treatment and baseline value in the model.
9.2.2. General Considerations for Analyses during the Extended 
Treatment Period (Period 3) 
Unless otherwise specified, Period 3 starts at the first injection of study treatment at Week 16 
(Visit 8) and ends on the date of Week 52 (Visit 15) or the ETV (between Weeks 16 and 52).
For the efficacy and health outcomes analyses, baseline is defined as the last available value 
before the first injection in Period 2 and, in most cases, will be the value recorded at Week 0 
(Visit 2).
Unless otherwise specified, for the safety analyses during Period 3, baseline is defined as the last 
available value before first injection of ixekizumab in Period 3.  In most cases, this will be the 
measure recorded at Week 16 (Visit 8).
All efficacy and safety data collected will be summarized using descriptive statistics.
9.2.3. General Considerations for Analyses during the Post-
Treatment Follow-Up Period (Period 4)
For the safety analyses during Period 4, baseline is defined as the last nonmissing assessment on 
or prior to entering Period 4, that is, on or prior to Week 52 (Visit 15), or ETV.  

I1F-MC-RHBW(d) Clinical Protocol
Page 68
LY2439821
Safety data collected will be summarized using descriptive statistics.
9.2.4. Analysis Populations 
The following analysis populations will be used:
Intent-to-Treat Population (ITT):  Unless otherwise specified, efficacy and health outcomes 
analyses for Period 2 will be conducted on the ITT population, defined as all randomized 
patients, even if the patient does not take the assigned treatment, does not receive the correct 
treatment, or otherwise does not follow the protocol.  Patients will be analyzed according to the 
treatment to which they were assigned.
Per-Protocol Set (PPS): In addition, the primary efficacy analysis will be repeated using the 
PPS, which is defined as all randomized patients who are compliant with therapy, who do not 
have significant protocol deviations, and whose investigator site does not have significant GCP 
issues that require a report to the regulatory agencies prior to Week 16 (Visit 8).  Compliance 
with therapy is defined to be missing no more than 20% of expected doses, not missing 
2 consecutive doses (all injections at a visit are counted as 1 dose), and not have any occurrence 
of double-dosing (that is, took more injections at the same time point than specified in the 
protocol) during Period 2.
Significant protocol deviations will be described in the SAP.  Patients will be analyzed according 
to the treatment to which they were assigned.
Safety Population: Safety analyses for Period 2 will be conducted on the Safety Population, 
defined as all randomized patients who received at least 1 dose of study treatment.  Patients will 
be analyzed according to the treatment to which they were assigned in that period.
Extended Treatment Period Population: Efficacy, health outcomes, and safety analyses for 
Period 3 will be conducted on the Extended Treatment Period Population, defined as all patients 
who received at least 1 dose of ixekizumab treatment during Period 3.
Follow-Up Population: Safety analyses for Period 4 will be conducted on the Follow-Up 
Population, defined as all randomized patients who received at least 1 dose of study treatment 
and have entered Period 4.  Patients will be analyzed according to the treatment they received 
before entering Period 4.
9.2.5. Missing Data Imputation 
In accordance with precedent set with other Phase 3 axSpA trials (van der Heijde et al. 2006; 
Inman et al. 2008), the following methods for imputation of missing data will be used.
9.2.5.1.
Nonresponder Imputation 
Analysis of categorical efficacy and health outcomes variables will be assessed using a 
nonresponder imputation (NRI) method.  Patients will be considered nonresponders for the NRI 
analysis if they do not meet the clinical response criteria or have missing clinical response data at 
the primary analysis time point.  All nonresponders at Week 16 (Visit 8), as well as all patients 
who discontinue study treatment at any time prior to Week 16 for any reason, will be defined as 

I1F-MC-RHBW(d) Clinical Protocol
Page 69
LY2439821
nonresponders for the NRI analysis at Week 16.  Randomized patients without at least 
1 postbaseline observation will also be defined as nonresponders for the NRI analysis.
The NRI may be applied at any time point specified for analysis.
9.2.5.2.
Modified Baseline Observation Carried Forward
An mBOCF analysis will be performed on efficacy and health outcomes variables in the major 
and other secondary objectives.  For patients discontinuing study drug due to an AE, the baseline 
observation will be carried forward to the corresponding time point for evaluation.  For patients 
discontinuing study drug for any other reason, the last nonmissing observation before 
discontinuation will be carried forward to the corresponding time point for evaluation.  
Randomized patients without at least 1 postbaseline observation will not be included for 
evaluation with the exception of patients discontinuing study treatment because of an AE.
9.2.5.3.
Last Observation Carried Forward
An LOCF analysis will be performed on continuous efficacy and health outcomes variables in 
the major secondary objectives.  This approach is identical to the mBOCF approach, with one 
exception:  For patients discontinuing study drug because of an AE, the last nonmissing 
postbaseline observation before discontinuation will be carried forward to the corresponding 
endpoint for evaluation.  Randomized patients without any postbaseline observation will not be 
included for evaluation.
9.2.6. Adjustment for Multiple Comparisons 
A multiple testing strategy for the primary and major secondary objectives will be implemented 
to control the overall family-wise type I error rate at a 2-sided α level of 0.05.  A graphical 
multiple testing procedure (Bretz et al. 2011) will be used (Figure RHBW.2). The graphical 
approach is a closed testing procedure; hence, it strongly controls the family-wise error rate 
(Alosh et al. 2014).  The following is a list of primary and major secondary outcomes to be tested 
for both ixekizumab 80 mg Q2W and Q4W regimens at Week 16:

Primary:
proportion of patients achieving an ASAS40 response [ASAS40]

Secondary 1: proportion of patients achieving an ASAS20 response [ASAS20]

Secondary 2: change from baseline (CFB) in ASDAS score [ASDAS CFB]

Secondary 3: proportion of patients achieving BASDAI50 [BASDAI50]

Secondary 4: change from baseline in BASFI [BASFI CFB]

Secondary 5: proportion of patients achieving ASDAS inactive disease [ASDAS 
inactive]

Secondary 6: change from baseline in SF-36 PCS score [SF-36 PCS CFB]

Secondary 7: change from baseline in ASAS HI [ASAS HI CFB]

Secondary 8: change from baseline in MRI of the spine [MRI spine SPARCC score
CFB].
The 8 secondary outcomes are grouped into 2 tiers (Figure RHBW.2) based on the clinical 
importance as well as statistical significance observed in historical axSpA studies. 
Figure RHBW.2 shows a general form of the graphical testing scheme.  

I1F-MC-RHBW(d) Clinical Protocol
Page 70
LY2439821
The primary outcome of ASAS40 will be tested for ixekizumab 80 mg Q2W versus placebo at a 
2-sided α=0.05.  If the null hypothesis is not rejected, no further testing is conducted, as the α for 
that test is considered “spent” and cannot be passed to other endpoints.  If the null hypothesis is 
rejected, the α will be distributed to the Tier 1 set of secondary outcomes for ixekizumab 80 mg 
Q2W and ASAS40 for ixekizumab 80 mg Q4W.  The testing process continues for the remaining 
outcomes by allocating the remaining α to the next set of outcomes as long as at least one 
hypothesis can be rejected.  Each time a hypothesis is rejected, the graph is updated to reflect the 
reallocation of α, which is considered “recycled” (Alosh et al. 2014).  This iterative process of 
updating the graph and reallocating α is repeated until all major secondary hypotheses have been 
tested or when no remaining hypotheses can be rejected at their corresponding α levels.  The 
weights along the edges for α allocation between ixekizumab 80 mg Q2W and ixekizumab 
80 mg Q4W outcomes, as well as within each of the tiers, will be prespecified in the SAP prior 
to the first patient randomization of the study.

I1F-MC-RHBW(d) Clinical Protocol
Page 71
LY2439821
Abbreviations:  ASAS = Assessment of Spondyloarthritis International Society; ASAS HI = ASAS Health Index; 
ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease 
Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; CFB = change from baseline; SF-36 
PCS = Short Form 36 physical component score; SPARCC = Spondyloarthritis Research Consortium of Canada; 
Q2W = every 2 weeks; Q4W = every 4 weeks.
Figure RHBW.2.
Illustration of graphical multiple testing procedure.
There will be no adjustment for multiple comparisons for any other analyses.  
9.3.
Treatment Group Comparability
9.3.1. Patient Disposition
All patients who prematurely discontinue from the study treatment and/or from the study will be 
identified, and the extent of their participation in the study will be reported. 
Tier 1 Q2W
ASAS20
ASDAS CFB
BASDAI50
BASFI CFB
ASDAS-Inactive
ASAS40
Q2W
α = 0.05
ASAS40
Q4W
Tier 2 Q2W
SF-36 PCS CFB
ASAS- HI CFB
MRI spine SPARCC CFB
Tier 1 Q4W
ASAS20
ASDAS CFB
BASDAI50
BASFI CFB
ASDAS-Inactive
Tier 2 Q4W
SF-36 PCS CFB
ASAS-HI CFB
MRI spine SPARCC CFB

I1F-MC-RHBW(d) Clinical Protocol
Page 72
LY2439821
Patient disposition will be summarized for each treatment period with reasons for 
discontinuation.  The reasons for discontinuation during Period 2 will be compared between 
treatment groups using Fisher’s exact test.
9.3.2.
Patient Characteristics
Patient characteristics and baseline clinical measures will be summarized for each treatment 
period.  Baseline characteristics will include sex, age, age category, weight, body mass index 
(BMI), race, geographic region, country, baseline disease activity (BASDAI), duration of 
disease, HLA-B27 positivity, baseline CRP (% of nonelevated or elevated), baseline MRI status, 
number of prior TNF inhibitors used, and history of extra-axial disease manifestations.  Baseline 
clinical measurements may include ASDAS, CRP, BASFI, BASMI, chest expansion, Fatigue 
NRS, Patient Global NRS, total back pain, spinal pain at night due to AS, spinal pain due to AS, 
inflammation (mean of questions 5 and 6 of BASDAI), MASES, SPARCC Enthesitis, TJC, and 
SJC.
Treatment group comparisons in Period 2 will be conducted using Fisher’s exact test for 
categorical data and an analysis of variance (ANOVA) with treatment as a factor for continuous 
data.
9.3.3. Concomitant Therapy
Previous and concomitant medications will be summarized for patients who enter each treatment 
period and will be presented by WHO Anatomic Therapeutic Class Level 4 and WHO preferred 
term.  Concomitant DMARDs, concomitant oral corticosteroids, and concomitant NSAIDs will 
also be summarized.  Treatment group comparisons in Period 2 will be conducted using Fisher’s 
exact test.
9.3.4. Treatment Compliance 
Treatment compliance with investigational product will be summarized for patients who enter 
each treatment period.  A patient will be considered overall compliant for each study period if 
he/she is missing no more than 20% of the expected doses, does not miss 2 consecutive doses,
and does not over-dose (that is, take more injections at the same time point than specified in the 
protocol).
Proportions of patients compliant by visit and overall will be compared between treatment 
groups during Period 2 using Fisher’s exact test.
9.4.
Primary and Secondary Analyses
9.4.1. Primary Analyses
The primary analysis, the proportion of patients with ASAS40 at Week 16 compared with 
placebo, will be based on the ITT Population.  In addition, an analysis of the PPS Population will 
be used to support the primary efficacy analysis.

I1F-MC-RHBW(d) Clinical Protocol
Page 73
LY2439821
Treatment comparisons between each ixekizumab treatment group and placebo in the proportion 
of patients achieving an ASAS40 response at Week 16 (Visit 8) will be analyzed using the 
logistic regression model defined in Section 9.2.1.  Missing data will be imputed using the NRI 
method described in Section 9.2.5.
Secondary analyses for ASAS40 at Week 16 will be conducted using categorical MMRM and 
Fisher’s exact test as described in Section 9.2.1.
9.4.2. Secondary Analyses 
9.4.2.1.
Major Secondary Analyses 
The major secondary analyses at Week 16 will be based on the ITT population for Period 2.  The 
major secondary comparisons will be based on the multiple testing procedure detailed in 
Section 9.2.6. Treatment comparisons in the proportion of patients achieving a categorical 
response at Week 16 (Visit 8) will be analyzed using the logistic regression model defined in 
Section 9.2.1. For categorical responses, missing data will be imputed using the NRI method 
described in Section 9.2.5.  Treatment comparisons in the continuous measures will be analyzed 
using the MMRM model defined in Section 9.2.1.
Table RHBW.5 summarizes the primary and major secondary outcomes and analysis methods.  
All analyses listed will be performed based on the ITT Population unless otherwise specified.

I1F-MC-RHBW(d) Clinical Protocol
Page 74
LY2439821
Table RHBW.5.
Primary and Major Secondary Outcome Analyses
Outcome Measure
Primary Analysis Method 
Secondary Analysis Method 
ASAS40 (primary efficacy 
outcome)
Logistic regression analysis 
with NRI 
Categorical MMRM
Fisher’s exact test with NRI
Logistic regression analysis with NRI on PPS 
ASAS20 (major secondary 
outcome)
Logistic regression analysis 
with NRI
Categorical MMRM
Fisher’s exact test with NRI
Logistic regression analysis with NRI on PPS
Change from baseline in ASDAS 
(major secondary outcome)
MMRM
ANCOVA with mBOCF/LOCF
BASDAI50 (major secondary 
outcome)
Logistic regression analysis 
with NRI
Categorical MMRM
Fisher’s exact test with NRI
Change from baseline in BASFI 
(major secondary outcome)
MMRM
ANCOVA with mBOCF/LOCF
ASDAS inactive disease (major 
secondary outcome)
Logistic regression analysis 
with NRI
Categorical MMRM
Fisher’s exact test with NRI
Change from baseline in SF-36 PCS 
(major secondary outcome)
MMRM
ANCOVA with mBOCF/LOCF
Change from baseline in the ASAS 
HI (major secondary outcome)
MMRM
ANCOVA with mBOCF/LOCF
Change from baseline in MRI of the 
spine [SPARCC score] (major
secondary outcome)
ANCOVA with observed 
case analysisa
Secondary analysis maybe specified in SAP
Abbreviations:  ANCOVA = analysis of covariance; ASAS = Assessment of Spondyloarthritis International Society; 
ASAS HI = Assessment of Spondyloarthritis International Society Health Index; ASDAS = Ankylosing 
Spondylitis Disease Activity Score; BASDAI50 = Bath Ankylosing Spondylitis Disease Activity Index 50; 
BASFI = Bath Ankylosing Spondylitis Functional Index; LOCF = last observation carried forward; mBOCF = 
modified baseline observation carried forward; MMRM = mixed-effects model of repeated measures; MRI = 
magnetic resonance imaging; NRI = nonresponder imputation; PPS = per-protocol set; SAP = statistical analysis 
plan; SF-36 PCS = Short Form-36 physical component scores; SPARCC = Spondyloarthritis Research 
Consortium of Canada. 
a
Only patients with both baseline and Week 16 MRI scores will be included in the observed case analysis. 
9.4.2.2.
Other Secondary Efficacy Analyses 
There will be no adjustment for multiple comparisons.  Analyses will be conducted for the other 
secondary efficacy objectives defined in Section 3.  Specific details of analyses will be specified 
in the SAP.
9.4.2.2.1. Period 2 (Blinded Treatment Dosing Period)
Unless otherwise specified, the other secondary analyses during Period 2 will be based on the 
ITT Population.
Treatment comparisons in the proportion of patients achieving a categorical response at specified 
time points will be analyzed using the logistic regression model defined in Section 9.2.1. 
Missing data will be imputed using the NRI method described in Section 9.2.5.
For all continuous efficacy variables that are collected at repeated visits, treatment group 
comparisons will be analyzed using the MMRM model defined in Section 9.2.1.  No imputation 

I1F-MC-RHBW(d) Clinical Protocol
Page 75
LY2439821
methods are applied to MMRM analysis.  Additional analyses will be conducted using the 
ANCOVA model defined in Section 9.2.1; missing data will be imputed by the mBOCF method 
as described in Section 9.2.5.  For continuous efficacy variables that are collected only once 
within Period 2, analyses will be made using the ANCOVA model with the mBOCF method.
9.4.2.2.2. Period 3 (Extended Treatment Period) 
Data collected in this study period will be summarized for the Extended Treatment Period 
Population.  The within-treatment group comparisons may be conducted as appropriate.  
9.4.3. Other Exploratory Analyses
Details about exploratory analyses will be included in the SAP or appropriate biomarker analysis 
plan.  
9.5.
Safety Analyses
Safety will be assessed by summarizing and analyzing AEs including adjudicated 
cerebrocardiovascular events, laboratory analytes including neutrophil counts, QIDS-SR16, 
C-SSRS, and vital signs.  The duration of treatment exposure will also be summarized.
For Period 2 (Blinded Treatment Dosing Period), safety data will be summarized for the Safety 
Population.  Treatment group comparisons will be performed on categorical safety data using 
Fisher’s exact test as described in Section 9.2.1; continuous safety data will be analyzed by an 
ANCOVA model.
For Period 3 (Extended Treatment Period), the safety data will be summarized and no treatment 
group comparisons will be performed.  
For Period 4 (Post-Treatment Follow-Up Period), safety data will be summarized according to 
the treatment patients were on prior to entering Period 4. 
The categorical safety measures will be summarized with incidence rates.  The mean change of 
the continuous safety measures will be summarized by visits.
Further details will be described in the SAP.
9.5.1. Adverse Events
Adverse events are classified based upon the Medical Dictionary for Regulatory Activities 
(MedDRA).  A treatment-emergent adverse event (TEAE) is defined as an event that first 
occurred or worsened in severity after baseline and on or prior to the date of the last visit within 
the treatment period.  Both the date/time of the event onset and the date/time of the first study 
drug injection are considered when determining TEAEs.  Treatment-emergent adverse events
will be assigned to the treatment period in which they first occurred or worsened.  A follow-up 
emergent adverse event (FEAE) is defined as an event that first occurred or worsened in severity 
after the date of Week 52 (Visit 15) or the ETV.  For events that are gender-specific, the 
denominator and computation of the percentage will include only patients from the given gender.

I1F-MC-RHBW(d) Clinical Protocol
Page 76
LY2439821
An overall summary of AEs will be provided for each of the treatment periods, including the 
number and percentage of patients who experienced TEAEs, TEAEs by maximum severity, 
deaths, SAEs, TEAEs related to study drug, discontinuations from the treatment due to an AE, 
and treatment-emergent AESIs.  Treatment-emergent adverse events (all, by maximum severity, 
and TEAEs possibly related to study drug by the investigator), SAEs including deaths, and AEs 
that lead to treatment discontinuation will be summarized and analyzed by MedDRA system 
organ class (SOC) and preferred term. 
In addition to general safety parameters, safety information on specific topics of AESIs will also 
be presented.  Potential AESIs will be identified by a standardized MedDRA query (SMQ) or a 
Lilly-defined MedDRA preferred term listing.
Follow-up emergent adverse events, SAEs including deaths, and AEs that lead to study 
discontinuation will be summarized for Period 4.  
9.5.2. Clinical Laboratory Tests
Laboratory assessments will be presented as mean changes from baseline, and as incidence of 
treatment-emergent abnormal, high, or low laboratory values (see below).  Shift tables will be 
presented for selected parameters.  

For categorical lab tests: 
o
Treatment-emergent abnormal value = a change from normal at all baseline visits 
to abnormal at any time postbaseline.

For continuous lab tests: 
o
Treatment-emergent high value = a change from a value less than or equal to the 
high limit at all baseline visits to a value greater than the high limit at any time 
postbaseline.  
o
Treatment-emergent low value = a change from a value greater than or equal to 
the low limit at all baseline visits to a value less than the low limit at any time 
postbaseline.
9.5.3. Vital Signs, Physical Findings, and Other Safety Evaluations
Vital signs will be presented as mean changes from baseline and as incidence of treatment-
emergent high or low values (see below) and will be summarized both pre- and postdose at 
Week 0 (Visit 2), Week 16 (Visit 8), and Week 20 (Visit 9) as applicable.

For treatment-emergent high and low:
o
A treatment-emergent high result is defined as a change from a value less than or 
equal to the high limit at baseline to a value greater than the high limit at any time 
that meets the specified change criteria during the treatment period.
o
A treatment-emergent low result is defined as a change from a value greater than 
or equal to the low limit at baseline to a value less than the low limit at any time 
that meets the specified change criteria during the treatment period.

I1F-MC-RHBW(d) Clinical Protocol
Page 77
LY2439821
The maximum postbaseline QIDS-SR16 total score will be summarized by treatment group, and 
a shift table will be produced for the change from baseline in QIDS-SR16 total score category.
Suicide-related thoughts and behaviors and self-injurious behavior with no suicidal intent, based 
on the C-SSRS, will be listed by patient.
9.6.
Pharmacokinetic/Pharmacodynamic/Immunogenicity Analyses
Observed ixekizumab serum concentrations will be summarized by treatment regimen, visit, and 
corresponding time when sampling occurred.
As appropriate, the PK and the exposure-response relationship between ixekizumab exposure 
and clinically important efficacy measures (for example, ASAS40 or ASAS20) may be explored 
using graphical methods and/or a modeling approach.  Pharmacokinetic and/or 
exposure-response data from this study may be combined with existing PK and/or exposure-
response data from other studies, if considered appropriate.  
If a trend or statistically significant difference between the ixekizumab dose cohorts and/or the 
placebo cohort is noted in any safety endpoint, the exposure relationship for this endpoint may be 
explored graphically.
In addition, the potential impact of immunogenicity on ixekizumab exposure and/or efficacy 
responses may be evaluated by graphical assessments, as appropriate, to compare drug exposure 
or efficacy responses between ADA negative and ADA positive patients at corresponding visits, 
or before and after ADA development for patients who develop ADA.  Both treatment-emergent 
only and all ADA positive/negative patients may be explored.  A similar approach may be taken 
if patients become NAb positive.  The effect of immunogenicity may be evaluated as a covariate 
in the population PK and exposure-response analyses, if applicable. 
9.7.
Other Analyses
9.7.1. Health Economics 
There will be no adjustment for multiple comparisons.  Analyses will be conducted for the other 
secondary health outcomes objectives as defined in Section 3.  
Period 2 (Blinded Treatment Dosing Period):  
Unless otherwise specified, the other secondary analyses during Period 2 will be based on the 
ITT Population.  
Treatment comparisons in the proportion of patients achieving a categorical response at specified 
time points will be analyzed using the logistic regression model defined in Section 9.2.1. 
Missing data will be imputed using the NRI method described in Section 9.2.5.
For all continuous health outcomes variables that are collected at repeated visits, treatment group 
comparisons will be analyzed using the MMRM model defined in Section 9.2.1.  No imputation 
methods are applied to MMRM analysis.  Additional analyses will be conducted using the 
ANCOVA model defined in Section 9.2.1; missing data will be imputed by the mBOCF method 

I1F-MC-RHBW(d) Clinical Protocol
Page 78
LY2439821
as described in Section 9.2.5.  For continuous health outcomes variables that are collected only 
once within the Period 2, analyses will be made using the ANCOVA model with the mBOCF
method.
Period 3 (Extended Treatment Period):  
Data collected in Period 3 will be summarized for the Extended Treatment Period Population.  
The within-treatment group comparisons may be conducted as appropriate.  
Additional analyses of health outcomes measures will be specified in the SAP.
9.7.2. Subgroup Analyses
Subgroup analyses will be conducted for ASAS40 and selective major secondary outcomes 
(defined in the SAP) at Week 16 (Visit 8) using the ITT Population. 
Subgroup analyses may be conducted based on gender, age category, race, baseline disease 
severity, country, geographic region, baseline CRP status, baseline MRI status, number of prior 
TNF inhibitors used, and presence of HLA-B27.
For ASAS40, a logistic regression model with treatment, subgroup, and the interaction of 
subgroup-by-treatment included as factors will be used.  The subgroup-by-treatment interaction 
will be tested at the significance level of 0.10.  Treatment group differences will be evaluated 
within each category of the subgroup using Fisher’s exact test, regardless of whether the 
interaction is statistically significant.  Missing data will be imputed using NRI as described in 
Section 9.2.5.  If any group within the subgroup is <10% of the total population, only summaries 
of the efficacy data will be provided (that is, no inferential testing).
For continuous efficacy outcome (for example, mean change from baseline in ASDAS), an 
ANCOVA model with treatment, baseline value, subgroup, and the interaction of subgroup-by-
treatment will be used.  The subgroup-by-treatment interaction will be tested at the significance 
level of 0.10.  Treatment group differences will be evaluated within each category of the 
subgroup using an ANCOVA model with treatment and baseline value as a covariate, regardless 
of whether the interaction is statistically significant.  Missing data will be imputed using the
mBOCF method as described in Section 9.2.5.
Detailed description of the subgroup variables will be provided in the SAP.  Additional subgroup 
analyses on efficacy or subgroup analyses on safety may be performed as deemed appropriate 
and necessary.
9.7.3. Immunogenicity
The analyses of ADA effects will be conducted on all evaluable patients within the defined 
safety population.  Evaluable patients will be defined as either a) patients with an evaluable 
baseline sample and at least 1 evaluable postbaseline sample (that is, sample after administration 
of study drug); or b) patients with no evaluable baseline sample whose evaluable postbaseline 
samples were all ADA negative.

I1F-MC-RHBW(d) Clinical Protocol
Page 79
LY2439821
A TE-ADA positive patient will be defined as any occurrence of a ≥4-fold or 2 dilution increase 
in immunogenicity titer over the baseline titer.  This is equivalent to an increase in titer to ≥1:10, 
in the case of a negative result at baseline.  The frequency and percentage (incidence) of patients 
with positive, negative, or inconclusive ADA at baseline and postbaseline (and NAb at baseline 
and postbaseline) will be summarized by treatment group.  Patients who are TE-ADA positive, 
TE-ADA persistent positive, and TE-ADA transient positive will also be summarized.
The potential impact of immunogenicity on ixekizumab exposure and/or efficacy responses will 
be evaluated, as appropriate. 
Assessment of immunogenicity with respect to safety will include comparison of patients who 
experience TEAEs of systemic allergy/hypersensitivity and of injection site reactions, and who 
also develop treatment-emergent anti-ixekizumab antibody positivity with patients who 
experience the same types of TEAEs but who remain treatment-emergent anti-ixekizumab 
antibody negative.  Anti-ixekizumab antibody titers will also be evaluated in anti-ixekizumab 
antibody positive patients who experience these events.
9.8.
Interim Analyses
An interim database lock and unblinding will occur, and interim analyses will be performed at 
the time (that is, a cutoff date) the last patient completes Visit 8 (Blinded Dosing Treatment 
Period [Period 2], Week 16) or ETV.  This interim database lock will include all data collected 
by the cutoff date, including the data from the Extended Treatment Period (Period 3) and follow-
up data from patients that have begun the Post-Treatment Follow-Up Period (Period 4).  The 
analyses from the Week 16 lock will be treated as a primary analysis because all primary and 
major secondary study objectives will be assessed at this time.
Additional analyses and snapshots of study data may be performed during Period 3 or after 
completion of Period 4 to fulfill the need for regulatory interactions or publication purposes. 
Unblinding details are specified in the blinding/unblinding plan.

I1F-MC-RHBW(d) Clinical Protocol
Page 80
LY2439821
10. Study Governance Considerations
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process
10.1.1. Informed Consent
The investigator is responsible for ensuring:

that the patient understands the potential risks and benefits of participating in the study

that informed consent is given by each patient or legal representative.  This includes 
obtaining the appropriate signatures and dates on the ICF prior to the performance of any 
protocol procedures and prior to the administration of investigational product.

answering any questions the patient may have throughout the study and sharing in a 
timely manner any new information that may be relevant to the patient’s willingness to 
continue his or her participation in the trial.
10.1.2. Ethical Review
The investigator must give assurance that the ERB was properly constituted and convened as 
required by International Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site(s).  Lilly or its representatives must approve the ICF, 
including any changes made by the ERBs, before it is used at the investigative site(s).  All ICFs 
must be compliant with the ICH guideline on GCP.
The study site’s ERB(s) will be provided with the following:

the current IB and updates during the course of the study

ICF

relevant curricula vitae.
10.1.3. Regulatory Considerations
This study will be conducted in accordance with:

consensus ethics principles derived from international ethics guidelines, including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines

applicable ICH GCP Guidelines

applicable laws and regulations.
Some of the obligations of the sponsor will be assigned to a third party.

I1F-MC-RHBW(d) Clinical Protocol
Page 81
LY2439821
10.1.4. Investigator Information
Licensed physicians with a specialty in rheumatology will participate as investigators in this 
clinical trial.
10.1.5. Protocol Signatures
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study.
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative.
10.1.6. Final Report Signature
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study.
The CSR coordinating investigator will be selected by the sponsor. If this investigator is unable 
to fulfill this function, another investigator will be chosen by Lilly to serve as the CSR 
coordinating investigator.
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study.
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:

provide instructional material to the study sites, as appropriate.

sponsor start-up training to instruct the investigators and study coordinators.  This 
training will give instruction on the protocol, the completion of the CRFs, and study 
procedures.

make periodic visits to the study site.

be available for consultation and stay in contact with the study site personnel by mail,
telephone, and/or fax.

review and evaluate CRF data and use standard computer edits to detect errors in data 
collection.

conduct a quality review of the database.
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives, and/or regulatory agencies, at any time.  Investigators will be given notice before 
an audit occurs.

I1F-MC-RHBW(d) Clinical Protocol
Page 82
LY2439821
The investigator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents.
10.2.1. Data Capture System
An electronic data capture system and an electronic source system will be used in this 
study. The site maintains a separate source for the data entered by the site into the sponsor-
provided electronic data capture system. Some or all of a patient’s data will be directly entered 
into the eCRF at the time that the information is obtained. In instances where direct data entry is 
not used, the site will maintain source documentation in the trial files, and the patient’s data will 
be transcribed into the eCRF. Paper documentation provided by the patient will serve as the 
source document, including a study drug administration log and an event-medication diary, that 
will be identified and documented by each site in that site’s study file.
In this study, patient-rated scales/questionnaires will be collected at office visits (or even at 
home) directly via an electronic patient-reported outcome (ePRO) tablet device as part of an 
ePRO/Clinical Outcome Assessment (COA) system. Data entered into the ePRO/COA system 
will serve as the source data.  Electronic PRO records are stored at a third party site.  Investigator 
sites will have continuous access to the source data during the study and will receive an archival 
copy at the end of the study for retention.  Any data collected within the ePRO instrument will 
serve as the source data and will be identified and documented by each site in that site’s study 
file.
Data managed by a central vendor, such as laboratory test data or ECG data, will be stored 
electronically in the central vendor’s database system. Data will subsequently be transferred 
from the central vendor to the Lilly generic labs system.
Data from complaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system.
10.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study site participation may be discontinued if Lilly or its designee, the investigator, or the ERB 
of the study site judges it necessary for medical, safety, regulatory, or other reasons consistent 
with applicable laws, regulations, and GCP.
10.3.2. Discontinuation of the Study
The study will be discontinued if Lilly or its designee judges it necessary for medical, safety, 
regulatory, or other reasons consistent with applicable laws, regulations, and GCP.

I1F-MC-RHBW(d) Clinical Protocol
Page 83
LY2439821
11. References
Alosh M, Bretz F, Huque M. Advanced multiplicity adjustment methods in clinical trials. Stat 
Med. 2014;33(4):693-713.
Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis 
assessment group preliminary definition of short-term improvement in ankylosing spondylitis. 
Arthritis Rheum. 2001;44(8):1876-1886.
[APA] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 
4th ed. Washington, DC: American Psychiatric Association; 1994.
Appel H, Heydrich R, Loddenkemper C, Hempfing A, Sieper J. In situ detection of IL-17 
secreting cells in the bone marrow of facet joints obtained from patients with ankylosing 
spondylitis. Arthritis Rheum. 2008;58(suppl S):S351.
Baeten D, Sieper J, Emery P, Braun J, Heijde D, McInnes I, van Laar JM, Landewe R, 
Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Berolino AP, Wright AM, Hueber W. 
The anti-IL-17A monoclonal antibody secukinumab (AIN457) showed good safety and 
efficacy in the treatment of active ankylosing spondylitis [poster]. Poster presented at: Annual 
Meeting of the American College of Rheumatology; 10 November 2010; Atlanta, GA. 
Available at:
http://www.abstracts2view.com/acr/view.php?nu=4350&type=abstract&sesId=541&num=AP
S&trk=). Accessed February 21, 2011.
Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, 
Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, 
Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Anti-
interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a 
randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705-1713. 
Erratum in: Lancet. 2014a;383(9928):1548.
Baeten D, Braun J, Baraliakos X, Sieper J, Dougados M, Emery P, Deodhar A, Porter B, Martin
R, Mpofu S, Richards H. Secukinumab, a monoclonal antibody to interleukin-17A, 
significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-
week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous 
maintenance dosing [abstract]. In: ACR/ARHP Annual Meeting Abstract Supplement. 14-19 
Nov 2014; Boston, MA. Arthritis Rheum. 2014b;66(S10):S360. Abstract 819.
Baraliakos X, Braun J, Laurent DD, Baeten D, van der Heijde D, Sieper J, Emery P, McInnes I, 
van Laar J, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Wright AM, Gsteiger S, 
Hueber W. Interleukin-17A blockade with secukinumab reduces spinal inflammation in 
patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance 
imaging. Arthritis Rheum. 2011;63(suppl 10):2486D.
Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl.
2006;78:4-11.
Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and 
preselection of criteria for short term improvement after anti-TNF alpha treatment in 
ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438-1444.

I1F-MC-RHBW(d) Clinical Protocol
Page 84
LY2439821
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379-1390.
Braun J, Sieper J. Treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp 
Rheumatol. 2009;27(4 suppl 55):S146-S147.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, 
Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, 
Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, 
Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van 
Royen B, van der Heijde D. 2010 update of the ASAS/EULAR recommendations for the 
management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. 
Biom J. 2011;53(6):894-913.
Calin A, Jones SD, Garrett SL, Kennedy LG. Bath Ankylosing Spondylitis Functional Index. 
Br J Rheumatol. 1995;34(8):793-794.
Cimzia [package insert]. Smyrna, Georgia: UCB; 2015. Available at: 
http://medlibrary.org/lib/rx/meds/cimzia/. Accessed October 19, 2015.
Columbia University Medical Center. Columbia–Suicide Severity Rating Scale (C-SSRS) web 
site. Available at: http://www.cssrs.columbia.edu. Accessed April 21, 2011.
Cosentyx [package insert]. East Hanover, New Jersey: Novartis; 2015. Available at: 
http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdf. Accessed October 19, 2015.
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, 
Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group. Recombinant 
human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a 
randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230-3236.
Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van 
der Heijde D. Golimumab reduces sleep disturbance in patients with active ankylosing 
spondylitis: results from a randomized, placebo-controlled trial. Arthritis Care Res (Hoboken).
2010;62(9):1266-1271.
Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, 
Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, 
Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman 
MH, Landewé RB. The concept of axial spondyloarthritis: joint statement of the 
spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis 
international Society in response to the US Food and Drug Administration’s comments and 
concerns. Arthritis Rheumatol. 2014;66(10):2649-2656.
de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans 
BA, Hazenberg BP, Wolbink GJ. Erythrocyte sedimentation rate, C-reactive protein level, and 
serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor 
treatment in ankylosing spondylitis. Arthritis Rheum. 2009;61(11):1484-1490.
Diggle PJ, Heagerty P, Liang K-Y, Zeger SL. Analysis of longitudinal data. Oxford: Oxford 
University Press; 1994.

I1F-MC-RHBW(d) Clinical Protocol
Page 85
LY2439821
Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127-2137.
Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde 
D. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical 
trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70(2):249-251.
[EMA] European Medicines Agency, Committee for Medicinal Products for Human Use 
(CHMP). Guideline on clinical investigation of medicinal products for the treatment of 
ankylosing spondylitis. 2009. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC50
0003424.pdf. Accessed October 26, 2015. 
Enbrel [package insert]. Thousand Oaks, California: Amgen Inc; 2015. Available at: 
http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Accessed October 19, 2015.
EuroQol Group. EQ-5D-5L user guide. Version 1.0. April 2011. Available at: 
http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_
EQ-5D-5L. Accessed September 14, 2012.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Activity Index. J Rheumatol. 1994;21(12):2286-2291.
Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, 
Braun D, Berclaz PY, Banerjee S. A phase II randomized study of subcutaneous ixekizumab, 
an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to 
biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis 
Rheumatol. 2014;66(7):1693-1704.
Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of 
treatment response and drug continuation in 842 patients with ankylosing spondylitis treated 
with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide 
DANBIO registry. Ann Rheum Dis. 2010;69(11):2002-2008.
Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A,
Fana V, Lindegaard HM, Nordin H, Rasmussen C, Ejstrup L, Jensen DV, Petersen 
PM,Hetland ML. Clinical response, drug survival and predictors thereof in 432 ankylosing 
spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the 
Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72(7):1149-1155.
Gottlieb AB, Mease PJ, Cuchacovich RS, Shuler CL, Lin CY, Burge RT, Samanta S, Lee CH, 
Gladman DD. Ixekizumab improves physical function, quality of life, and work productivity in 
biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis 
[abstract]. Arthritis Rheumatol. 2015;67(suppl 10).
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson 
J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp 
K, UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept 
or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from 
two phase 3 randomised trials. Lancet. 2015;6736(15):60125-8.

I1F-MC-RHBW(d) Clinical Protocol
Page 86
LY2439821
Haibel H, Specker C. Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and 
ankylosing spondylitis. Clin Exp Rheumatol. 2009:27(4 suppl 55):S159-S163.
Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK. 
The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients 
with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a 
longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234-240.
Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van ver Tempel H, Mielants 
H, Dougados M, van der Heijde D. Assessment of enthesitis in ankylosing spondylitis. Ann 
Rheum Dis. 2003;62(2):127-132.
Humira [package insert]. North Chicago, IL: AbbVie Inc; 2015. Available at: 
http://www.rxabbvie.com/pdf/humira.pdf. Accessed October 19, 2015.
Inman RD, Davis JC Jr, van der Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, 
Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in patients 
with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase 
III trial. Arthritis Rheum. 2008;58(11):3402-3412.
Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating 
polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis 
Rheum. 2008;58(8):2307-2317.
Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal 
mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol.
1994;21(9):1694-1698.
Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, 
Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J. Development of a health index in 
patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the 
ICF guided by ASAS. Ann Rheum Dis. 2013;74(5):830-835.
Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, 
Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville 
M, Sieper J. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis 
including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-
controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39-47.
Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rødevand E, Koldingsnes W, Kaufmann C, 
Kvien TK. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data 
from the NOR-DMARD register. Ann Rheum Dis. 2011;70(1):157-163.
Machado P, Castrejon I, Katchamart W, Koevoets R, Kuriya B, Schoels M, Silva-Fernández L, 
Thevissen K, Vercoutere W, Villeneuve E, Aletaha D, Carmona L, Landewé R, van der Heijde 
D, Bijlsma JW, Bykerk V, Canhão H, Catrina AI, Durez P, Edwards CJ, Mjaavatten MD, Leeb 
BF, Losada B, Martín-Mola EM, Martinez-Osuna P, Montecucco C, Müller-Ladner U, 
Østergaard M, Sheane B, Xavier RM, Zochling J, Bombardier C. Multinational 
evidence-based recommendations on how to investigate and follow-up undifferentiated 
peripheral inflammatory arthritis: integrating systematic literature research and expert opinion 
of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 
2011a;70(1):15-24.

I1F-MC-RHBW(d) Clinical Protocol
Page 87
LY2439821
Machado PM, Landewé RB, van der Heijde DM. Endorsement of definitions of disease activity 
states and improvements scores for the Ankylosing Spondylitis Disease Activity Score: results 
from OMERACT 10. J Rheumatol. 2011b;38(7):1502-1506.
Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D, Assessment of 
SpondyloArthritis International Society. Ankylosing Spondylitis Disease Activity Score 
(ASDAS): defining cut-off values for disease activity states and improvement scores. Ann 
Rheum Dis. 2011c;70(1):47-53.
Machado P, Navarro-Compán V, Landewé R, van Gaalen FA, Roux C, van der Heijde D. 
Calculating the ankylosing spondylitis disease activity score if the conventional C-reactive 
protein level is below the limit of detection or if high-sensitivity C-reactive protein is used: an 
analysis in the DESIR cohort. Arthritis Rheumatol. 2015;67(2):408-413.
Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, Sampalis J, 
Conner-Spady B. Development and validation of the Spondyloarthritis Research Consortium 
of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948-953.
Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol. 
2010:6(2):75-81.
Mease PJ, van der Heijde D, Ritchlin CT, Cuchacovich R, Shuler CL, Lee CH, Samanta S, Lin 
C-Y, Gladman DD, Vangerow H. A randomized, double-blind, active- and placebo-controlled 
phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in 
patients naive to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis 
[abstract]. Arthritis Rheumatol. 2015;67(suppl 10).
Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z, Liao F, Xia G, Wang S, Xu S, Xu J, Zhang L, Ye 
D. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin 
Rheumatol. 2011;30(2):269-273.
Moreland L. Unmet needs in rheumatoid arthritis. Arthritis Res Ther. 2005;7(suppl 3):S2-S8.
Naegeli AN, Flood E, Tucker J, Devlen J, Edson-Heredia E. The patient experience with fatigue 
and content validity of a measure to assess fatigue severity: qualitative research in patients 
with ankylosing spondylitis (AS). Health Qual Life Outcomes. 2013;11(11):192.
Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet 
Dis. 2013;5(1):45-54.
Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of 
Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric 
suicidal risk analysis of antidepressants. Am J Pyschiatry. 2007;164(7):1035-1043.
Reilly Associates. Health Outcomes Research web site. 2002. Available at: 
http://www.reillyassociates.net/. Accessed September 14, 2012.
Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and 
responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing 
spondylitis. Rheumatology (Oxford). 2010;49(4):812-819.
Reveille JD. The genetic basis of spondyloarthritis. Ann Rheum Dis. 2011;70(suppl 1):i44-i50.

I1F-MC-RHBW(d) Clinical Protocol
Page 88
LY2439821
Reveille JD, Wittier JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: 
estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64(6):905-910.
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, 
Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, 
Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J. 
The development of Assessment of SpondyloArthritis International Society classification 
criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 
2009;68(6):777-783.
Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329-338.
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, 
Hermann KG, Landewé R, Maksymowych W, van der Heijde D. The Assessment of 
SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. 
Ann Rheum Dis. 2009;68(suppl 2):ii1-ii44.
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, 
Pangan AL. Efficacy and safety of adalimumab in patients with non-radiographic axial 
spondyloarthritis: results from a phase 3 study. Presented at: Annual Meeting of the American 
College of Rheumatology; 4-9 November 2011; Chicago, IL. Presentation number 2486A.
Sieper J, Braun J, Baraliakos X, Baeten D, Dougados M, Emery P, Deodhar A, Porter B, 
Andersson M, Mpofu S, Richards H. Secukinumab, a monoclonal antibody to interleukin-17A, 
significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 
3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing
[poster]. Poster presented at: American College of Rheumatology 2014 Annual Scientific 
Meeting; 14-19 November 2014; Boston, MA. Poster 536.
Simponi [package insert]. Horsham, PA: Janssen Biotech Inc; 2015. Available at: 
http://medlibrary.org/lib/rx/meds/simponi/. Accessed October 19, 2015.
Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY, Griffiths 
CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD. British Association of 
Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 
2009;161(5):987-1019.
Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM. Prevalence of axial 
spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis 
International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res
(Hoboken). 2013;65(8):1299-1306.
van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J;
Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study 
Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a 
randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582-591.
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille 
JD, Wong RL, Kupper H, Davis JC Jr; ATLAS Study Group. Efficacy and safety of 
adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, 
double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136-2146.

I1F-MC-RHBW(d) Clinical Protocol
Page 89
LY2439821
van der Heijde D, Landewé R, Feldtkeller E. Proposal of a linear definition of the Bath 
Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 
10-step definitions. Ann Rheum Dis. 2008;67(4):489-493.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
spondylitis. a proposal for modification of the New York criteria. Arthritis Rheum.
1984;27(4):361-368.
Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, 
Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Predicting the 
outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70(6):973-981.
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka 
J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, 
Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, 
Yu DT, Miller AS, Reveille JD, Caplan L. American College of Rheumatology/Spondylitis 
Association of America/Spondyloarthritis Research and Treatment Network 2015 
Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial 
Spondyloarthritis. Arthritis Rheumatol. 2015. doi: 10.1002/art.39298 [Epub ahead of print].
Ware JE Jr. SF-36 health survey update. Spine. 2000;25(24):3130-3139..
Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover 
markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007;74(3):304-305.
Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a 
promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol.
2014;26(4):361-370.
Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, 
Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, 
Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van 
Royen BJ, Braun J, ASsessment in AS international working group, European League Against 
Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. 
Ann Rheum Dis. 2006;65(4):442-452.
Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing 
Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale 
(ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing 
Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), 
Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), 
and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care 
Res (Hoboken). 2011;63(suppl 11):S47-S58.

I1F-MC-RHBW(d) Clinical Protocol
Page 90
LY2439821
Appendix 1.
Abbreviations and Definitions
Term
Definition
ADA
anti-drug antibodies
AE
adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI
adverse event of special interest
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
AS
ankylosing spondylitis:  currently referred to as radiographic axial spondyloarthritis 
(rad-axSpA)
ASAS
Assessment of Spondyloarthritis International Society
ASAS HI
Assessment of Spondyloarthritis International Society Health Index
ASDAS
Ankylosing Spondylitis Disease Activity Score.  In this study, it refers to the ASDAScrp
score which includes high sensitivity C-reactive protein (CRP).
ASSpiMRI-Berlin
Ankylosing Spondylitis Spinal Magnetic Resonance Imaging Activity–Berlin Score
AST
aspartate aminotransferase
axSpA
axial spondyloarthritis:  a single disease entity with a subset defined by the presence of 
clear structural damage (rad-axSpA) and a subset with no clear structural damage as 
defined by conventional x-rays (nonrad-axSpA)
BASDAI50
Bath Ankylosing Spondylitis Disease Activity Index 50
BASFI
Bath Ankylosing Spondylitis Functional Index
BASMI
Bath Ankylosing Spondylitis Metrology Index
blinding
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
bDMARD
biological disease-modifying antirheumatic drug

I1F-MC-RHBW(d) Clinical Protocol
Page 91
LY2439821
Term
Definition
cDMARD
conventional disease-modifying antirheumatic drug
CEC
Clinical Events Committee
complaint
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CRP
C-reactive protein
C-SSRS
Columbia–Suicide Severity Rating Scale
DMARD
disease-modifying antirheumatic drug
ECG
electrocardiogram
enroll
The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter
Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
EQ-5D-5L
European Quality of Life–5 Dimensions–5 Level
GCP
good clinical practice
IB
Investigator’s Brochure
IBD
inflammatory bowel disease (eg, Crohn’s disease and ulcerative colitis)
ICF
informed consent form
investigational 
product
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT
intent-to-treat:  The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating on the basis of the intention to treat a patient (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence that 
patients allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWRS
interactive web-response system
JSEQ
Jenkins Sleep Evaluation Questionnaire
LOCF
last observation carried forward
MASES
Maastricht Ankylosing Spondylitis Enthesitis Score

I1F-MC-RHBW(d) Clinical Protocol
Page 92
LY2439821
Term
Definition
mBOCF
modified baseline observation carried forward
MMRM
mixed-effects model of repeated measures
mNY
modified New York criteria
MRI
magnetic resonance imaging
nonrad-axSpA
nonradiographic axial spondyloarthritis:  a subset of axSpA in which there is no clear 
structural damage as defined by conventional imaging
NRI
nonresponder imputation
NRS
numeric rating scale
NSAID
nonsteroidal anti-inflammatory drug
PK/PD
pharmacokinetics/pharmacodynamics
PPS
per-protocol set:  The set of data generated by the subset of patients who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
Q2W
every 2 weeks
Q4W
every 4 weeks
rad-axSpA
radiographic axial spondyloarthritis:  a subset of axSpA in which there is evidence of 
disease features on radiographic imaging
SAE
serious adverse event
SAP
statistical analysis plan
screen
The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SF-36 MCS
Short Form 36 mental component score
SF-36 PCS
Short Form 36 physical component score
SIJ
sacroiliac joints
SpA
spondyloarthritis
SPARCC
Spondyloarthritis Research Consortium of Canada
TEAE
treatment-emergent adverse event:  Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to 
have a causal relationship with this treatment.
TNFi
tumor necrosis factor inhibitor

I1F-MC-RHBW(d) Clinical Protocol
Page 93
LY2439821
Term
Definition
ULN
upper limit of normal
WPAI-SpA
Work Productivity Activity Impairment–Spondyloarthritis

I1F-MC-RHBW(d) Clinical Protocol
Page 94
LY2439821
Appendix 2.
Schedule of Activities

I1F-MC-RHBW(d) Clinical Protocol
Page 95
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW (Periods 1-2)
Screening
(Period 1)
Baseline 
Randomization
Blinded Treatment Dosing Period (Period 2)a
CRF Visit (V) Number
V1
V2
V3
V4
V5
V6
V7
V8
Weeks Since Randomization
W0
W1
W2
W4
W8
W12
W16
Study Days
Up to -42 d
0
7 ± 2d
14 ± 2d
28 ± 2d
56 ± 4d
84 ± 4d
112 ± 4d
Informed consent
X
Demographicsb
X
Physical examinationc
X
X
Vital signs (BP and pulse)d
X
Xd
X
X
X
X
X
Xd
Weightz
X
X
X
X
X
X
Height
X
Habitse
X
Body temperature
X
Posterior anterior chest x-rayf
X
Inclusion/Exclusion criteriag
X
X
Evaluate presence of SpA features
X
X
Randomization
X
X
Concomitant medications
X
X
X
X
X
X
X
X
NSAID use
X
X
X
X
X
X
X
X
Preexisting conditions and medical historyh
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
Eye symptom assessmenti
X
X
X
X
X
X
X
X
Dispense IP
X
X
X
X
X
X
Administer IP on sitej
X
X
IP compliance
X
X
X
X
X
Dispense SDAL
X
X
X
X
X
X
Collect, review, and enter data from SDAL
X
X
X
X
X
X

I1F-MC-RHBW(d) Clinical Protocol
Page 96
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW (Periods 1-2)
Screening
(Period 1)
Baseline 
Randomization
Blinded Treatment Dosing Period (Period 2)a
CRF Visit (V) Number
V1
V2
V3
V4
V5
V6
V7
V8
Weeks Since Randomization
W0
W1
W2
W4
W8
W12
W16
Study Days
Up to -42 d
0
7 ± 2d
14 ± 2d
28 ± 2d
56 ± 4d
84 ± 4d
112 ± 4d
Clinical Efficacy/Health Outcomes
X-ray of the SIJk
X
X-ray of the spinel
X
Linear BASMI
X
X
X
Chest expansion
X
X
X
Occiput to wall distance
X
X
X
Enthesitis (MASES and SPARCC)
X
X
X
Assessment of TJC/SJC (46/44)
X
X
X
Healthcare resource utilization
X
X
X
Patient Global (Assessment of Disease 
Activity NRS)
X
X
X
X
X
X
X
X
Spinal pain
X
X
X
X
X
X
X
X
BASFI
X
X
X
X
X
X
X
X
BASDAI
X
X
X
X
X
X
X
X
Fatigue NRS
X
X
X
X
SF-36
X
X
X
X
X
ASAS HI
X
X
X
X
X
QIDS-SR16
X
X
X
C-SSRSm
X
X
X
X
X
X
X
Self-Harm Supplement Formm
X
X
X
X
X
X
X
EQ-5D-5L
X
X
WPAI-SpA
X
X
JSEQ
X
X
X

I1F-MC-RHBW(d) Clinical Protocol
Page 97
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW (Periods 1-2)
Screening
(Period 1)
Baseline 
Randomization
Blinded Treatment Dosing Period (Period 2)a
CRF Visit (V) Number
V1
V2
V3
V4
V5
V6
V7
V8
Weeks Since Randomization
W0
W1
W2
W4
W8
W12
W16
Study Days
Up to -42 d
0
7 ± 2d
14 ± 2d
28 ± 2d
56 ± 4d
84 ± 4d
112 ± 4d
Laboratory Tests
HLA-B27n
X
CRP
Xo
X
X
X
X
X
X
X
Administer PPD/Collect QuantiFERON®-
TB Gold/T-SPOT®p
X
ECG
X
FSHq
X
HIV/HCV
X
HBV
Xr
Xr
Xr
Serum pregnancy tests
X
Urine pregnancy tests
X
X
Serum chemistry
X
X
X
X
X
X
PTT, PT/INR
X
X
Lipid panel (fasting)t
X
X
Hematology
X
X
X
X
X
X
Urinalysis
X
X
TSH and free T4
X
Non-pharmacogenetic biomarker 
exploratory storage samples (urine, serum, 
plasma, RNA, and whole blood)u
X
Xv
Xv
X
Xv
Xv
X
Pharmacogenetic exploratory sample
(DNA)u,aa
X
Immunogenicity testingw
X
X
X
X
X
X
X
PK samplingw,x
X
X
X
X
X
X
X

I1F-MC-RHBW(d) Clinical Protocol
Page 98
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW (Period 3)
Extended Treatment Period
(Period 3)a
ETV
CRF Visit (V) Number
V9
V10
V11
V12
V13
V14
V15
ETV
Weeks Since Randomization
W20
W24
W28
W32
W36
W44
W52
Study Days
140 ± 4d
168 ± 4d
196 ± 4d
224 ± 4d
252± 4d
308 ±7d
364 ± 7d
Physical examinationc
X
X
Vital signs (BP and pulse)d
X
X
X
X
X
X
X
X
Weightz
X
X
X
X
X
X
X
X
Concomitant medications
X
X
X
X
X
X
X
X
NSAID use
X
X
X
X
X
X
X
X
Preexisting conditions and medical historyh
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
Eye symptom assessmenti
X
X
X
X
X
X
X
X
Dispense IP
X
X
X
X
X
X
IP compliance
X
X
X
X
X
X
X
X
Dispense SDAL
X
X
X
X
X
X
Collect, review, and enter data from SDAL
X
X
X
X
X
X
X
X
Clinical Efficacy/Health Outcomes
Linear BASMI
X
X
X
X
Chest expansion
X
X
X
X
Occiput to wall distance
X
X
X
X
Enthesitis (MASES and SPARCC)
X
X
X
X
Assessment of TJC/SJC (46/44)
X
X
X
X
Healthcare resource utilization
X
X
X
X
Patient Global (Assessment of Disease Activity NRS)
X
X
X
X
X
X
X
X
Spinal Pain
X
X
X
X
X
X
X
X
BASFI
X
X
X
X
X
X
X
X
BASDAI
X
X
X
X
X
X
X
X
Fatigue NRS
X
X
X

I1F-MC-RHBW(d) Clinical Protocol
Page 99
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW (Period 3)
Extended Treatment Period
(Period 3)a
ETV
CRF Visit (V) Number
V9
V10
V11
V12
V13
V14
V15
ETV
Weeks Since Randomization
W20
W24
W28
W32
W36
W44
W52
Study Days
140 ± 4d
168 ± 4d
196 ± 4d
224 ± 4d
252± 4d
308 ±7d
364 ± 7d
SF-36
X
X
X
ASAS HI
X
X
X
QIDS-SR16
X
X
X
C-SSRSm
X
X
X
X
X
X
X
X
Self-Harm Supplement Formm
X
X
X
X
X
X
X
X
EQ-5D-5L
X
X
WPAI-SpA
X
X
JSEQ
X
X
X
Laboratory Tests
CRP
X
X
X
X
X
X
X
X
HBV
Xr
Xr
Xr
Xr
Xr
Urine pregnancy tests
X
X
X
X
X
Serum chemistry
X
X
X
X
X
X
X
X
PTT, PT/INR
X
X
X
Lipid panel (fasting)t
X
X
X
Hematology
X
X
X
X
X
X
X
X
Urinalysis
X
X
X
X
Non-pharmacogenetic biomarker exploratory storage 
samples (urine, serum, plasma, RNA, and whole 
blood)u
X
Xv
Xv
X
Immunogenicity testingw
X
X
X
X
X
PK samplingw,x
X
X
X
X
X

I1F-MC-RHBW(d) Clinical Protocol
Page 100
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW (Period 4)
Post-Treatment Follow-Up for Patients Discontinuing Treatment at or After Week 16
(Period 4)y
Required Follow-Up Visits
As-Needed Follow-Up Visits
CRF V (visit) number
V801
V802
V803 and onwards
Study Weeks
LV + 4W
LV + 12W
LV + 24 W
Study Days
±14d
±14d
±14d
Concomitant medications
X
X
X
Vital signs (BP and pulse)d
X
X
X
Weightz
X
X
X
Preexisting conditions and medical historyh
X
X
X
Adverse events
X
X
X
C-SSRSm
X
X
X
Self-Harm Supplement Formm
X
X
X
HBV
Xr
Serum chemistry
X
X
X
Hematology
X
X
X
Non-pharmacogenetic biomarker exploratory storage samples
(urine, serum, plasma, RNA, and whole blood)u
Xv
Xv
Immunogenicity testingw
X
X
PK samplingw,x
X
X

I1F-MC-RHBW(d) Clinical Protocol
Page 101
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW (Period 4)
Patients who discontinue treatment prior to Week 16 are to use the timetable below to schedule activities for Post-Treatment Follow-Up visits.
Discontinued Week No. (Visit No.)
Corresponding V801 
(LV + 4 weeks)
Corresponding V802
Corresponding V803 
(LV + 24 weeks)
Week 1 (Visit 3)
Week 5
Week 16
Week 25
Week 2 (Visit 4)
Week 6
Week 16
Week 26
Week 4 (Visit 5)
Week 8
Week 16
Week 28
Week 8 (Visit 6)
Week 12
Week 16
Week 32
Week 12 (Visit 7)
Week 16
Week 24
Week 36
Post-Treatment Follow-Up for Patients Discontinuing Treatment Prior to Week 16
(Period 4)y
Required Follow-Up Visits
As-Needed Follow-Up Visits
CRF (V) Visit Number
V801
V802
V803 and onwards
Study Days
±14d
±14d
±14d
Concomitant medications
X
X
X
Vital signs (BP and pulse)d
X
X
X
Weightz
X
X
X
Preexisting conditions and medical historyh
X
X
X
Adverse events
X
X
X
C-SSRSm
X
X
X
Self-Harm Supplement Form m
X
X
X
HBV
Xr
Xr
Serum chemistry
X
X
X
Hematology
X
X
X
Non-pharmacogenetic biomarker exploratory storage 
samples (urine, serum, plasma, RNA and whole blood)u
Xv
Xv
Immunogenicity testing w
X
X
PK samplingw,x
X
X
Patient Global (Assessment of Disease Activity NRS)
X
X
Spinal pain
X
X
BASFI
X
X
BASDAI
X
X
CRP
X
X

I1F-MC-RHBW(d) Clinical Protocol
Page 102
LY2439821
Schedule of Activities, Protocol I1F-MC-RHBW
Abbreviations:  ASAS HI = ASAS Health Index; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis 
Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; BP = blood pressure; CRF = case report form; CRP = high sensitivity C-reactive 
protein; C-SSRS = Columbia–Suicide Severity Rating Scale; d = days; DNA = deoxyribonucleic acid; ECG = electrocardiogram; EQ-5D-5L = European 
Quality of Life–5 Dimensions–5 Level; ETV = early termination visit; FSH = follicle stimulating hormone; HBcAb+ = positive for anti-hepatitis B core 
antibody; HBsAb = anti-hepatitis B surface antibody; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus; HLA = 
human leukocyte antigen; INR = international normalized ratio; IP = investigational product; JSEQ = Jenkins Sleep Evaluation Questionnaire; LV = last visit; 
MASES = Maastricht Ankylosing Spondylitis Enthesitis Score; NRS = numeric rating scale; NSAID = nonsteroidal anti-inflammatory drug; PK = 
pharmacokinetic; PPD = purified protein derivative; PT = prothrombin time; PTT = partial thromboplastin time; QIDS-SR16 = Quick Inventory of Depressive 
Symptomatology–Self-Report (16 Items); rad-axSpA = radiographic axial spondyloarthritis; RNA = ribonucleic acid; SDAL = Study Drug Administration 
Log; SF-36 = Short Form 36; SIJ = sacroiliac joints; SJC = swollen joint count; SpA = spondyloarthritis; SPARCC = Spondyloarthritis Research Consortium 
of Canada; T4 = thyroxine; TB = tuberculosis; TJC = tender joint count; TSH = thyroid stimulating hormone; V = study visit; W = study week; WPAI-SpA = 
Work Productivity Activity Impairment Questionnaire–Spondyloarthritis.
a
If a patient who has received at least 1 dose of IP discontinues from study treatment early, the patient will complete the ETV and then enter the 
Post-Treatment Follow-Up Period (Period 4).  If a patient discontinues prior to Week 16, the patient will complete additional activities during Period 4.
b
Demographics includes recording of year of birth, gender, race, and ethnicity.
c
One complete physical examination (excluding pelvic, rectal examination) will be performed at screening.  All physical examinations throughout the study 
must include a symptom-directed physical as well as examination of heart, lungs, abdomen, eyes, and visual examination of the skin.
d
BP and pulse will always be measured in sitting position and will be recorded before IP dosing at all visits; in addition, BP and pulse will be recorded 
approximately 1 hour post-dosing at baseline (Week 0) and Week 16.  Refer to Section 8.4.2 for more details.
e
Habits include recording of caffeine, alcohol, and tobacco consumption.
f
A posterior anterior chest x-ray will be taken locally at screening unless one has been obtained within 6 months of screening (Visit 1) (provided the x-ray 
and/or report are available for review).  Refer to Section 8.4.6 for more details.
g
Refer to rescreening guidance as appropriate (Section 5.3).
h
Evaluation includes historical events and preexisting conditions.
i
Patients need to be asked about presence of eye symptoms; if eye symptoms are present, then an eye examination is required.  Refer to Section 8.4.5 for 
specific instructions.
j
Refer to Section 6.1.1 for specific IP administration instructions.
k
An x-ray of the SIJ will be performed during the Screening Period (Period 1) unless an x-ray taken prior to screening is available for central reading, is of 
good quality, and confirms diagnosis of rad-ax-Spa.  All x-rays require central reading ONLY, regardless of date taken.  Central reading will define eligibility 
using the modified New York (mNY) criteria.  If central reading of a preexisting x-ray is not consistent with rad-axSpA by central reading, a new x-ray of the 
SIJ may be taken during Period 1 and sent in for central reading.
l
Cervical and lumbar spine only; serves:  1) as baseline for later assessments of structural changes and 2) to evaluate presence of total ankylosis at screening 
(refer to Section 5.2, Exclusion Criterion [11]).  X-ray of the spine does not need to be repeated if one is available that was taken ≤3 months prior to screening
and has passed quality assessment by central reading vendor. 

I1F-MC-RHBW(d) Clinical Protocol
Page 103
LY2439821
m A Self-Harm Follow-Up Form is to be completed for each discrete self-harm event identified on the C-SSRS and the Self-Harm Supplement Form.
n
HLA-B27 test will be performed centrally.
o
Approval from the Lilly clinical research physician or clinical research scientist must be obtained before a CRP retest is permitted.  If the CRP lab is retested, 
the most recent value will be used for randomization.
p
In countries where the QuantiFERON®-TB Gold test or T-SPOT® is available, either test may be used instead of the PPD TB test.  The QuantiFERON®-TB 
Gold test may be performed locally or centrally; the T-SPOT® must be performed locally.  PPD tests must be read 2-3 days after Visit 1.  Refer to 
Section 8.4.6 for more details.
q
For female patients ≥40 and <60 years of age who have had a cessation of menses for at least 12 months, an FSH test will be performed to confirm 
nonchildbearing potential (FSH ≥40 mIU/mL or ≥40 IU/L).  FSH test will be performed centrally.
r
All patients will be tested for HBV at screening.  Patients that are HBcAb+ at screening, regardless of HBsAb status, will have a serum HBV DNA obtained 
by the central laboratory. Patients that are found to be HBV DNA positive (detectable) at screening will be excluded from the trial. Patients that are HBV 
DNA negative (undetectable) may be enrolled into the study with required HBV DNA monitoring every 3 months during treatment and 12 weeks after the last 
dose of ixekizumab.  If the result of the HBV DNA testing is positive, the patient is to be discontinued from the study and is to receive appropriate follow-up 
medical care (refer to Section 8.4.10.2 for further information regarding the timing of discontinuation).
s
Only for females of childbearing potential.  Serum pregnancy test will be done at Visit 1 only and will be performed centrally.  Patients determined to be 
pregnant will be discontinued from treatment and will no longer be administered IP (see Section 7.1).  Patients will undergo urine pregnancy testing at the 
clinic during scheduled visits through Week 52.  Additional urine pregnancy testing can be performed at the investigator’s discretion.  If required per local 
regulations, testing can occur at other intervals during the study treatment period and/or follow-up period.
t
For the fasting lipid profile, patients are not to eat or drink anything except water for 12 hours prior to test.
u
Where collection is allowed by local regulations.
v
Only serum and plasma are collected at this visit.
w Immunogenicity samples may also be analyzed for ixekizumab serum concentration to facilitate in the interpretation of immunogenicity data.  An additional 
blood sample will be collected, when possible, for any patient who experiences a potential systemic allergic/hypersensitivity reaction during the study as 
judged by the investigator.
x
PK samples are to be collected before IP injection.
y
Patients receiving IP who discontinue at any time prior to the end of the study or who complete the study (Week 52) and do not choose to enroll in Study 
RHBY, will have safety Follow-Up Visits 801 and 802 at 4 and 12 weeks, respectively, after the date of their last visit.  Visit 803 will occur if a patient’s 
neutrophil counts have not returned to the criteria defined in Section 8.4.10.1.
z
Weight is only captured on eCRF at V2, V8, V10, V15, and/or ETV.  Body weight collected at other visits is used only for calculation of creatinine 
clearance.
aa If not completed at Visit 2, the sample should be collected as soon as possible at the next scheduled visit.

I1F-MC-RHBW(d) Clinical Protocol
Page 104
LY2439821
Appendix 3.
Clinical Laboratory Tests
Clinical Safety Laboratory Tests to be Performed by Sponsor-Designated Laboratory
Hematologya:
Serum Chemistrya:
Hemoglobin
   Sodium
Hematocrit
   Potassium
Erythrocyte count (RBC)
   Bicarbonate
Mean cell volume (MCV)
   Chloride
Mean cell hemoglobin concentration (MCHC)
   Phosphorus
Leukocytes (WBC)
   Total bilirubin
Platelets
   Direct bilirubin
Absolute counts of: 
   Alkaline phosphatase
Neutrophils, segmented
   Alanine aminotransferase (ALT/SGPT)
Neutrophils, juvenile (bands)
   Aspartate aminotransferase (AST/SGOT)
Lymphocytes
   Blood urea nitrogen (BUN)
Monocytes
   Uric acid
Eosinophils
   Creatinine
Basophils
   Calcium
Urinalysis (dipstick)a:
   Glucose
Color
   Albumin
Specific gravity
   Cholesterol (total)
pH
   Total protein
Protein
   Calculated creatinine clearanceb
Glucose
   Creatine phosphokinase (CPK)
Ketones
   Triglycerides
Bilirubin
   Gamma-glutamyl transferase (GGT)
Urobilinogen
Blood
Lipid Panelc:
Nitrite
   Low density lipoprotein (LDL)
Urine creatinine
   High density lipoprotein (HDL)
Leukocyte esterase
   Very low density lipoprotein (VLDL)
Other Tests:
Human immunodeficiency virus antibody (HIV)f
Pregnancy test (serum)d
Hepatitis B surface antigen (HBsAg)f
Follicle-stimulating hormone (FSH)e
Anti–hepatitis B surface antibody (HBsAb)f
Thyroid-stimulating hormone (TSH) and free T4
Anti–hepatitis B core antibody (HBcAb)f
Ixekizumab serum concentration (pharmacokinetic [PK])
Anti–hepatitis C antibodyf,h
Partial thromboplastin time (PTT)
HBV DNAg
Prothrombin time/international normalized ratio (PT/INR)
High sensitivity C-reactive protein (hsCRP)
Exploratory storage samples (urine, serum, plasma, RNA, 
and whole blood)
Purified protein derivative (PPD)i
Urine pregnancy testd (assayed by clinical study site)
Pharmacogenetic sample (DNA)
QuantiFERON®-TB Gold test i
Immunogenicity testing (anti-ixekizumab Ab)
T-SPOT®i
HLA-B27

I1F-MC-RHBW(d) Clinical Protocol
Page 105
LY2439821
Clinical Safety Laboratory Tests
Abbreviations:  Ab = antibody; DNA = deoxyribonucleic acid; HBV = hepatitis B virus; RNA = ribonucleic acid; 
RBC = red blood cells; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic pyruvic 
transaminase; T4 = thyroxine; WBC = white blood cells.
a
Unscheduled blood chemistry, hematology, and urinalysis panels may be performed at the discretion of the 
investigator.  
b
Cockcroft-Gault calculation is used for the calculated creatinine clearance.
c
For the fasting lipid profile, patients are not to eat or drink anything except water for 12 hours prior to test.  
Fasting is not required for the screening visit (Visit 1).
d
Serum pregnancy test for all women <60 years of age who are still of childbearing potential at Visit 1 only and 
will be performed centrally; after Visit 1, urine pregnancy test performed locally for women of childbearing 
potential.
e
Women ≥40 and <60 years of age who have had a cessation of menses for ≥12 months will have an FSH test 
confirming nonchildbearing potential (≥40 mIU/mL).
f
Test required at Visit 1 to determine eligibility of patient for the study.  
g
HBV DNA testing will be done in those patients who are HBcAb+ at screening.
h
See exclusion criteria (Section 5.2) specific to Hepatitis C antibody.  A confirmatory test for HCV will be 
performed if the patient is positive for HCV antibody.
i
In countries where the QuantiFERON®-TB Gold test or T-SPOT® is available, either test may be used instead 
of the PPD TB test.  The QuantiFERON®-TB Gold test may be performed locally or centrally; the T-SPOT® 
must be performed locally.

I1F-MC-RHBW(d) Clinical Protocol
Page 106
LY2439821
Appendix 4.
Hepatic Monitoring Tests for 
Treatment-Emergent Abnormality
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may 
be required in follow-up with patients in consultation with the clinical research physician from 
Lilly or its designee.
Hepatic Monitoring Tests
Hepatic Hematologya
Haptoglobina
Hemoglobin
Hematocrit
Hepatic Coagulationa
RBC
Prothrombin time
WBC
Prothrombin time, INR
Neutrophils, segmented
Lymphocytes
Hepatic Serologiesa,b
Monocytes
Hepatitis A antibody, total
Eosinophils
Hepatitis A antibody, IgM
Basophils
Hepatitis B surface antigen
Platelets
Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistrya
Hepatitis C antibody
Total bilirubin
Hepatitis E antibody, IgG
Direct bilirubin
Hepatitis E antibody, IgM
Alkaline phosphatase
ALT
Anti-nuclear antibodya
AST
GGT
Anti–smooth muscle antibody
Alkaline phosphatase isoenzymesa
CPK
Anti-Actina
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
a
Assayed by Lilly-designated or local laboratory.
b Reflex/confirmation dependent on regulatory requirements and/or testing availability.

I1F-MC-RHBW(d) Clinical Protocol
Page 107
LY2439821
Appendix 5.
Spondyloarthritis Features
To be included in Study RHBW, patients must have sacroiliitis defined radiographically 
according to the mNY criteria based on central reading
AND
at least one of the spondyloarthritis features (from Box 4, ASAS criteria for classification of 
axSpA [to be applied in patients with chronic back pain ≥3 months and age at onset of back pain 
<45 years]) bulleted below:

Inflammatory back pain (IBP):  According to experts, 4 out of 5 of the following 
parameters present: (1) age at onset <40 years, (2) insidious onset, (3) improvement with 
exercise, (4) no improvement with rest, (5) pain at night (with improvement upon getting 
up).

Arthritis: Past or present active synovitis diagnosed by a doctor.

Enthesitis (heel):  Heel enthesitis:  past or present spontaneous pain or tenderness at 
examination at the site of the insertion of the Achilles tendon or plantar fascia at the 
calcaneus.

Uveitis: Past or present uveitis anterior, confirmed by an ophthalmologist.

Dactylitis: Past or present dactylitis diagnosed by a doctor.

Psoriasis: Past or present psoriasis diagnosed by a doctor.

Crohn’s/Colitis: Past or present Crohn’s disease or ulcerative colitis diagnosed by a 
doctor.

Good response to NSAIDs: At 24 to 48 hours after a full dose of NSAID, the back pain 
was not present anymore or much better.
Note: As patients enrolling into the study should have failed 2 NSAIDs or be intolerant 
to NSAIDs, a doctor should assess whether patients had “good” prior response to 
NSAIDs.

Family history for SpA: Presence in first-degree or second-degree relatives of any of 
the following: (a) AS, (b) psoriasis, (c) uveitis, (d) reactive arthritis, (e) IBD.
Note: A doctor should confirm with his/her patient there was a clear diagnosis (not self-
diagnosis) for any of these in first- or second-degree relatives.

HLA-B27: Positive testing according to standard laboratory techniques.

Elevated CRP: CRP >5.00 mg/L in the presence of back pain, after exclusion of other 
causes for elevated CRP concentration.
References: Rudwaleit et al. 2009; Sieper et al. 2009.

I1F-MC-RHBW(d) Clinical Protocol
Page 108
LY2439821
Appendix 6.
Protocol Amendment I1F-MC-RHBW(d) 
Summary:  A Multicenter, Randomized, Double-Blind, 
Placebo-Controlled 16-Week Study Followed by 
Long-Term Evaluation of Efficacy and Safety of 
Ixekizumab (LY2439821) in TNFi-Experienced Patients 
with Radiographic Axial Spondyloarthritis
Overview
Protocol I1F-MC-RHBW, A Multicenter, Randomized, Double-Blind, Placebo-Controlled 
16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab 
(LY2439821) in TNFi-Experienced Patients with Radiographic Axial Spondyloarthritis, has been 
amended.  The new protocol is indicated by amendment (d) and will be used to conduct the study 
in place of any preceding version of the protocol.
The overall changes and rationale for the changes made to this protocol are as follows:

The additional Exclusion Criterion added to Protocol Amendment I1F-MC-RHBW(c) 
was numbered incorrectly.  Inclusion/Exclusion Criterion [58] is being used in a protocol 
addendum.  In Protocol Amendment (d), the Exclusion Criterion has been correctly 
renumbered as [59].  Text referring to the new Exclusion Criterion numbering was also 
updated.

The ASDAScrp formula contained typographical errors.  These were corrected in Protocol 
Amendment (d).

I1F-MC-RHBW(d) Clinical Protocol
Page 109
LY2439821
Revised Protocol Sections
Note:
Deletions have been identified by strikethroughs.
Additions have been identified by the use of underscore.
Section 5.2. Exclusion Criteria
Patients will be excluded from study enrollment if they meet any of the following criteria at
screening or as specified:
[58] This criterion is applicable only to patients enrolled in the MRI subgroup and was 
assigned in a Protocol Addendum.
[59] Do not meet the enrollment requirements for the open cohort once the other cohorts 
have closed (Section 6.2).
Section 5.3. Screen Failures
Patients who do not qualify at screening for the elevated CRP cohort and therefore do not qualify 
for the study under Exclusion Criterion [58][59] may be rescreened once at least 4 weeks after 
the initial screening.  If the CRP is elevated (>5.00 mg/L) during rescreening, patients may be 
enrolled via the elevated CRP cohort, provided all other entry criteria are met.
Section 8.1.2.9. Ankylosing Spondylitis Disease Activity Score
The ASDAScrp is calculated with the following equation:  0.1216 × total back pain + 0.1106 × 
patient global + 0.0736 × peripheral pain/swelling + 0.0586 × duration of morning stiffness + 
0.5796 × Ln(CRP+1) (Machado et al. 2015).  (Note:  CRP is in mg/liter, the range of other 
variables is from 0 to 10; Ln represents the natural logarithm.)

PPD
Leo Document ID = bfaa70a9-3abe-47ae-8e9d-83b7a54d1943
Approver: 
Approval Date & Time: 01-Jun-2017 22:33:33 GMT
Signature meaning: Approved
Approver:
Approval Date & Time: 02-Jun-2017 05:49:24 GMT
Signature meaning: Approved
PPD